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This research explores factors influencing treatment decision-making in 
cancer consultations with Māori patients and whānau (extended families) to 
ascertain if any of these factors could be contributing to cancer treatment 
inequities experienced by Māori. 
Design 
Māori centred research using case study and qualitative methods. 
Participants 
Five adult Māori patients who had recently received a cancer diagnosis 
participated in this study along with their whānau and three oncology 
specialists with whom they had a consultation where a treatment option was 
discussed. 
Methods 
Consultations were audio-recorded and soon after patients and whānau were 
interviewed.  Specialists self-recorded a brief debrief using a prompt 
questionnaire. 
Results 
Within and across cases, a range of factors appeared to influence 
patients’/whānau treatment decision-making: comorbidity, disease and 
treatment factors. Whānau involvement and support was significant as was 
the specialist’s treatment recommendation.  They also identified positive 
experiences with the specialist.  Specialists attended the consultation 
prepared to offer one medical treatment option in each of the cases studied 
and patient factors such as fitness for treatment, family history and 
symptoms appeared important to their treatment decision-making.  
Information shared by specialists with patients indicated comorbidity, 
disease, treatment and health care system factors such as multidisciplinary 
ii 
 
team decision-making had influenced the development of the treatment 
option offered in the consultation. 
Conclusion 
This research provides valuable information about the range of factors that 
influence both specialists’ and patients’/whānau treatment decision-making 
in cancer consultations.  Whānau and specialists treatment recommendations 
appeared important to patients’ decision-making and medical factors and 
patient factors to specialists’.  In some cases, comorbidity requires greater 
attention given the impact it has on treatment decision-making. 
While it did not appear as if any of these factors were likely contributors to 
cancer treatment inequities there were signs to suggest that health care 
system treatment decision-making processes could be improved.  Further 
exploration for factors influencing treatment decision-making earlier in the 
treatment decision-making pathway may also provide clues to potential 
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Chapter 1 – Introduction 
Cancer is a leading cause of illness and death amongst indigenous people 
world-wide (Jemal et al., 2004; Paltoo & Chu, 2004; Sheppard, Chiarelli, 
Marrett, Nishri, & Trudeau, 2011; Soeberg, 2012; Valery, Coory, Stirling, & 
Green, 2006).  Cancer inequities between indigenous and non-indigenous 
peoples are also evident worldwide (United Nations, 2009).  In New Zealand 
(NZ) cancer is the second leading cause of death for Māori, accounting for 
nearly a third of all Māori deaths (Robson & Harris, 2007).  Of all cancers, 
lung cancer is the leading cause of death for Māori women and the second 
leading cause of death for Māori men (Ministry of Health, 2015d).  A higher 
burden of cancer is borne by Māori compared to the general population and 
Māori with cancer have higher rates of comorbidity than non-Māori (Hill, 
Sarfati, Blakely, Robson, Purdie, Dennett, et al., 2010; Ministry of Health, 
2015a; Sarfati et al., 2009). 
Comorbidities are a key determinant for treatment decisions and an 
important prognostic factor for long term survival from cancer (Hill, Sarfati, 
Blakely, Robson, Purdie, Chen, et al., 2010; Sogaard, Thomsen, Bossen, 
Sorensen, & Norgaard, 2013). Differences in treatment after diagnosis have 
been identified as a contributing factor to Māori experiencing poorer 
outcomes (Hill, Sarfati, Blakely, Robson, Purdie, Dennett, et al., 2010; Stevens, 
Stevens, Kolbe, & Cox, 2008).  Thus, the focus of this thesis is on factors 
influencing treatment decision-making in cancer consultations with Māori, 
paying particular attention to comorbidities. 
This research explores the research questions from the patients’/whānau 
and specialists’ perspectives guided by a Māori centred research approach 
(Cunningham, 2000; Foster, 2003).  Qualitative methods were used to gather, 
analyse and interpret the data.  This research aims to contribute knowledge 
to inform the development of interventions designed to reduce health 
inequities for Māori.  Furthermore, this research is exploratory as there do 
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not appear to be any studies which specifically identify factors which 
influence treatment decision-making in consultations with Māori. 
Research aim 
The aim of this thesis is to understand the factors which influence treatment 
decision-making in cancer consultations with Māori patients and whānau by 
asking:  
1. What impact do comorbidities have on treatment decision-making in 
cancer consultations with Māori patients/whānau? 
2. What other factors influence treatment decision-making in cancer 
consultations with Māori patients/whānau? 
Researcher position 
This thesis is based on work undertaken as part of a three year study (2011-
2014) funded by the Health Research Council of NZ (HRC) the ‘Cancer Care 
Journeys and Clinical Decision Making Qualitative study’ (C3 Qual).  The C3 
Qual study is part of a larger Cancer, Comorbidity and Care (C3) research 
programme led by Professor Diana Sarfati (Otago University).  Clinical and 
Māori Community Oversight groups provided advice to the C3 research 
programme.  The C3 Qual project was led by Associate Professor Louise 
Signal (University of Otago) and Professor Chris Cunningham (Massey 
University).  Signal is also the primary supervisor of this thesis, with Lis 
Ellison-Loschmann (Massey University) as second.  Other team advisors 
include Diana Sarfati, Kevin Dew, Lesley Batten and Maureen Holdaway.  The 
C3 Qual study comprises four phases: (1) processes of clinical decision-
making in multidisciplinary meetings; (2) decision-making in cancer 




This thesis presents the experiences of five Māori cancer patients who were 
study participants in the second phase of the C3 Qual study. There were also 
13 NZ European cancer patients who participated in this phase. I was 
responsible for developing the ethics application, the research protocol, 
information sheets, consent forms and questionnaires, with supervision and 
with input from other team members.  I set up and led the data collection.  In 
total I undertook 14 interviews (four Māori and ten NZ European patients), 
five of which were completed with research assistant, Virginia Signal.  
Analysis of the Māori participants’ data for this thesis was undertaken by 
myself and overseen by my supervisors, Signal and Ellison-Loschmann.  
Team members Dew and Sarfati also cross checked data analysis. 
Personal position 
My interest in this research topic is linked to my personal experiences of 
cancer among whānau members and friends, and in my professional capacity 
as a public health practitioner with a nursing background concerned with 
achieving health equity for Māori. 
I have the privilege of having two fathers, one of whom was taken by lung 
cancer at the age of 50.  Mum, my sister, my Dad’s GP, the district health 
nurses, whānau and I cared for Dad at home for the final few months of his 
life.  The smell of cancer is never forgotten.  The emaciated man resembling a 
concentration camp survivor, confined to bed, passed before the break of 
dawn one cold spring morning.  He no longer resembled the quiet, animal 
loving, hard worker of a dad I remembered.  That devastating experience is 
permanently imprinted on my brain and in my senses for time ever more, as 
no doubt it was for everyone involved.  Over time a number of other family 
members have also succumbed to cancer. 
While undertaking this thesis my sister (39 years) and a dear friend (42 
years) were both diagnosed with breast cancer, further ensuring my personal 
connection to the topic.  Thankfully they continue to fight the ‘good fight’ and 
it serves as a stark reminder that you just never know what may be waiting 
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around the corner.  While a cancer diagnosis might feel like a death sentence, 
advances in screening and treatment gives us hope - and the diagnosis 
reminds us all of what is truly important, friends and whānau.  I believe that 
my personal experiences enabled me to undertake this research with 
compassion, commitment and understanding combined with the respect that 
these participants, their whānau and specialists deserved. 
My work in Māori public health has focused largely on health promotion, 
cancer screening, and primary care in the community.  During that time I 
noted advances in cancer health promotion, prevention, early detection, and 
treatment.  Yet, over the past few decades, cancer incidence and mortality 
rates continue to show that Māori experience a greater burden of cancer 
when compared to NZ Europeans.  Why I ask myself are there persistent and 
unfair differences in health status between Māori in ‘modern day’ NZ that are 
unnecessary and potentially avoidable? 
Therefore, when the opportunity to participate in the C3 research 
programme arose it seemed both a natural and logical pathway to pursue.  
The programme provided not only an opportunity to learn about the 
experiences of patients, whānau and specialists along the cancer journey but 
more importantly, the chance to identify interventions to address inequities.  
This thesis is undertaken to complete a Masters of Public Health from the 
University of Otago. 
Te Tiriti o Waitangi  
Te Tiriti o Waitangi (Te Tiriti), was signed in 1840 and is the founding 
document between the Queen of England (the Crown) and many of the 
indigenous tribes of NZ (collectively referred to as Māori).  Te Tiriti was 
negotiated with many Māori Chiefs by representatives of the Queen and 
recognises Māori as the tangata whenua (people of the land) of Aotearoa/NZ 
(Ministry for Culture and Heritage, 2016).  Te Tiriti contains three main 
articles: Article one, where Māori essentially conferred governorship to the 
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Queen;  Article Two, protects Māori Chieftainship over lands, villages and 
treasurers and allows Māori to sell land to the Queen and Article Three, 
which guarantees Māori the protection of the Queen of England and the same 
rights as British subjects.  Under Article Three, it has been suggested that 
Māori are therefore entitled to enjoy the same level of health as non-Māori 
(Reid & Robson, 2007). 
Te Tiriti paved the way for large numbers of mainly English immigrants to 
settle in Aotearoa/NZ.  Although Te Tiriti was designed to protect Māori, the 
Crowns’ inability to honour it over time has resulted in detrimental effects on 
Māori.  Examples include poorer health for Māori compared to NZ Europeans, 
loss of life from infectious disease and firearms, effects on education, 
employment, land, language and wairua (spiritual wellbeing) (Cram, Smith, & 
Johnstone, 2003; Durie, 1998; Kunitz, 1998; Sorrenson, 1956).   Large scale 
settlement essentially disrupted fundamental elements of Māori life including 
food supplies, social networks and the economic base.  Many of these factors 
are now considered to be social determinants of health. 
In a modern context social determinants of health can be considered in three 
sub-sets.  Firstly, the socio-economic and political context (the cause of the 
causes), secondly the social determinants of health inequities, and thirdly 
intermediary factors such as the health care system (Solar & Irwin, 2010).  
Social determinants of health have been found to contribute significantly to 
health inequities, more so than the health care system in some instances 
(Hosseinpoor et al., 2006). 
In this thesis inequalities refer to “the observed differences in health status 
between groups” (Blakely & Simmers, 2011).  Inequities are defined as: 
“... differences which are unnecessary and avoidable, but in 
addition are considered unfair and unjust.  So, in order to 
describe a certain situation as inequitable the cause has to 
be examined and judged to be unfair in the context of what 
is going on in the rest of society” (Whitehead, 1992).  
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Elements of health differences include social determinants of health such as 
income, housing conditions and social networks, alongside other factors such 
as ‘natural, biological variation’ (Marmot, 2005; Whitehead, 1992) which may 
also (but not always) contribute to the development of health inequalities 
and inequities. 
British authority was later transferred to the NZ Parliament and while Te 
Tiriti is recognised by the NZ Government as evidenced in legislation such as 
the Treaty of Waitangi Act 1995 it appears to be absent from social policy 
legislation (Durie, 1994; Government., 2016).  Consequently Te Tiriti is the 
only mechanism in NZ that Māori are able to call on to ensure their rights as 
the indigenous people of Aotearoa/NZ are being upheld.  Māori have a right 
to equitable health outcomes (Robson & Harris, 2007), and it is particularly 
important that cancer inequalities between Māori and non-Māori are 
addressed.  On the international stage the World Health Organization 
encourages member states such as NZ to recognise the rights of indigenous 
people (including Māori) to high standards of health. 
Any study involving Māori decision-making must consider the cultural 
context.  Durie (1994) describes how pre-colonisation, Māori had well 
established systems for treating ill-health at the individual and population 
level while also being cognizant of the importance of social, environmental 
and spiritual elements pertaining to both the individual, whānau (extended 
family) and hapū (kinship group).  An important part of the Māori ‘public 
health’ system were Tohunga (traditional healers).  Tohunga led activities to 
remedy physical signs and symptom which were often considered 
manifestations of spiritual imbalance (Leske, 2007; Voyce, 1989).  Traditional 
methods of healing at the individual level often involved rongoā (herbal 
medicines), karakia (prayer), mirimiri (massage) and wai (water) (Cram et 
al., 2003; Durie, 1994; Institute of Environmental Science and Research Ltd, 
2008).  In part due to colonisation, Māori people now largely access health 
care services from the New Zealand health care system which is founded on 
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Western medical philosophy.  Although Tohunga have become scarce in 
modern times, traditional healing practices continue. 
While people who form the different iwi groups in Aotearoa/NZ are 
collectively referred to as Māori this is also where any sense of ‘sameness’ 
ceases.  As Durie (1994) notes “Māori live in diverse cultural worlds.  There is 
no one reality nor is there any longer a single definition which will encompass 
the range of Māori life-styles” (pg.214).  Although Māori vary greatly in terms 
of their diversity, they are still Māori, and Durie (1994) reminds us of the 
relevance of culture to illness and treatment.  Based on an examination of 
medical practice and hospital procedures pre-1994 he concluded that 
“cultural heritage continued to shape ideas, attitudes, and reactions, 
particularly at times of illness” for Māori patients (pg. 68). 
When exploring decision-making in cancer consultations with Māori patients, 
it is important that it is inclusive of the whānau [family] context.  In 2014 the 
Ministry of Health re-released He Korowai Oranga (Māori Health Strategy), 
which provides the framework for achieving the best health outcomes for 
Māori (Ministry of Health, 2014b).  The strategy emphasises whānau ora 
(healthy families) and mauri ora (healthy individuals) as two of three key 
elements which contribute to pae ora (healthy futures for Māori).   
Recognition of whānau and a focus on whānau as a whole rather than 
individual family members has been emphasised more recently by the 
Whānau Ora approach led by Te Puni Kōkiri (Te Puni Kokiri, 2010) which 
now provides the main policy direction for health and social services in NZ 
(Provost, 2015).  With a focus on building and strengthening capability 
within families together with addressing health care needs at the family level, 
Whānau Ora offers a unique opportunity for NZ to provide global leadership 
on how health services can be jointly improved for everyone and reduce 
health inequities. 
Therefore, in the context of this thesis, individual patients and whānau are 
recognised as inter-connected and therefore collectively able to influence 
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cancer treatment decision-making.  Recognising the diversity between 
patients and whānau means the ways in which decision-making occurs may 
vary. 
When studying Māori decision-making it is important to understand the 
foundations upon which this may occur.  Democratic voting for example was 
introduced into NZ as part of the colonisation process and continues to 
underpin many societal level approaches to decision-making.  Shaw’s (2011) 
study of democratic decision making describes how Māori decision-making, 
referred to as “deliberative decision-making without democracy”, is at odds 
with Western based democratic decision-making (Shaw, 2011).  The 
Kīngitanga (Māori King Movement) where decision-making occurs via 
rūnanga (assembly discussion) with tribal members seemingly aligns with 
deliberative non-democratic decision-making.  In contrast the Ngāti Porou 
(East Coast Tribal grouping) Rūnanga recently held an election for Rohenga 
Tīpuna (marae and hapū clusters) representatives involving a democratic 
voting process (Te Runanga o Ngati Porou, 2015). 
Policy and programme context  
In response to the growing burden of cancer and the emergence of medical 
treatment able to improve patient outcomes, NZ like many other ‘Western’ 
countries has developed cancer control policy, plans and strategies the first 
of which was launched in 2003 by the Minister of Health (Minister of Health, 
2003).  The Cancer Control Strategy’s objective of reducing the impact and 
incidence of cancer also linked clearly to the NZ Health Strategy (King, 2000).  
Cancer strategies aim to reduce cancer incidence, morbidity and mortality 
across the cancer spectrum and involve activities in the following areas: 
primary prevention, screening and early diagnosis, treatment and symptom 
control, rehabilitation and support, and palliative care. 
Cancer has been prioritised by the NZ Government over the past few years.  
This is evidenced by the investment of resources to improve outcomes 
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through the delivery of higher quality services and care to people 
experiencing cancer (King, 2000, 2001; Minister of Health, 2003).  The more 
recent programme of cancer related activities for government agencies is 
centred on a strategic framework for action contained in the NZ Cancer Plan 
2015-2018 (NZ Cancer Plan) (Ministry of Health, 2014c).  The framework has 
a focus on equity and requires, amongst other things, that all people, have 
timely access to high-quality cancer treatment. 
The NZ Cancer Plan acknowledges that the impact of cancer is higher on 
Māori than the ‘general’ population and identifies He Korowai Oranga (Māori 
health strategy) as a guiding framework to improve outcomes for Māori 
(Ministry of Health, 2014b, 2014c).  An Equity of Health Care for Māori 
framework (Ministry of Health, 2014a) sits along-side He Korowai Oranga 
and provides direction across three domains: leadership, knowledge and 
commitment.  These domains are directed to three levels: the health system, 
health organisations and health practitioners, and contain practical strategies 
which can be implemented at each level to reduce health inequalities for 
Māori. 
Increasingly over the past decade, evidence of cancer treatment inequities 
has emerged (Hill, Sarfati, Blakely, Robson, Purdie, Chen, et al., 2010; Hill, 
Sarfati, Blakely, Robson, Purdie, Dennett, et al., 2010; Hill, Sarfati, Robson, & 
Blakely, 2013; Robson & Ellison-Loschmann, 2016; Seneviratne, Campbell, 
Scott, Shirley, Peni, et al., 2015).  Reducing treatment inequities is an 
important public health issue because they are essentially unfair and 
contribute to cancer deaths, an important factor to be considered in the 
multidimensional population approach required to improve outcomes.  
Additionally they breach the obligations to Māori under Te Tiriti.  Recent 
activities to improve the quality of treatment in New Zealand have been led 
by regional cancer networks, and the Ministry of Health (MoH), drawing on 
specialist knowledge within working groups (National Bowel Cancer Tumour 
Standards Working Group, 2013; National Breast Cancer Tumour Standards 
Working Group, 2013). 
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The MoH led ‘Faster Cancer Treatment Programme’ is another example of 
activities focused on improving quality of care.  The development of more 
than ten tumour standards is one example of a Faster Cancer Treatment 
Programme quality improvement activity (National Bowel Cancer Tumour 
Standards Working Group, 2013; National Breast Cancer Tumour Standards 
Working Group, 2013).  Those standards are to be implemented by District 
Health Boards (DHB) at a regional level, and are to commence with DHBs 
reviewing services against the standards and implementing improvement 
strategies.  Some improvement strategies are focused on equity issues and 
tailored to meet the specific needs of different population groups such as 
Māori who experience poorer outcomes.  Unfortunately, while DHBs are 
expected to implement the standards, they are not mandatory.  It is too soon 
to determine if the standards have been implemented as intended or if they 
will address cancer disparities experienced by Māori.  If Māori do not benefit 
from the tumour standards at the same rate or better than others there is the 
perverse potential for inequities to persist or increase rather than decrease. 
Internationally the United Nations (UN) and the World Health Organisation 
(WHO) have identified non-communicable diseases (of which cancer is a key 
one) as a major challenge and one that countries must act against to prevent, 
control and monitor (United Nations, 2012a, 2012b).  An example initiative is 
“The Commission on Social Determinants of Health” (The Commission) which 
was established by the WHO to support tackling avoidable health inequities 
and the social causes of ill health (Commission on Social Determinants of 
Health, 2008).  According to The Commission “health inequities are the result 
of a complex system operating at a global, national and local levels”.  
Furthermore the Commission suggests that attention be given to social 
factors as determinants of health inequities and country specific policy must 
be used to address those social factors that underlie the determinants of 





In 2012, 7969 of all deaths for non-Māori were from cancer (age 
standardized 116.5/100,000) compared to 936 Māori deaths (age 
standardized 199.4/100,000) (Ministry of Health, 2015a).  The difference in 
mortality rates between Māori and non-Māori is striking.  Leading sites of 
cancer mortality for Māori are lung, female breast, colorectal, prostate, 
stomach, pancreas and liver.  Lung cancer alone causes over 30% of all cancer 
deaths in Māori (Cormack, Purdie, & Robson, 2007; Robson, Purdie, & 
Cormack, 2010). 
Survival 
Māori adults have a greater risk of dying from cancer and poorer survival 
rates than non-Māori (Hill, Sarfati, Blakely, Robson, Purdie, Chen, et al., 2010; 
Jeffreys, Wright, t Mannetje, Huang, & Pearce, 2005; Robson et al., 2010; 
Signal et al., 2015; Stevens et al., 2008).  Additionally, for some cancers, Māori 
are more likely to be diagnosed later, with more advanced disease (Robson et 
al., 2010) and have a greater likelihood of metastatic disease (Stevens, 
Stevens, Kolbe, & Cox, 2007) than non-Māori.  Trends in cancer survival for 
the period 1991-2004 found Māori had poorer survival than non-Māori 
across 17 of 21 cancer sites and cancer mortality was on average 29% worse 
for Māori compared to non-Māori (Soeberg, 2012). 
Explanations for persistent ethnic cancer survival gaps between Māori and 
non-Māori may include: access to cancer screening and tumor biology (for 
example in breast cancer) (McKenzie, Jeffreys, t Mannetje, & Pearce, 2008; 
Seneviratne, Campbell, Scott, Shirley, & Lawrenson, 2015; Seneviratne, 
Campbell, Scott, Shirley, Peni, et al., 2015), access to treatment influenced by 
increased prevalence of comorbidities such as cardiovascular and respiratory 
disease, all of which may impact on treatment outcomes, disease stage, 
diagnosis, prognosis and access to and co-ordination of cancer treatment 
services (Cormack, Robson, Purdie, Ratima, & Brown, 2005; Hill, Sarfati, 
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Blakely, Robson, Purdie, Chen, et al., 2010; Sarfati, Koczwara, & Jackson, 
2016; Signal et al., 2015; Stevens et al., 2008).  There is a dearth of knowledge 
about treatment decision-making in cancer consultations with Māori in NZ 
and with other indigenous peoples.  Similarly, there is a scarcity of 
information about the impact comorbidities may have on treatment decision-
making in cancer consultations.  As a result both factors should be 
investigated further to ascertain if they contribute to persistent ethnic 
survival gaps between Māori and non-Māori.  
Treatment inequities 
Treatment inequities between Māori and non-Māori are evident across the 
entire treatment spectrum including time to treatment, treatment approach 
and type of treatment (Stevens et al., 2008).  A recent study by Signal et al. 
(2015) found that Māori with stomach cancer had differential access to 
specialised surgical services for Māori compared to non-Māori (Signal et al., 
2015).  This study found Māori were less likely to be treated in a main centre 
(44% Māori vs 87% non-Māori), and were less likely to have their surgery 
performed by a specialist upper gastrointestinal surgeon (38% Māori vs 79% 
non-Māori).  The authors suggest these findings should be viewed cautiously 
due to the small sample size (n =335). 
Māori have also been found to receive less treatment than NZ Europeans.  A 
study comparing treatment of Māori and non-Māori with colon cancer found 
similar surgical treatment rates but Māori were less likely to receive adjuvant 
chemotherapy (Hill, Sarfati, Blakely, Robson, Purdie, Chen, et al., 2010).  Two 
NZ studies of lung cancer also found that Māori diagnosed with lung cancer 
are more likely to receive palliative rather than curative treatment than NZ 
Europeans (Christmas & Findlay, 2004; Stevens et al., 2008).  Adjusting for 
disease characteristics and patient comorbidity did not account for the 
differences found in these studies. 
It is also concerning to note that although there have been improvements in 
cervical cancer incidence and mortality outcomes for Māori women 
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compared to non-Māori women, health inequities persist (Lawrenson et al., 
2016; Ministry of Health, 2015d).  Both breast and cervical cancer have good 
treatment options and are potentially curable if detected early.  Health 
providers in McLeod et al.’s (2011) cervical cancer inequities study suggest 
improved treatment standards have helped improve outcomes for Māori 
women but that further work is needed and suggest work focuses on 
improving service accessibility (McLeod et al., 2011). 
Comorbidity 
Comorbidity is the simultaneous existence of disease in addition to the 
disease of interest (Feinstein, 1970).  Māori with cancer experience higher 
rates of comorbidity and are more likely to have multiple comorbidities than 
non-Māori (Hill, Sarfati, Blakely, Robson, Purdie, Chen, et al., 2010; Hill, 
Sarfati, Blakely, Robson, Purdie, Dennett, et al., 2010; Sarfati, Tan, Blakely, & 
Pearce, 2011; Stevens et al., 2008).  Comorbidities have also been found to 
influence cancer survival disparities (Hill, Sarfati, Blakely, Robson, Purdie, 
Chen, et al., 2010; Hill, Sarfati, Blakely, Robson, Purdie, Dennett, et al., 2010; 
Stevens et al., 2008) although little is known about how this occurs for Māori. 
Comorbidities may increase the clinical complexity of treating cancer, 
resulting in less than optimal access to major treatments and reduced 
treatment effectiveness while also being an important influencing factor for 
survival from cancer (Extermann, 2000a, 2000b, 2007; Hong, Ambrosone, & 
Goodwin, 2015; Sarfati et al., 2016; Satariano & Silliman, 2003; Sogaard et al., 
2013).  The Institute of Medicine’s (2013) report on delivering high quality 
cancer care indicates that specialists are not well skilled to manage patients 
comorbidities which may have an adverse effect on patient outcomes 
(Institute of Medicine, 2013). 
Comorbidities can affect survival in a range of ways.  Comorbidities may 
increase the physiological burden of disease on an individual and also 
indirectly affect treatment options, quality and effectiveness.  Comorbidities 
may also influence the likelihood of an individual being offered active 
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treatment (Sarfati et al., 2009; Stevens et al., 2008).  For example, in a NZ 
study of patients with lung cancer, Stevens et al. (2008) found patients with a 
Charlson score (a measure of comorbidity, with higher scores indicating 
higher comorbidity) of two or more were about half as likely to be referred to 
cancer treatment as those with a score of zero. 
Recent studies suggest that those with comorbidity may be able to tolerate 
and benefit from advanced treatments (Hill, Sarfati, Blakely, Robson, Purdie, 
Chen, et al., 2010; Sarfati et al., 2009).  For example, a NZ study of people with 
advanced colon cancer (stage III) found that 84% of those with a Charlson 
score of zero were offered adjuvant chemotherapy compared with 19% of 
those with  score of three or more (Hill, Sarfati, Blakely, & Robson, 2009).  
Sarfarti et al.’s (2009) NZ based study found a 60% reduction in excess 
mortality for those with high levels of comorbidity when they received 
chemotherapy treatment (Sarfati et al., 2009).  This finding indicates that for 
some cancers the burden of comorbidity on cancer mortality may be 
modifiable. 
Māori models of health 
In response to frustrations with a health sector focused on biological 
dysfunction and a desire for perspectives which consider the person as a 
whole and interconnected (socially and ecologically), Māori models of health 
emerged from the 1970s (Durie, 1994; Ratima, 2001).  They did so alongside 
other holistic and integrative indigenous models which also began to develop 
worldwide (Chino & Debruyn, 2006; First Nations Health Authority, 2014).  
Te Whare Tapa Whā (a four sided house) is possibly the most well-known 
Māori model of health (Durie, 1994).  This model is holistic in its approach 
and consists of four dimensions of health: taha wairua (spiritual side), taha 
hinengaro (mental side), taha tinana (physical side) and taha whānau 
(extended family side).  This model also seeks to emphasise traditional 
beliefs while remaining mindful of Western medicine.  Pere’s Te Wheke (the 
octopus) model of health focuses more on the family health perspective 
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(Ministry of Health, 2016) and incorporates similar domains to Te Whare 
Tapa Whā while adding additional dimensions such as mana ake (uniqueness 
of the individual, family and positive identity). There are also many which 
have been developed in the service delivery, mental health and policy areas 
(Durie, 1994; Ministry of Health, 2016; Pitama, Huria, & Lacey, 2014; Ratima, 
2001; Te Rau Matatini, 2015). 
The Waikare o te Waka o Meihana model (an indigenous framework) has 
arisen more recently to guide the training of new medical personnel in 
undertaking effective clinical assessments with Māori patients and whānau 
(Pitama et al., 2014).  Māori models of health enable Māori to define the 
direction and exert control over understandings of Māori health.  Māori 
models also provide a comprehensive approach to the range of responses 
needed in order to improve Māori health outcomes. 
Astutely in 1994, Durie identified “…a lack of shared decision-making and 
limited recognition of Māori views” as one reason for Māori experiencing a 
sense of alienation and strained relationships with health professionals (pg. 
74).  In response, increasing numbers of organisational policy statements 
address culturally appropriate and holistic care by incorporating models 
such as Te Whare Tapa Whā and the Meihana models (Pitama et al., 2014) 
into training and practice. 
The consultation  
The primary purpose of the consultation following a cancer diagnosis is to 
provide an opportunity for specialists, patients and family members to come 
together to discuss the disease (symptoms, diagnosis), impact of the 
diagnosis and management/treatment options.  Participants give and obtain 
information, which provides an opportunity for concerns to be aired.  
Consultations are also the place where specialists, patients and family 
members establish a relationship (Ministry of Health, 2010a). 
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The body of cancer consultation literature reveals that attention has largely 
focused on describing what occurs (communication, patient participation, 
decision-making, interactions) in the consultation (Brown et al., 2012; Gaston 
& Mitchell, 2005; Kunneman et al., 2016; Laidsaar-Powell et al., 2013; Scott, 
Entwistle, Sowden, & Watt, 2001; Shepherd, Tattersall, & Butow, 2007).  In 
more recent times there has been a growing focus on interventions (e.g. 
communication training for specialists, patient aids) to improve the quality of 
consultations (Bernhard et al., 2012; Hacking et al., 2013; Kamal et al., 2011).  
While these studies provide insight and information useful for designing 
models of best practice for example, few studies attend to different cultural 
groups as part of their methodology or in their analysis.  For example, Leppin 
et al.’s (2015) study into decision status concordance between patients and 
clinicians only included 3.1% non-white participants (Leppin et al., 2015).  
While the Arora et al. (2009) study of physician decision-making styles and 
patient psychological outcome had a greater proportion (26.2%) of study 
participants who identified as minorities, there did not appear to contain any 
analysis to demonstrate if there were similarities or differences between 
racial groups (Arora, Weaver, Clayman, Oakley-Girvan, & Potosky, 2009). 
The lack of research in the cancer field inclusive of or centred on indigenous 
and racial and ethnic minority people, such as Māori is noted.  The lack of 
cancer research on groups other than the ‘general population’ is also relevant 
for those with differing education levels, English as a second language or 
through having a disability - all of whom have the right to good care.  While 
the generalisability of these findings as they apply to other population 
groupings is largely unknown, it is nonetheless important to emphasise the 
need for improved approaches to the quality and interaction exchange within 
consultations. 
Approaches to care 
The past twenty or so years have seen a move away from paternalistic 
approaches (where specialists assume authority) (K. Taylor, 2009), to 
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patient-centred care (Epstein & Street, 2007).  The Institute of Medicine 
defines patient-centered care as: "Providing care that is respectful of and 
responsive to individual patient preferences, needs, and values, and ensuring 
that patient values guide all clinical decisions” (Institute of Medicine, 2001).   
An international study by Stewart (2001, p 445) involving clinicians and 
patients has described patient-centred care as care which: 
(a) explores patients’ main reasons for the visit, concerns, 
and need for information; (b) seeks an integrated 
understanding of patients worlds – that is, their whole 
person, emotional needs, and life issues; (c) finds common 
ground on what the patients problem is and mutually 
agrees on management; (d) enhances prevention and 
health promotion; and (e) enhances the continuing 
relationship between the patient and the doctor.  
Mead and Bower (2000) identify five key dimensions of patient-centred care 
that have synergies with Stewart’s (2001) description.  The five dimensions 
are; the biopsychosocial perspective, ‘patient-as-person’, sharing power and 
responsibility, therapeutic alliance, and ‘doctor-as-person’ (N. Mead & Bower, 
2000).  More recent literature suggests cultural safety and cultural 
competence are key and underpin effective patient-centred care when 
considering the context of indigenous people (Ellison-Loschmann & Pearce, 
2006; Lacey, Huria, Beckert, Gilles, & Pitama, 2011; Nguyen, 2008).  Cultural 
safety and culturally competent health practitioners are important as the 
culture of indigenous people accessing healthcare is often different to 
Western culture dominated systems.  Difficulties experienced by indigenous 
people may be overcome when doctors recognise cultural diversity, and 
acknowledge how their own culture and views may impact on the patient 
interaction.  A positive outcome can occur when both parties have mutual 
respect for each other (New Zealand Medical Council, 2013) . 
In the NZ context, legislation such as the Health Practitioners Competency 
Assurance Act (Government., 2003), the Medical Council guide for Conduct 
(Legislative and Ethical Standards and Guidelines) (New Zealand Medical 
Council, 2013) and Practice and Patient Code of Rights (Health and Disability 
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Commissioner, 1996) identify requirements important to patient-centred 
care and cultural competence.  It is also important to note however, that 
cultural safety is different to other models which focus primarily on 
culturally sensitive or competent care (Leininger, 1996; Theunissen, 2011; 
Wilson & Barton, 2012) in two key respects.  The first is with regard to the 
definition of ‘culture’, which in cultural safety encompasses any differences 
between the health professional and the patient including gender, religion, 
politics, sexuality, age and culture.  The second major difference is that 
cultural safety overtly seeks to address the power imbalance which may 
affect the one-to-one interactions between health professionals and their 
patients.  This is done through the training programmes of health 
professionals (which simultaneously also effect structural changes through 
education) whereby students are exposed (many for the first time in any of 
their education experience) to the history of colonisation and its effects on 
the health of Māori, in order to provide relevant context for how these effects 
continue to have impact today (Ramsden, 1997). 
Treatment decision-making in the cancer context 
Cancer treatment decision-making can be complex and is a key component of 
consultations involving patients, specialists and in many instances family, 
following the receipt of a cancer diagnosis (Doherty & Associates, 2006; E. L. 
Mead et al., 2013; Noble-Adams, 2012; Obeidat, Homish, & Lally, 2013; 
Pardon et al., 2010; Tranberg et al., 2015).  Often cancer patients have many, 
rather than just one, decision to make in consultations (Mendick, Young, 
Holcombe, & Salmon, 2010) ranging from disease profiling and tests to 
inform treatment planning, through to participation in clinical trials, all of 
which add to the decision-making ‘burden’.  Patient-centred care requires 
patient values and preferences to be considered in addition to biomedical 




Over the past two decades patient participation in treatment decision-
making with specialists has increased (Chewning et al., 2012).  Over a similar 
period, significant advances in cancer treatments have occurred, some 
offering control and others cure, with an overall increase in the numbers of 
people who are now cancer ‘survivors’ (DeSantis et al., 2014).  
Correspondingly, there are also many more people who are having to 
participate in often complex treatment decision-making (DeSantis et al., 
2014). 
Prior to the consultation, patients in many instances have already made 
many decisions regarding screening, symptoms and diagnostic procedures 
(e.g. biopsy and scans), some of which may have involved partners and 
family.  Diagnostic procedures will, in most instances, have been determined 
in collaboration with a general practitioner (GP) or specialist.  Initial 
discussions about treatment options are also likely to have begun with health 
professionals (e.g. nurses, physicians, surgeons, radiologists) and family and 
friends prior to the consultation. 
To determine best patient outcomes, information is required on a range of 
factors including the cancer (for example: size, location, genetic profile, 
hormonal status), the evidence base for treatment options, patient and family 
(health, comorbidities, values, preferences), treatment benefit (for example: 
tumour reduction or elimination), treatment risks (for example: short or long 
term heart damage), acute and long term side-effects and quality of life 
(Cancer Society of New Zealand, 2016; National Bowel Cancer Tumour 
Standards Working Group, 2013; National Breast Cancer Tumour Standards 
Working Group, 2013; Reyna, Nelson, Han, & Pignone, 2015).  Patients and 
family may be offered one or a number of treatment possibilities with more 
than one treatment pathway to consider, including the option of deferring or 
doing nothing (Whitney et al., 2008).  Each different cancer pathway has its 
own set of possible therapeutic effects and side effects to consider.  Utilising a 
breast cancer scenario, potential possibilities might include choosing 
between treatments with similar outcomes (e.g. breast conserving surgery vs 
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mastectomy) or choosing which combination of treatment to have (e.g. 
chemotherapy and hormone therapy combined or chemotherapy alone).  In 
addition patients and family may be asked to consider the order of 
treatments (e.g. chemotherapy followed by surgery or vice versa), all the 
while recognising they may also choose surveillance (watchful waiting) or to 
opt-out of treatment entirely. 
For patients with metastatic, recurrent or terminal disease, additional factors 
may also be considered when making treatment decisions.  Such factors may 
include how aggressively to treat the cancer and deciding to continue with or 
to stop treatment.  Adopting a palliative care approach focused on 
maximising quality of remaining life is another option that might be 
considered in such circumstances. 
The number and type of participants present in cancer consultations where 
treatment decision-making occurs is also increasing.  At a minimum, the 
specialist and patient are present and this dyad (two participants) is 
commonly the focus of research.  And, although often present with roles that 
influence care and decision-making, family members or important others 
attending consultations have only recently begun to be considered by 
researchers exploring activities occurring in consultations such as 
communication (Laidsaar-Powell et al., 2013).  In recognition of the roles 
family can play Johnson et al. (2009) propose a family and patient approach 
to care in which family are considered a member of the ‘health care team’ 
rather than a ‘visitor’ (B. H. Johnson, Abraham, & Shelton, 2009).  In addition, 
cancer nurse specialists are increasingly participants in cancer consultations 
and demand for their services grows as the number of patients increase and 
policy directions change (Ministry of Health, 2007).  To date, there appears to 
be a paucity of NZ literature on the influence they have on the consultation 
and decision-making in particular, and there is very little work 
internationally which has focused on this area (Holloway, Baker, & Lumby, 
2009; McCullough, McKinlay, Barthow, Moss, & Wise, 2010; McKinlay, 2001; 
Neufeld, Degner, & Dick, 1993). 
21 
 
Decision aids have evolved in many countries to enable quality decision-
making in complex circumstances (International Patient Decision Aid 
Standards Collaboration, 2016; Stacey et al., 2014).  Evidence based 
information is provided to patients using decision aids when there are 
preference sensitive treatment options to make (Adsul et al., 2015; Nicholas, 
Butow, Tesson, & Boyle, 2016).  Decision aids take different forms and may 
be web based or may involve videos and pamphlets.  Most often they are 
given to patients prior to the consultation and provide balanced information 
about the differing treatment options, their harms and benefits (Stiggelbout 
et al., 2012). 
Research outline 
This thesis is divided into five chapters plus appendices.  Chapter one has 
introduced and outlined the thesis.  This chapter has also presented 
background information regarding cancer inequities experienced by Māori 
along with strategic, policy and service developments relevant to cancer in 
NZ.  An overview of consultations, approaches to care and treatment 
decision-making in the cancer context is also provided.  Chapter two provides 
a critical review of the relevant literature pertaining to cancer consultations 
and decision-making by specialists, Māori, other indigenous people and racial 
and ethnic minority populations.  Attention is paid to the role of participants 
including specialists, patients and whānau; communication; and decision-
making approaches and models.  Chapter three describes the methodological 
approach and methods utilised in this study to collect and analyse data.  It 
outlines the Māori Centred Research methodology (Cunningham, 2000; 
Foster, 2003) which requires Māori participation, a Māori focus and tangible 
benefits for Māori that will result from the research.  Chapter four presents 
the findings of the research for each of the five cases included in the study.  
Chapter five provides a discussion of the study’s key findings in relation to 
the literature on this topic, identifies the strengths and limitations of this 
study and discusses the potential implications of this study on policy and 
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Chapter two - Literature review 
This chapter presents a narrative literature review examining factors that 
influence cancer treatment decision-making in consultations involving 
medical specialists and Māori patients and whānau.  A secondary area of 
interest explored was how comorbidity influences treatment decision-
making in consultations involving specialists, Māori and whānau.  An initial 
review found 
 No studies which examined factors influencing treatment decision-
making in cancer consultations involving specialists, Māori patients 
and whānau. 
 No studies which examined how comorbidity influences treatment 
decision-making in cancer consultations involving specialists, Māori 
patients and whānau. 
 A paucity of studies which examined factors influencing cancer 
treatment decision-making in the consultation setting with specialists 
and indigenous people. 
Therefore, the review was broadened to include published literature 
examining factors influencing cancer treatment decision-making in 
indigenous populations, racial and ethnic minority groups from non-Western 
countries (e.g. Asia and the Middle East), not limited to the consultation 
setting.  Literature was also reviewed to identify factors which influence 
specialists’ cancer treatment decision-making.  The aims of the literature 
review were to: 
1. Describe decision-making in cancer consultation literature and 




2. Identify factors (including comorbidity) which influence cancer 
treatment decision-making by indigenous people and racial/ethnic 
minority patients. 
3. Identify factors (including comorbidity) which influence specialists’ 
treatment decision-making in cancer consultations. 
Literature sources 
Studies were identified using a search of electronic databases, including 
Medline (OvidSP), CINAHL, Cochrane and Google Scholar.  Studies that 
reported the findings of original research which met the following criteria 
were included in this review: (i) published from 1972 to 2016, in the English 
language, and in peer-reviewed journals, (ii) investigated cancer treatment 
decision-making in indigenous, racial and ethnic minority populations and 
treatment decision-making by specialists.  Systematic reviews undertaken 
overseas as well as studies and information sources using NZ literature were 
sought.  The reference list of retrieved articles was hand-searched and advice 
sought from experts in the field. 
Broad search terms were used to ensure all relevant articles were identified.  
Databases were searched with combinations of terms and variations of the 
following: ‘decision-making’, ‘neoplasm’, ‘cancer’, ‘consult*’, ‘Māori’, 
‘indigenous’, ‘aboriginal’, ‘ethnic’, ‘minority’, ‘clinician’, ‘specialist’, ‘physician’ 
‘oncologist’ and ‘surgeon’.  Studies were categorised and findings synthesised 
using narrative summary.  Cancer was a prerequisite for inclusion of a study 
but it could also contain other conditions e.g. lung cancer and COPD. 
Grey literature, not identified in the searches above, was sourced from NZ 
and international organisations.  Unpublished literature was accessed via the 
Internet through searches of organisational websites using the Google 
platform.  Search terms included ‘cancer treatment decision-making 




The majority of literature covered in this review was published in the past 15 
years, perhaps indicative of the growing focus on patient centred care and 
shared decision-making in Western medicine (Institute of Medicine, 2001; 
Legare, Ratte, Gravel, & Graham, 2008; E. L. Mead et al., 2013; Tzelepis et al., 
2014).  Doctors who provide care are referred to by many names in the 
literature, some common examples include: clinician, physician, surgeon, 
oncologist along with their area of specialty.  For ease of reading I mainly 
refer to them collectively as specialists in this review.  Similarly a range of 
people who attend consultations with patients are referred to in the 
literature in various ways including family, companion, caregiver, carer and 
spouse.  This group is mainly referred to collectively as ‘family’. 
Organisation of the literature review findings 
Examination of the studies revealed themes, which were then assigned to 
either the specialist or patient/whānau depending on whose decision-making 
was most influenced.  Two significant themes, decision-making approaches 
and models and communication overlapped considerably and are presented 
in dedicated sections. 
Section 1:  Decision-making in cancer consultations, approaches and models 
draws attention to studies that explore how these influence patients’ and 
specialists’ decision-making. 
Section 2:  Communication looks at how this influences decision-making by 
specialists and patients. 
Section 3:  Factors influencing patients’ decision-making explores specialist, 
whānau/family, patient and medical factors (comorbidity, disease and 
treatment). 
Section 4:  Factors influencing specialists’ decision-making explores patient, 
medical (including comorbidity, disease and treatment), specialists and 
setting/system factors.  
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Section 1:  Decision-making in cancer consultations, 
approaches, models and styles  
Decision-making in cancer consultations 
Decision-making in cancer consultations has largely been studied from 
perspectives of: communication (Hagerty, Butow, Ellis, Dimitry, & Tattersall, 
2005; M. Johnson, 2012; Tariman, Berry, Cochrane, Doorenbos, & Schepp, 
2012); information (Cavalli-Björkman, Glimelius, & Strang, 2012; Chouliara, 
Kearney, Stott, Molassiotis, & Miller, 2004; Eggly et al., 2006; Eggly et al., 
2013; Gaston & Mitchell, 2005; Hack et al., 2012; I. O'Brien, Lambie, & Stacy-
Baynes, 2009; Puts, Papoutsis, Springall, & Tourangeau, 2012); and decision-
making (Back & Huak, 2005; Cordella, 2011; Denberg, Melhado, & Steiner, 
2006; Dovidio & Fiske, 2012; El Turabi, Abel, Roland, & Lyratzopoulos, 2013; 
Elwyn & Miron-Shatz, 2010; Entwistle & Watt, 2006; Gaston & Mitchell, 2005; 
Guadagnoli & Ward, 1998; Joseph-Williams, Elwyn, & Edwards, 2014; 
Kimball et al., 2013; Laidsaar-Powell et al., 2013; Mendick et al., 2010; 
Mendick, Young, Holcombe, & Salmon, 2011; Salmon, Mendick, & Young, 
2011; Shepherd, Tattersall, & Butow, 2008; van Ryn et al., 2011).   Factors 
identified span across a range of levels including: systems, patients and 
specialists. Other bodies of work have focused on the components of 
decision-making models, definitions, characteristics, how to monitor and 
measure it and tools to aid or improve shared decision-making (Elwyn et al., 
2012; Legare et al., 2010; McCullough et al., 2010; Scholl et al., 2011; Siminoff 
& Step, 2005). 
A significant amount of decision-making in the cancer literature reviewed 
utilised qualitative methods to gather data including interviews, both semi-
structured and face to face, observations and consultation recordings, focus 
groups, scenarios and telephone interviews (Cavalli-Björkman et al., 2012; 
Chouliara, Miller, et al., 2004; Mendick et al., 2010, 2011; M. A. O'Brien et al., 
2013; Salmon et al., 2011).  Some quantitative data collection methods were 
also used such as surveys and questionnaires (Eggly et al., 2013; El Turabi et 
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al., 2013; Hagerty, Butow, Ellis, Lobb, et al., 2005; Shepherd et al., 2008).  
Common qualitative methods of analysis were also undertaken when 
examining the data, including: framework analsyis, inductive content 
analysis, constant comparison, cross case qualitative analysis, and some drew 
on discourse analysis, conversation analysis and interactional sociolinguistics 
(Cavalli-Björkman et al., 2012; Chouliara, Miller, et al., 2004; Cordella, 2011; 
Mendick et al., 2010; M. A. O'Brien et al., 2013; Salmon et al., 2011).  Some 
innovative techniques were also undertaken including specialists reviewing 
video of their consultations (M. A. O'Brien et al., 2013).  Perspectives of 
patients and specialists were commonly reported as they were most often the 
participants in the research, with family and other health professional’s 
involvement occurring less often (Chouliara, Miller, et al., 2004; Laidsaar-
Powell, Butow, Bu, Charles, et al., 2016; Laidsaar-Powell, Butow, Bu, Fisher, & 
Juraskova, 2016; McCullough et al., 2010; M. A. O'Brien et al., 2013; Shepherd 
et al., 2008). 
General limitations of the literature reviewed include a significant proportion 
of the literature stemmed from research involving a limited number of cancer 
types, commonly breast cancer.  Due to gender biases and treatment 
advances breast cancer may not be representative of all cancers.  Little 
literature involved family members, important others or other health 
professionals such as cancer nurse specialists.  Very little literature explored 
indigenous, racial or ethnic minority group perspectives.  Some studies have 
recognised this limitation and are currently exploring methods to enable this 
(Brown et al., 2011).  Given much of the literature regarding decision-making 
comes from the United States (Denberg et al., 2006; Puts et al., 2015) Canada 
(Hack et al., 2012; M. A. O'Brien et al., 2013) and the United Kingdom (El 
Turabi et al., 2013; Mendick et al., 2010, 2011; Salmon et al., 2011), 
generalisability and applicability to the NZ context requires careful 
consideration.  Only one NZ study was found which reported a model of 
treatment decision-making in the cancer context (McCullough et al., 2010).  
Additional understudied areas identified include cancers other than breast 
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and specialists’ cultural competency to undertake shared decision-making.  
Finally, and perhaps more important is the lack of research investigating 
system level issues that support and enable decision-making activities with 
the potential to address ethnic cancer inequities. 
Decision-making models, approaches and styles 
Over time there has been an increase in the use of decision-making theory 
and models in the literature.  From a psychological perspective Reyna et al. 
(2015) describe decision-making theory which includes classical, 
computational and psychophysical theory (Reyna et al., 2015).  Three key 
models of decision-making are commonly identified in the literature, 
paternalistic (specialist decides), shared (patient and specialist decide 
together) and informed decision-making (patient decides based on 
information provided) (Figure.1) (Charles, Gafni, & Whelan, 1997; Kon, 2010; 
Makoul & Clayman, 2006; Towle & Godolphin, 1999; Whitney et al., 2008).  
Key models largely focus on decision control.  Epstein and Street (2007) 
suggest three stages - information exchange, deliberation and making the 
final decision occur regardless of who has control (Epstein & Street, 2007).  
Evidenced based patient choice is a decision-making model referred to less 
often in the literature (Whitney et al., 2008). 
Disagreement is not uncommon in decision-making therefore one could 
suggest that when one treatment option has been offered by a specialist three 
decision outcomes are possible (Whitney et al., 2008).  The first decision-
outcome may occur when the patient and specialist make a consensus 
decision to accept a treatment option.  The second decision-outcome could be 
a non-consensus decision (when the patient rejects the option/s offered by 
the specialist).  The patient may or may not seek alternative options.  Thirdly, 
the patient may choose to defer decision-making. The first two decision 
outcomes mentioned align with decision types identified by Whitney et al.’s 
(2008) two dimensional decision-making model.  
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Figure 1:  Key models of decision-making. 
 
In the NZ context, once a specialist has completed specialty training there 
appears to be a greater focus on professional development in areas related to 
treatment rather than topics such as communication and shared decision-
making (A. Simpson, personal communication, 2014).  Although not well 
evaluated, shared decision-making training programmes for health 
professionals exist in many countries (Legare et al., 2012) however none 
were identified in NZ. 
Paternalistic decision-making 
In the paternalistic decision-making model, also known as the parental or 
priestly model, the specialist decides what treatment is best for the patient 
(Emanuel & Emanuel, 1992).  Within this model Emanuel and Emanuel 
(1992) describe how the specialist’s approach may vary and move between 
seeking a patient’s consent or, with a more authoritarian style, go so far as to 
inform the patient of the treatment that will be administered.  Specialists 
operating under this model are often portrayed as the patients ‘guardian’ of 
health, and patients accept the guardian’s treatment decision.  While not 
currently a favoured model of decision-making in the cancer field, it may be 
appropriate in other circumstances where timely treatment is critical such as 










Informed decision-making  
Informed decision-making appears to have grown from a desire to expand 
informed consent in decision-making to informed decision-making involving 
informed choice (where alternatives such as watchful waiting are disclosed).  
An aim of informed decision-making is to ensure meaningful conversation 
occurs between the patient and specialist rather than the specialist simply 
informing the patient of treatment risks, benefits and alternatives (Braddock, 
Edwards, Hasenberg, Laidley, & Levinson, 1999).  This model has similar 
elements to shared decision-making discussed further on, but applies in 
situations where there is only one medically indicated treatment option. 
Several approaches have been developed to measure informed decision-
making (Braddock et al., 1999; Roter & Larson, 2002; Street & Gordon, 2006).  
Most approaches have evolved out of the United States using differing 
conceptual frameworks involving theories, patient participation, 
communication behaviors and informed consent.  The methods used to 
assess informed decision-making capture both patient and physician 
elements and differ in complexity from 41 categories in the Roter 
Interactional Analysis System (a method of coding dialogue), to five in the 
Street Coding Method (Roter & Larson, 2002; Street & Gordon, 2006). 
An Australian study of informed decision-making by 118 cancer patients with 
incurable disease found that while most were informed about treatment 
aims, less than half were informed about alternatives and a third were 
offered a treatment choice (Gattellari, Voigt, Butow, & Tattersall, 2002).  
More informed patients might be expected to make treatment choices aligned 
to best care.  However this may not always be the case.  In a prospective 
observational cohort study approximately one third of female newly 
diagnosed breast cancer patients with high knowledge scores chose 
mastectomy over breast conserving surgery despite an association with 
equivalent outcomes (Collins et al., 2009; Lantz, Zemencuk, & Katz, 2002).  
Informed decision-making cancer literature largely refers to the screening 
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context (Mullen et al., 2006).  This may indicate a gap in the literature or that 
informed decision-making is less common in the cancer treatment context. 
Shared decision-making 
‘Shared decision-making’ is a term commonly used in the 21st century to 
describe a largely Western based decision-making model particularly attuned 
to those interested in providing patient-centred care (Barry & Edgman-
Levitan, 2012).  Shared decision-making sits on the decision-making 
spectrum between the paternalistic and informed models (Charles et al., 
1997; Makoul & Clayman, 2006) (Figure 1).  Shared decision-making can 
engender patients to express tino rangatiratanga (self-determination) with 
regard to their health and well-being and has the potential for family to 
participate in a meaningful way.  Although there does not appear to be one 
internationally agreed definition of shared decision-making, it has been 
described as a model of decision-making that aligns to ethical principles, 
takes a patient-centred approach (Barry & Edgman-Levitan, 2012) and aims 
for decision-making that corresponds with patients wishes (Barton et al., 
1996; Charles et al., 1997; Kon, 2010; Makoul & Clayman, 2006).  According 
to Barry and Edgman-Levitan (2012, p. 780), shared decision-making is 
considered “the Pinnacle of Patient-Centred Care” due to its patient-centred 
approach where patient values and preferences are considered paramount. 
Despite shared decision-making’s growing popularity dissent remains 
regarding its applicability when the specialist presents only one treatment 
option.  Charles et al. (1997) propose that several treatment options are 
required to undertake shared decision-making (Charles et al., 1997), 
however, patient-centred approaches to care would suggest the process of 
shared decision-making itself is of utmost importance rather than the 
number of options available or decisions made. 
Literature on shared decision-making has grown exponentially since the 
1990s (Blanc et al., 2014; Makoul & Clayman, 2006), seemingly in parallel to 
a time when many Western countries were moving towards greater 
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recognition of patient rights and autonomy.  NZ for example established 
Patient Rights and enacted the Health and Disability Commissioner Act in 
1994 (Health and Disability Commissioner, 1996), while in the United 
Kingdom (UK) there are an increasing number of shared decision-making 
reports and publications (Coulter, 2009; Coulter & Collins, 2011; Elwyn et al., 
2010).  The UK National Health Service has also established a website 
dedicated to shared decision-making for patients and health professionals as 
part of a ‘Right Care Shared Decision-Making Programme’ which aims to, 
among other things, promote patient-centred care as part of a Quality 
Improvement Programme (National Health Service, 2016).  Internationally, 
participants from 18 countries attended the Salzburg Global Seminar to 
consider the role patients can and should play in healthcare decisions and 
produced a statement in which clinicians are said to have an ethical 
imperative to share important decision-making with patients, and that 
patients have a right to participate equally in their care (Salzburg Global 
Seminar, 2011). 
Despite the lack of consensus about characteristics which contribute to 
optimal shared decision-making (Brown et al., 2011), common themes are 
identifiable.  Firstly, it involves at least two participants including the patient 
and specialist (but may also include family, friends and the wider health care 
team).  Secondly, information is shared between the parties involved, with 
the specialist offering option/s and descriptions of benefit/s and risk/s.  
Thirdly, discussion occurs which may involve the patient expressing values 
and preferences, and building agreement about the preferred treatment.  
Finally, a decision is made about which treatment to proceed with (Barry & 
Edgman-Levitan, 2012; Charles et al., 1997).  Opinions vary about whether 
the decision has to be mutually agreed (Charles et al., 1997; Legare et al., 
2008; Makoul & Clayman, 2006). 
Recognising that decision-making may take different forms in different 
situations, Kon (2010) describes a version of shared decision-making which 
encompasses models previously discussed and suggests they exist on a 
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“shared decision-making continuum” (Kon, 2010).  This two dimensional 
shared decision-making continuum, involves a patient-specialist dyad and 
considers both who is driving the decision and who is taking responsibility.  
The goal of this model is for patient desires to drive decision-making which in 
turn will determine where they will sit on the spectrum.  How realistic 
achieving this goal is in treatment decision-making consultations given time 
constraints, complex decision making compounded by comorbidities and a 
power dynamic that sits with the specialists is questionable. 
In NZ, the New Zealand Medical Association and Medical Council (NZMC) 
(New Zealand Medical Council, 2013) advocate for the shared decision-
making model.  The NZMC gives clear instructions about the need for 
informed choice and consent which requires practitioners to undertake 
activities such as explaining to the patient his or her condition, options 
available and expected risks (New Zealand Medical Council, 2013).  These 
essential elements align to both shared and informed decision-making. 
Knowledge produced from shared decision-making research to date 
primarily privileges non-indigenous, white and racial majority groups, as is 
evidenced by the scarcity of literature reporting inclusivity of minority or 
racial groups in comparison to others (E. L. Mead et al., 2013).  Given cancer 
disparities experienced by indigenous populations, a greater comorbidity 
burden and the need for culturally safe patient-centred care it is essential 
that specialists facilitate patient involvement in shared treatment decision-
making that meets the needs of these populations (E. L. Mead et al., 2013). 
Decision-making styles 
Some studies have investigated factors that influence patients’ and 
specialists’ decision-making styles (Kaplan, Greenfield, Gandek, Rogers, & 
Ware, 1996; Weber, Solomon, & Meyer, 2013).  A large survey involving 
patients and physicians by Kaplan et al. (1996) assessed personal 
characteristics associated with the likelihood of specialists involving patients 
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in diagnostic and treatment decision-making.  This study found specialists’ 
background, training, professional autonomy and practice volume influenced 
their decision-making style (Kaplan et al., 1996).  More recent models have 
arisen, some due to perceived limitations with the Kaplan model and others 
which attempt to take a more holistic picture (Arora et al., 2009; Halkett, 
Arbon, Scutter, & Borg, 2005).  Halkett et al.’s (2005) qualitative study 
involving women who had received treatment for breast cancer suggests 
specialists are influenced by factors such as “the perceptions and expectation 
that they have of the women, their personal treatment preference, informed 
consent, their background training and knowledge of guidelines and protocols, 
and multidisciplinary clinics” (p. 250).  Arora et al.’s (2009) survey involving 
623 cancer survivors determined specialists’ decision-making styles by 
ascertaining information from patients about their interaction with the 
specialist, which were then linked with patient outcomes such as quality of 
life (Arora et al., 2009). 
While there have been many studies which attend to patients’ preferences for 
ultimately making the final decision (Arora & McHorney, 2000; Degner & 
Sloan, 1992; Hawley et al., 2007; Weber et al., 2013), less attention has been 
given to their decision-making styles.  Of those studies which considered 
decision-making style, Pierce (1993) identified three decision-making styles 
among a group of patients with breast cancer.  Firstly, ‘the deferrer’ (patient 
defers decision-making to another); secondly, ‘the delayer’ (patient delays 
decision-making until a clear preference is ascertained); and thirdly, ‘the 
deliberator’ (patient purposefully takes personal responsibility for making a 
quality decision) (Pierce, 1993). Pierce (1993) determined  participants’ 
styles by considering  patients’ perceptions of treatment options, how they 
coped with decisional conflict, how they engaged in information seeking, how 
they assessed risks related to treatment options, and their deliberation of 
options (Pierce, 1993). 
Halkett et al.’s (2005) study mentioned previously developed a conceptual 
model of decision-making also involving women with early stage breast 
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cancer.  The nature and level of patient involvement in decision-making in 
this study was found to be influenced by seven key issues: information 
provided, reaction to diagnosis, previous knowledge of cancer, urgency, 
support people, body image and demographics (Halkett et al., 2005).  Finally, 
a recent qualitative study by Weber et al. (2013) involving largely Caucasian 
breast cancer survivors, identified five treatment decision-making styles: 
medical expert, self-efficacy, relationship embedded, inhibition, and 
constellation of information (Weber et al., 2013).  Styles were differentiated 
by low versus high information needs, and ‘self’ versus ‘other’ preferences.  
Weber et al.’s (2013) study demonstrates the evolution of thinking to include 
elements such as relationships (where decisions were influenced by loved 
ones), and constellation styles (involving several influences).  Pierce’s (1993) 
early work provides useful insight to factors which may influence patient 
decision-making, however it appears limited to the patient physician dyad 
with a clinical focus.  More recent studies in this field indicate that a broader 
range of factors may influence patient decision-making, and acknowledge the 
role family or important others play (Halkett et al., 2005; Weber et al., 2013). 
In summary, decision-making has been increasingly studied since the 1990s, 
using both qualitative and quantitative methods.  More recently thinking in 
this area has evolved in response to a greater drive towards patient 
autonomy and rights.  Common models of decision-making include, 
paternalistic, shared and informed decision-making with the patient and 
specialist having differing levels of control and autonomy.  A range of factors 
were found to influence specialists’ styles including training, knowledge and 
volume of patients seen.  In contrast patient styles were influenced by 
engagement, risk assessment, and more recent literature identified 
complexity and the role of family as influential. 
Section 2: Communication  
There is a very small body of literature pertaining to Māori and 
communication in the health domain.  From the literature it is clear that 
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effective communication is vitally important and can be challenging for 
different reasons.  Regardless of which stage of the cancer journey people are 
at, Māori patients and whānau value good communication (Cormack et al., 
2005; Doherty & Associates, 2006; T. Walker et al., 2008).  A number of 
communication factors were raised in Walker et al.’s (2008) qualitative study 
using focus groups and interviews with Māori cancer patients.  
Communication was identified as something which influences patients’ 
emotional experiences, determines how informed patients feel about their 
disease, and that treatment and can also influence the whānau experience.  
Good communication could be as simple as asking the patient what they want 
to know, and was associated with aiding recovery and sense of support.  
Health professionals who were not responsive to patients’ needs were more 
likely to be described as having poor communication similarly to those who 
were not forthcoming with information.  Poor communication may limit 
patient access to both knowledge and essential support systems.  For 
example, some people in this study reported using a range of tactics such as 
assertiveness to facilitate access to pain relief and basic care, while other 
patients found it difficult to know what questions to ask.  Information deficits 
can ultimately result in treatment decision regret (T. Walker et al., 2008). 
The context that communication about treatment decision-making occurs 
within also has the ability to influence decision-making.  Patients attending 
consultations to discuss treatment have all experienced a period of 
uncertainty regarding their ‘situation’ and are likely attending the 
consultation to seek answers and/or a plan of action (Slater et al., 2013).  The 
formal length of a consultation where treatment options are discussed in NZ 
is largely determined by hospital systems. Different specialties may also have 
different requirements, for instance medical oncology consultations are often 
scheduled for and take longer than radiation oncology consultations.  In the 
hospital setting, specialists have power, within system constraints, to 
influence the length of time consultations take. 
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Some participants in Slater et al..’s (2013, p. 311) qualitative study of Māori 
cancer patients’ and whānau experiences of health services identified that  
appointment times with specialists were ‘not long enough’ and reported the 
same experience occurring in the primary care setting.  These participants 
also noted that there was insufficient ‘space’ and opportunity to ask 
questions and that it was difficult to develop and maintain relationships with 
multiple health professionals.  The presence of comorbidities in addition to 
cancer may also increase the likelihood that more time is needed in 
consultations.  These issues can result in gaps in patient information and 
knowledge, thereby influencing their ability to access support - potentially 
important factors in decision-making. 
Information about cancer and treatment is often communicated, both 
verbally and in written form, to patients from a range of health professionals, 
including specialists and nurses pre and post consultations.  In the 
consultation setting patients receive information from the specialist, support 
people/whānau present and in some cases nurse specialists (Slater et al., 
2013; T. Walker et al., 2008).  Specialists may also have additional 
information to communicate to patients with comorbidity as a there is a 
greater risk of complexity regarding the diagnosis and treatment options.  
Other sources of information may include family, friends, colleagues, the 
internet (Dew et al., 2014) and Māori health providers (Slater et al., 2013; T. 
Walker et al., 2008).  For treatment decision-making it is important that 
information is consistent, meaningful, timely (Slater et al., 2013) and 
produced in such a way that patients are able to understand it (T. Walker et 
al., 2008). 
NZ’s  Ministry of Health (2010) defines health literacy as “the capacity to 
obtain, process and understand basic health information and services in order 
to make informed and appropriate health decisions” (Ministry of Health, 
2010b).  While the main focus of this definition is on the patient’s capability, 
it is clear that health literacy is important to treatment decision-making and 
thus more likely to be inclusive of both health care providers and patients.  
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Māori cancer patients with low health literacy may limit what information 
they share and want (Dew, Signal, et al., 2015).  A recent review of health 
literacy by the Ministry of Health indicates a shift from a patient focus to one 
inclusive of the health care system, providers and practitioners in supporting 
patient access and understanding of health services (Ministry of Health, 
2015b).  A health literacy action plan template contained within the review 
report to guide service and organisational action to improve health literacy, 
further signals the important role providers have. 
Who communicates information to patients is important, especially 
‘sensitive’ information such as diagnosis (Dew, Signal, et al., 2015; Slater et 
al., 2013; T. Walker et al., 2008).  Many patients prefer key information to be 
given by someone they trust, and ideally have an established relationship 
with.  When accessing specialist care however, many ‘sensitive’ 
conversations such as those regarding treatment, occur between patients and 
specialists who have only just met.  In Dew et al.’s (2015) qualitative study 
involving 19 Māori patients, poor patient experience with a ‘junior’ doctor’s 
communication of the patient diagnosis resulted in a negative patient 
experience.  Some patients prefer important information to be given by a 
senior doctor (Dew, Signal, et al., 2015).  Given the seriousness of a cancer 
diagnosis for patients, the desire for this information to be given by a senior 
doctor may provide patients with a greater sense of trust. 
Although there is a scarcity of literature that considers cultural influences on 
communication in consultations involving Māori specifically, there is some 
work which has been undertaken in other cancer settings.  For example, a NZ 
study of ideal communication behaviours in the palliative care setting 
identified important cultural issues (Oetzel, Simpson, Berryman, & Reddy, 
2015).  In this study, non-Māori palliative care workers and kaumātua 
(elder/s with status) focused on avoiding prejudice and cultural mistakes.  In 
contrast, whānau and Māori palliative care workers identified tikanga 
(correct procedure/custom) as important to upholding well-being and 
improving the quality of care (Oetzel, Simpson, Berryman, & Reddy, 2015). 
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A range of cultural concepts are identified in the literature as influencing 
communication between Māori and health professionals.  For example, Māori 
holistic models of care were found to be in conflict with hospital care models 
by some participants in Walker et al.’s (2008) study.  They described 
hospitals as only dealing with the physical and not the mental and spiritual 
elements of a person (T. Walker et al., 2008).  Whakama (to be ashamed/shy) 
is another important cultural concept which can influence communication 
between Māori and health professionals.  This can be further intensified for 
patients as often their concerns or issues are only able to be addressed by 
non-Māori health professionals who may lack the cultural competence to deal 
appropriately with the issue (Kidd, Gibbons, Kara, Blundell, & Berryman, 
2013).  Aroha (love/compassion) for the people is a key cultural concept that 
many Māori value (Durie, 1994; T. Walker et al., 2008).  How specialists 
communicate with patients and whānau is one vehicle for expressing their 
aroha.  It is important to understand cultural differences and important 
cultural values which may influence communication. 
Whether communication is affected by congruence between the ethnicity of 
patients and specialists is uncertain.  Some patients in Walker et al.’s (2008) 
study reported finding it easier to relate to health professionals who were 
Māori while the majority reported that the ‘qualities demonstrated’ were 
more important than ethnicity.  Similarly, a NZ qualitative palliative care 
study identified greater communication challenges when palliative care 
workers were of a different culture to patients (Bellamy & Gott, 2013). 
As mentioned earlier, whānau often attend consultations with their family 
member who are unwell and play an integral role in their cancer experience 
(Dew, Signal, et al., 2015; Slater et al., 2013; T. Walker et al., 2008).  Walker et 
al. (2008) identified that whānau often act as advocates and found 
communication between patients and health professionals improved when 
whānau members played a central liaison role with specialists.  Similarly the 
importance of whānau members aiding patients’ understanding of 
information and facilitating interactions with specialists was identified in 
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Slater et al.’s (2013) study of Māori patients access to and through cancer 
services (Slater et al., 2013).  In addition to the patient, whānau may be 
another valuable source of information on comorbidity and cancer in 
consultations. 
However, it is important to acknowledge that there may not always be 
concordance between what the patient wants and the views of whānau. 
Differing views may lead to tension and pressure in relation to treatment 
decision-making (Dew, Signal, et al., 2015).  Additionally whānau may be 
perceived as ‘difficult’ by some care workers (Oetzel, Simpson, Berryman, Iti, 
& Reddy, 2015).  The appointment of a whānau spokesperson is one strategy 
identified in the literature to manage communication in conflict situations 
involving multiple whānau members (Oetzel, Simpson, Berryman, Iti, et al., 
2015).  Ultimately it is imperative that specialists, and indeed all health 
professionals, recognise that whānau may be present throughout the whole 
cancer journey and beyond, regardless of the outcome, and that they are 
therefore critical to include in communication.  Being informed and 
connected to what is occurring with the ill whānau member enables whānau 
to carry out their role in a manner which maintains mana and protects 
patient dignity (e.g. avoiding misunderstandings).  Patients without whānau 
or other support systems may be disadvantaged as they lack the additional 
support around receiving and interpreting information about treatment and 
care.  Alternatively, they may seek support from other sources. 
Establishing rapport with patients in consultations is core to communication, 
and a key objective of specialists which aids the development of a 
relationship and connection with the patient.  Both Slater et al. (2013) and 
Lacey (2011) concur that developing rapport in face to face interactions with 
Māori is important (Lacey et al., 2011; Slater et al., 2013).  Key components of 
rapport identified by Māori include the doctors taking time to listen, using 
understandable language, taking an interest in whānau health history, and 
engaging with the patient to deliver a collaborative style of healthcare (Cram 
et al., 2003).  Health professionals and other health personnel (e.g. 
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receptionists) have not always established good rapport with Māori patients 
both in the cancer (T. Walker et al., 2008) and primary care fields 
(McCreanor & Nairn, 2002; Penney, Barnes, & McCreanor, 2011; Pitama, 
Ahuriri-Driscoll, Huria, Lacey, & Robertson, 2011).  Specialists able to 
establish rapport with Māori patients and whānau may then be better able to 
ascertain issues of concern and assist to resolve them (T. Walker et al., 2008). 
A number of key recommendations have been made by researchers to 
improve communication with Māori.  Oetzel et al. (2015) suggests one way 
for parties to enhance communication is by the different parties sharing and 
ascertaining their respective preferences (Oetzel, Simpson, Berryman, & 
Reddy, 2015).  Training health professionals to enhance their cultural 
competency skills is also identified by several studies (Lacey et al., 2011; 
Oetzel, Simpson, Berryman, & Reddy, 2015; Pitama et al., 2014; T. Walker et 
al., 2008).  The development of Māori specific resources and receipt of good 
information in different forms is also identified as a strategy to improve 
communication (Cormack et al., 2005; Slater et al., 2013; T. Walker et al., 
2008). 
In summary, good communication is vital to enabling informed and 
appropriate treatment decision-making.  Communication is influenced by 
many factors including time, system constraints and the ability to establish 
relationships and rapport.  Patient comorbidity may add further complexity 
to information communicated to patients in consultations.  Additionally it is 
important for specialists to be sufficiently trained to communicate with 
patients and whānau of different cultures. 
Section 3:  Factors influencing patient decision-making 
This section considers literature pertaining to factors that influence patient 
decision-making.  Māori models of health, outlined in chapter one, alongside 
Mead et al.’s (2013) conceptual model of shared decision-making (Figure 2) 
were drawn on to guide the presentation of literature in this section.  Mead’s 
42 
 
model was developed by refining major themes identified from a systematic 
literature review of racial/ethnic minority groups with cancer and shared 
decision-making (see figure 2).  Internationally, there is a small body of 
literature focused on factors that influence indigenous, racial and ethnic 
minority patient treatment decision-making.  The literature in this section is 
grouped into themes: whānau, specialist, patient and medical (including 
comorbidity), disease and treatment. 
Figure 2:  A conceptual model of influences on cancer treatment decision making 
among racial/ethnic and minority patients 
 Note:  (E. L. Mead et al., 2013, p. 19).  Permission to use this image was obtained from 
corresponding author – A. Morris by email, 10/1/2017.) 
Whānau  
Whānau are important in the cancer journey.  Their importance has been 
identified by a few recent qualitative studies investigating Māori experiences 
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of cancer (Dew, Signal, et al., 2015; Egan et al., 2016; Slater et al., 2013; T. 
Walker et al., 2008).  In these studies whānau are attributed with playing a 
multitude of largely supportive roles.  Slater et al.’s (2013) study of 
facilitators and inhibitors to cancer care access interviewed patients with a 
mixture of cancers and their whānau.  Their study found support was often 
provided by one key family member who themselves could find the role 
stressful.  A range of supportive roles and activities undertaken by whānau 
were identified across studies including: emotional support at appointments, 
transport, acquisition and interpretation of health information, and financial 
support (Egan et al., 2016; Slater et al., 2013; T. Walker et al., 2008). 
Similarly to Slater et al.’s (2013) study, another qualitative study of roles and 
Māori experiences of cancer care identified whānau as important in the 
patient journey and providers of support, both physically and cultural (Dew, 
Signal, et al., 2015).  Conversely however, whānau were also identified in this 
study as a potential source of tension regarding treatment particularly when 
whānau treatment preferences were in conflict with western medicine 
options on offer. For example, one whānau preferred traditional healing 
methods to chemotherapy and radiotherapy which were likened to 
“poisoning and burning your body”.  In this particular scenario the patient 
chose to compromise by accepting western medicine combined with some 
cultural healing practices like karakia (ritual chants, prayers) and aroha 
(love, concern, compassion) (Dew, Signal, et al., 2015). 
As mentioned, providing support for un-well whānau member can also be a 
burden.  The costs for whānau involved with caring for family with cancer 
were identified as significant in two studies, with some whānau incurring 
debt and even bankruptcy (Egan et al., 2016; Gott, Allen, Moeke-Maxwell, 
Gardiner, & Robinson, 2015).  Costs associated with the provision of support 
were identified and found to occur at different levels including, personal, 
interpersonal, sociocultural and structural.  Costs incurred by whānau were 
also reported as being both direct in the form of transport, food and 
medication and indirect (e.g. employment related) with little financial 
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support available from government agencies.  Although this study did not 
solely focus on Māori, nearly 40% of the participants identified as Māori 
(Egan et al., 2016). 
Whānau may also require support to facilitate their ability to assist their un-
well whānau member although it is difficult to determine as published 
literature on this topic is sparse.  Two interventions designed to support 
families and people with cancer during the assessment, diagnosis and 
treatment phases were identified in a recent literature review which 
explored factors that could improve Māori access to cancer services (Cram, 
2014a).  The two studies focused on native Hawaiian women and their 
families (Mokuau, Braun, Wong, Higuchi, & Gotay, 2008) and African 
American families with a parent who had cancer (Davey, Kissil, Lynch, 
Harmon, & Hodgson, 2012).  The findings of these two studies suggest 
culturally responsive interventions are potentially effective, and can increase 
satisfaction and improve communication.  In NZ the ‘Kia Ora E te Iwi’ 
kaupapa Māori based cancer support programme was developed to provide 
education and support for patients and whānau (Central Cancer Network, 
2016).  The programme was designed to improve cancer outcomes for Māori 
and was developed collaboratively by Iwi, Māori Health Providers and the NZ 
Cancer Society (Ministry of Health, 2015c). 
Whānau however, may not always be able to provide support and 
alternatives may be sought.  Two studies identified Māori health providers as 
acceptable substitutes for whānau, when whānau were unable to carry out 
their role.  Māori health providers who often have established relationships 
with patients were seen to provide a sense of comfort, trust and familiarity 
(Slater et al., 2013; T. Walker et al., 2008). 
While there appears to be an absence of literature that considers decision-
making by Māori in relation to cancer, there is a small body of work in which 
it is considered in other health and related topic areas such as breastfeeding 
(Glover, Manaena-Biddle, & Waldon, 2007), death (Nikora, Masters-Awatere, 
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& Te Awekotuku, 2012) and research (Hope Tupara, 2012).  These studies 
identify whānau as key to the decision-making process.  For example, Glover 
et al.’s (2007) study of Māori women’s breastfeeding decisions identified 
whānau as having a key role in decision-making.  In this study, while women 
sought advice and support from whānau in decision-making and whānau 
were supportive, they did not appear to perceive they had a role in making 
the final decision, suggesting it was for the feeding mothers to make. 
The role of family in regard to cancer care and decision-making has been 
broadened in light of the lack of direct relevant literature on the topic.  
Family have become more prominent in recent international literature.  
Several systematic reviews of decision-making support the notion that family 
are important and play a key role in cancer care including decision-making 
for indigenous, minority and non-Western peoples (E. L. Mead et al., 2013; 
Obeidat et al., 2013; Tranberg et al., 2015).  These specific groups however do 
not appear to be homogenous with regard to the importance and role family 
plays in decision-making. 
Connection to family was identified as part of a cultural theme thought to 
influence decision-making.  In Tranberg et al.’s (2015) review involving five 
studies of Aboriginal and Torres Strait Islander people, cultural values 
relating to family and kinship were perceived to strongly influence responses 
to diagnosis and treatment.  For some families, cancer was thought to have 
been caused by breaches of cultural traditions.  Such situations had the 
potential to bring shame on the family.  While for others, particularly those 
from rural and remote areas, members of the family felt responsibility for the 
person needing treatment and the patient in turn felt responsibility to the 
family.  Regardless of these two factors, the availability of support was found 
to have a significant impact on treatment initiation and maintenance.  This 
systematic review of factors influencing cancer treatment decision-making by 
indigenous peoples was limited in that only five qualitative studies were 
identified, furthermore all five studies pertain to Australian Aboriginal and 
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Torres Strait Islander people (Tranberg et al., 2015).  Despite these 
limitations, families were identified as important to decision-making. 
Mead et al.’s (2013) systematic review of shared decision-making among 
racial and ethnic minorities with cancer, identified 23 articles which utilised 
both qualitative and quantitative methods, the majority of which originated 
in the United States.  Patients involved in the studies commonly had a 
diagnosis of breast cancer.  Ethnic minority populations represented were 
African-American’s, Latina (defined by language preference, English or 
Spanish), Asian (Chinese and Punjabis) and Jewish populations.  Among these 
studies, low acculturated Latina and Asian peoples appeared to have greater 
family participation in decision-making than African Americans for instance.  
In addition to identifying that family plays an important role in treatment 
decision-making, this review also explored in more depth the roles and 
impact family may have on decision-making and treatment outcomes (E. L. 
Mead et al., 2013).  Areas such as family participation, advocacy and 
communication were identified. 
Decision-making at a whānau level (of which patient individuals are 
members) may appear complex to non-Māori who are unaware of the 
culturally bound traditions which underpin it (Richie, 1992).  Many whānau 
form hapū (extended whānau) and many hapū form an iwi (tribe/extended 
kinship group) a Māori social construct.  Whānau formation occurs as the 
result of people sharing common ancestry (whakapapa whānau) or a 
common purpose (kaupapa whānau).  Many iwi are patriarchal while others, 
such as Ngāti Porou, are matriarchal (Mahuika, 1972). 
Māori are described by Patterson (1992) as having collective principles and 
wealth and power are attributed to the whānau, hapū or iwi rather than the 
individual (Patterson, 1992).   Roles and responsibilities of different whānau 
members may be determined by cultural traditions such as birth order.  
Tuākana (first born male child) for instance often inherit leadership roles 
while tēina (all but first born children) and pōtiki (youngest child) play roles 
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in decision-making designed to ensure honesty and thoughtfulness by the 
tuākana (Nikora et al., 2012). 
Holistic care and nurturing are key roles attributed to whānau and 
consequences are apparent for whānau when there are role transgressions 
(Durie, 1994, p. 73).  Durie (1994) suggests that Western aligned attributes 
such as self-sufficiency and self-realization are at odds with a Māori sense of 
health and that ‘interdependence’ rather than ‘independence’ is a healthier 
goal. 
When considering the role of whānau in decision-making we must be mindful 
of societal changes affecting whānau.  Changes include, Māori migration post 
World-War II, urbanisation and in more recent times immigration to 
Australia by many whānau in search of better living and working conditions.  
Many Māori are now separated geographically from their whānau, hapū and 
iwi (tribe).  Adaptation to this separation has resulted in culture changes to 
birth and death rituals for instance.  It is plausible to suggest that isolated 
individuals separated from whānau and living in urban settings may be more 
likely to adopt Western ways including individualist thinking and self-
sufficiency. 
Traditionally, collective decision-making is a phenomenon among Māori 
(Bishop, 1995; H. Tupara, 2009).  Tupara (2009, p. 20) suggests this 
phenomenon “always existed in Māori society”. Māori decision-making often 
occurred and still does in many instances in the context of hui (gathering of 
people).  Inclusiveness is an important principle underlying the hui process, 
and hui may vary in size from a few whānau members to hundreds 
depending on the kaupapa (purpose for the hui).  Many hui begin with 
karakia (ritual chant/prayers) and participants are provided the opportunity 
to kōrero (speak) and listen to the views of others.  Discussion and debate on 




Processes associated with hui align somewhat to those ascribed to shared 
decision-making, discussed earlier.  However, the shared decision-making 
literature does not appear to incorporate the potential for a consensus not 
being able to be reached, in contrast to hui, which do.  For example, in hui 
when a consensus cannot be reached, decision-making may be deferred while 
the advice of experts (such as kaumātua) is sought.  Other participants might 
withdraw as a form of protest or to avoid conflict (Nikora et al., 2012). 
In her doctoral thesis and a retrospective qualitative case study of decision 
experiences of members involving three whānau kin groups participating in 
genetic research, Tupara identified four key processes considered critical to 
Māori decision-making (H. Tupara, 2009; Hope Tupara, 2012).  Firstly, a hui 
is called; secondly, rangatiratanga (meanings including authority, ownership, 
autonomy) occurs; thirdly, manaakitanga (process of showing respect, 
generosity and care for others) is shared; and finally, kotahitanga (unity, 
togetherness, solidarity, collective action) is reached.  Māori decision-making 
is largely a collective activity however not exclusively (Durie, 1994; Nikora et 
al., 2012).  Individual autonomy is acknowledged and occurs in a manner 
which enables the integrity of the whānau to be maintained.  In addition to 
personal attributes, authority and control, fears, values, beliefs, information 
and role-modeling are also identified by Tupara (2012) as factors which 
influence the Māori decision-making process. 
The vision of He Korowai Oranga (Māori Health Strategy), mentioned earlier, 
is to achieve Pae Ora (Healthy Futures), a holistic state of health involving 
three interconnected elements: healthy individuals, whānau and 
environments (Ministry of Health, 2014b).  The most recent iteration of this 
strategy aims to strengthen earlier versions by the addition of core 
components which have been woven into the framework (King & Turia, 
2002; Ministry of Health, 2014b).  Two core components of the framework 
are particularly relevant to decision-making.  Firstly, Māori participation is 
identified as one of three principles, underpinning the relationships between 
the Crown and Māori with regard to Te Tiriti o Waitangi.  This principle calls 
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for whānau to be involved in decision-making at all levels (planning, 
development and delivery) of health and disability services (Ministry of 
Health, 2014b).  Secondly, knowledge (high quality information) is identified 
as a core component to support evidence-based whānau decision-making 
(Ministry of Health, 2014b). 
Specialists 
Mead et al.’s (2013) review identified how racial and ethnic groups respect 
specialists and identify them as authority figures.  Of all factors identified as 
influencing patients’ decision-making, specialists’ treatment preferences and 
recommendations were found to have the greatest impact (E. L. Mead et al., 
2013).  Alternatively, this review also found the reverse was true.  For 
example, if specialists did not advocate for a particular treatment then 
treatment uptake by patients was found to be less.  Patients were also more 
likely to experience decision regret and dissatisfaction when they choose to 
relinquish their role in decision-making to the specialist. 
To date, it appears no NZ studies have explored the influence of the specialist 
on patient treatment decision-making with Māori or other ethnic groups in 
NZ. 
Patient 
Mental and spiritual well-being 
There appears to be little NZ literature on how mental, spiritual and 
emotional states may influence cancer treatment decision-making for Māori 
or others, and few studies internationally which specifically address this 
topic in indigenous, racial and ethnic minority groups (E. L. Mead et al., 2013; 
Obeidat et al., 2013; Tranberg et al., 2015).  Of studies that did, spirituality 
(not prayer alone) was identified as an important coping mechanism, 
particularly for African Americans with cancer, and found to influence the 
decision-making process (E. L. Mead et al., 2013).  Patient spirituality was 
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also linked positively to patient faith in specialists, relationships with 
providers, and compliance with treatment recommendations.  Spirituality is 
considered a core element of key Māori health models such as Te Whare Tapa 
Whā mentioned earlier.  In a recent qualitative study by Egan et al. (2015) 
spirituality was reported as important to Māori patients’ understandings and 
experiences of cancer. 
Attitudes 
Patients’ attitudes were also identified in Mead et al.’s (2013) systematic 
review as having the potential to influence decision-making.  In this review 
conflict was found to intensify anxiety while findings from some studies 
suggest that adopting a ‘positive attitude’ was central to treatment decision-
making for some.  However, the definition or actions taken to express a 
‘positive attitude’ by racial and ethnic groups varied.  One group expressed 
this attitude by taking an active approach to decision-making while another 
ethnic group deferred treatment decision-making to specialists. 
Fatalism and fear 
Fatalism occurs when people believe an outcome is predetermined and they 
are powerless to change (Merriam-Webster, 2016).  There is a paucity of 
literature considering fatalism and decision-making among Māori.  However, 
fatalism was identified as relevant to decision-making in two key reviews 
involving indigenous people and racial/ethnic minority patients (E. L. Mead 
et al., 2013; Tranberg et al., 2015).  Mead et al.’s (2013) review identified a 
study where patient decision-making was limited due to the perception that 
their cancer diagnosis and treatment outcomes were ‘God’s will’ and they 
relied on prayer (E. L. Mead et al., 2013).  Similar fatalistic views were found 
by Tranberg et al. (2015) in their review which identified cancer diagnosis 
could be linked to negative family experiences of cancer.  In combination with 
cultural beliefs, cancer could be linked to retribution for broken laws and 
customs.  Therefore, some thought nothing could be done in these 




Not dissimilar to many other indigenous populations, Aborigine and Torres 
Strait Islander participants in the studies reviewed by Tranberg et al. (2015) 
considered the body as sacred and maintaining wholeness as very important.  
Even talking about cancer was discouraged in these cultures for fear “it could 
make it happen”(p. 7). 
Fear of cancer and the unknown, like chemotherapy treatment for example, 
seems a ‘normal’ reaction for many.  However, for some whānau a cancer 
diagnosis can also result in fear, not just for the affected individual but for 
themselves and the wider whānau (Dew, Signal, et al., 2015).   
Medical: comorbidity, disease and treatment  
No NZ literature was found which considers how medical factors such as, 
disease and treatment factors influence cancer treatment decision-making by 
Māori.  International literature identified a few studies in Mead et al.’s (2013) 
systematic review pertaining to racial and ethnic minority groups which 
identified biomedical and treatment related topics (E. L. Mead et al., 2013; 
Tranberg et al., 2015).  Specifically, concerns about disease recurrence, 
survival and treatment effects were found to be prominent in shaping 
treatment decision-making, particularly for Latina and African American 
women.  These studies showed that in countries where treatment is not free, 
treatment costs are of concern and potentially influence decision-making. 
Comorbidity was not identified as a factor influencing patient treatment 
decision-making in the literature reviewed. 
In summary, there are a number of factors found in the literature that 
influence patient treatment decision-making including whānau, the specialist 
and patient factors such as their mental well-being and attitudes.  
Furthermore, international literature found disease and treatment factors 
were prominent in treatment decision-making by minority populations. 
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Section 4: Factors influencing specialists’ decision-
making  
This section considers literature pertaining to factors that influence 
specialists’ decision-making.  Internationally, there is a small body of 
literature focused on factors that influence specialists’ treatment decision-
making.  The literature in this section is grouped into themes: medical 
(including comorbidity, disease and treatment), patient, specialist and 
healthcare system. 
Medical: comorbidity, disease and treatment 
Cancer treatment planning is often a complex process and requires specialist 
consideration of a vast array of medical factors when preparing treatment 
options.  A key goal of many treatment options is to maximise survival, while 
other goals often aim to lessen unpleasant treatment related side-effects.  
The presence of comorbidities has been linked with treatment selection and 
lower treatment rates in cancer patients (Koppie et al., 2008; Sarfati et al., 
2016).  Hall et al.’s (2005) review suggests that to correctly determine best 
treatment, which he suggests has been inappropriately influenced by 
patients’ age and comorbid illness, comorbidities must be integrated into 
treatment decisions by specialists (Hall, Jani, Ryu, Narayan, & Vijayakumar, 
2005).  Comorbidities were also identified in Shepherd et al.’s (2008) large 
survey of over 600 Australian cancer specialists as a factor which added 
difficulty to treatment decision-making.  Specialists working with Māori 
patients are likely to encounter comorbidities often given the higher 
prevalence of common comorbid conditions such as diabetes and 
cardiovascular disease in the Māori population compared with NZ Europeans 
(Robson & Harris, 2007). 
Patient cancer treatment management plans are often prepared by specialists 
in consultation with multidisciplinary teams (Ung, Campbell, Duplan, Ball, & 
David, 2016).  Patient comorbidities have been identified as one reason for 
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multidisciplinary team treatment recommendations having not been 
implemented (Blazeby et al., 2006).  In addition to multidisciplinary teams, 
specialists commonly utilise risk prediction programmes such as ‘Adjuvant! 
Online’ to determine if adjuvant treatment will be of benefit to patients 
(Ravdin et al., 2001).  A recent review of 20 risk prediction models identified 
‘Adjuvant! Online’ as the sole model which included patient comorbidity in 
calculations (Engelhardt et al., 2014).  The lack of consideration of patient 
comorbidities by multidisciplinary teams and risk prediction models 
suggests specialists must define and determine if patient comorbidities 
influence the development of treatment management plans. 
In addition to patient comorbidity specialists also consider disease and 
treatment factors.  A triangulation study of treatment decisions involving 
eight surgical specialists in the UK treating breast cancer patients identified 
that treatment options were only presented when specialists considered 
there to be clinically equivocal options that maximized survival (Mendick et 
al., 2010).  Alternative options were likely to be offered when ‘best practice’ 
was unclear, or when the outcome would not be significantly affected by 
choice (Mendick et al., 2010). 
Specialists make many complex decisions about treatment and new 
knowledge regularly results in changes to treatment approaches.  Specialist’s 
beliefs about the strength of evidence underpinning treatments have been 
found to affect treatment selection (Showalter et al., 2012; Tariman et al., 
2012).  For example, a recent survey involving radiation oncology and 
urology specialists which aimed to evaluate beliefs and practices regarding 
adjuvant radiation therapy after radical prostatectomy found 
recommendations for radiotherapy varied by specialty (Showalter et al., 
2012).  This variation occurred despite the authors suggesting there is 
sufficient evidence from randomized control trials to support adjuvant 
radiation therapy after radical prostatectomy.  The authors suggest future 
studies should define toxicity factors and identify specific patient groups that 
would benefit from adjuvant treatment to better guide specialists’ decision-
54 
 
making.  The low response rate in this survey (20%), a disproportionate 
number of academic specialists in the response group, and limited 
consideration of training bias limit the generalisability of these findings 
(Showalter et al., 2012). 
Other medical factors such as tumor type, cytogenetic profile and physiologic 
status were identified in Tariman et al.’s (2012) review as integral to 
specialists decision-making (Tariman et al., 2012).  For example, cytogenetic 
profiles which identify node and hormone receptor status can assist 
specialists to determine, in combination with treatment algorithms, which 
chemotherapy regimen is likely to be of greatest value for patients when 
planning breast cancer chemotherapy and hormone therapy treatment.  This 
review was limited to literature concerning ‘older’ (≥65yrs) adult patients 
with cancer and some of the studies included have methodological flaws such 
as poor response rates. 
Patient 
A range of patient factors were found to influence specialist decision-making 
including; patients’ living situation, education status, willingness to accept 
treatment (Cavalli-Björkman et al., 2012), comorbidities (Shepherd et al., 
2008; Tariman et al., 2012), age (Tariman et al., 2012) and family (Back & 
Huak, 2005; Cavalli-Björkman et al., 2012; Laidsaar-Powell et al., 2013). 
Cavalli-Bjorkman et al.’s (2012) qualitative study interviewed 20 Swedish 
oncologists and found that chemotherapy treatment combinations used for 
cancer patients were affected by patient living situations (Cavalli-Björkman 
et al., 2012).  Fear of treatment toxicity for patients who lived alone 
underpinned oncologists’ decisions to consciously use less combination 
therapy for these patients. 
Families were identified in the literature as having the potential to influence 
specialists’ treatment decision-making (Back & Huak, 2005; Cavalli-Björkman 
et al., 2012; Laidsaar-Powell et al., 2013), and they could either help or 
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hinder decision-making.  In Cavalli-Bjorkman et al.’s (2012) study, some 
specialists reported that persuasive family could be challenging while others 
felt outnumbered (Cavalli-Björkman et al., 2012).  Similarly, Laidsaar-Powell 
et al.’s 2013 review identified some specialists felt burdened by family 
participating in consultations (Laidsaar-Powell et al., 2013). 
Specialists’ perceptions and opinions of families vary.  Laidsaar-Powell et al.’s 
(2013) recent systematic review of triadic medical consultations (involving 
three participants, often the patient, specialist and a family member) 
identified a number of family factors potentially able to influence specialists’ 
decision-making (Laidsaar-Powell et al., 2013).  Family were recognised as a 
helpful source of medical information (history, medications and symptoms) 
and important to treatment decision-making by specialists.  However, their 
presence in consultations could also increase the complexity of the 
consultation with some specialists expressing concern that family may take 
time away from the specialist’s ability to discuss important issues with the 
patient.  Other specialists also suggested that family limit their ability to 
discuss sensitive issues with patients, while others considered family 
involvement compromised their ability to answer patients’ questions 
(Laidsaar-Powell et al., 2013). 
Other patient factors such as age were identified as influencing specialists’ 
decision-making in another review which investigated specialist, patient and 
contextual factors that affect decision-making in older adults diagnosed with 
cancer (Tariman et al., 2012).  This review, involving literature sourced from 
1966-2010, identified how specialists’ judgments of patient age could 
influence and bias their perceptions of patient life expectancy.  Age bias for 
example was found to result in under-treatment for some older cancer 




Personal factors (e.g. values, beliefs and bias), emotional factors and 
professional expertise was identified in the literature as having influenced 
specialists’ treatment decision-making.  Specialists’ values for example, 
appear to influence a vast array of treatment decision-making related factors 
(Dew, Stubbe, et al., 2015; Schildmann, Tan, Salloch, & Vollmann, 2013; 
Tariman et al., 2012) and are fundamentally important in decision-making.  
How their values are expressed may or may not benefit the patient, nor may 
they align to patient values and preferences (Winkler, Hiddemann, & 
Marckmann, 2011).  Tariman et al.’s (2012) review identified specialist 
values and beliefs as factors which influence their perception of quality of 
life, who should be involved, and what information is important to consider 
in decision-making (Tariman et al., 2012).  Attention to the expression of 
specialists’ values is important to consider, as how values are expressed can 
influence the decision-making process and priorities aligned to treatment 
goals like length or quality of life, and ultimately health outcomes for cancer 
patients. 
Some early studies identified that specialists believed they should have more 
decision-making authority than cancer patients based on their view that they 
were the expert (Beisecker, Helmig, Graham, & Moore, 1994).  The type of 
decision-making, where patients play a minimal role and specialists largely 
decide, aligns predominately with a paternalistic decision-making model 
discussed earlier (Emanuel & Emanuel, 1992).  Strands of this view appear to 
persist in contemporary studies where specialists articulated their belief that 
they determine the option/s offered to patients in consultations, therefore 
they control decision-making (Mendick et al., 2010).  The consequences of 
paternalistic models of decision-making have been linked to under-treatment 
of cancer in older populations (Bouchardy, Rapiti, Blagojevic, Vlastos, & 
Vlastos, 2007), with the reasons for this being unclear. 
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The work of specialists may be highly rewarding, however it may also be 
stressful and demanding.  Dealing with pressure situations is part of their 
daily life, and at times their emotional responses to these situations may 
affect their treatment decision-making.  For example, a specialist may have to 
inform patients (with young children) they have a terminal illness (Koedoot 
et al., 2004).  While having young children has been found to influence cancer 
patients perceptions of treatment factors (Lux et al., 2013), there appears to 
be little, if any literature which considers how treating patients with young 
children impacts on specialists. 
Making life and death decisions involving toxic treatments can also affect 
emotions and stress levels (Shanafelt & Dyrbye, 2012).  A Swedish study of 
factors oncologists consider when making treatment decisions, identified 
how their desire to please patients and family influenced their response to 
treatment demands (Cavalli-Björkman et al., 2012).  At times oncologists 
would prescribe patients treatment even when they thought it had limited 
efficacy.  And, although Salmon et al. (2011) note emotional talk may be 
absent from some consultations, many specialists describe their relationships 
with patients as being both personal and emotional (Salmon et al., 2011).  
Given the emotional toll working in cancer care can take, it is unsurprising to 
learn from Shanafelt and Dyrbye’s (2012) review that psychological 
responses in the form of depression, anxiety and fatigue, collectively referred 
to as ‘burnout’ is high amongst specialists working in the cancer field. 
Other personal characteristics such as ethnic bias, expressed sometimes as 
prejudice and/or discrimination (Dovidio & Fiske, 2012) are identified in the 
literature as influencing quality of care and decision-making by specialists 
(Smedley, Stith, & Nelson, 2003), at times despite their best intentions.  
Biases may be either explicit (conscious) or implicit (below conscious 
awareness).  Cultural and racial differences between the patient and clinician 
may lead to differential treatment as could the gender of both the patient and 
clinician.  These factors along with comorbidity, which is common among 
Māori (Hill, Sarfati, Blakely, Robson, Purdie, Chen, et al., 2010), are likely to 
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exacerbate clinical uncertainty for clinicians who are already dealing with 
highly stressful and complex decision-making situations.  Literature in this 
area is limited but growing. 
The literature regarding ethnic bias and specialists originates largely from 
the US and primarily concerns African American and Latino populations.  
Within this body of literature, ethnic bias is identified as a potential factor 
contributing to treatment inequities between African Americans and Latinos 
when compared with Whites (Baldwin et al., 2005; Dovidio & Fiske, 2012; 
Jessup, Stewart, Greene, & Minsky, 2005; Shavers & Brown, 2002; van Ryn et 
al., 2011).  Ethnic bias may also impact on relationships (van Ryn et al., 
2011), communication (Cooper et al., 2012; Martin, Roter, Beach, Carson, & 
Cooper, 2013), care (Cooper et al., 2012), and treatment decision-making 
(Alibhai et al., 2004; Smedley et al., 2003). 
While ethnic bias has not explicitly been studied in the NZ cancer context, 
experiences of racial discrimination by health professionals have recently 
been reported.  Harris et al. (2012) conclude from their analysis of 
2006/2007 Health Survey data that “Experience of racial discrimination in 
both health care and other settings may influence health care use and 
experiences of care and is a potential pathway to poor health” (Harris et al., 
2012, p. 1012). 
Fatigued and burdened specialists are identified in literature reviewed by 
Dovidio and Fiske (2012) as being at increased risk of prejudiced and 
discriminatory practice (Dovidio & Fiske, 2012).  These conditions are 
considered to limit specialists’ cognitive abilities to control their own biased 
behaviour.  While specialist biases are more likely to be implicit rather than 
explicit (Moskowitz, Stone, & Childs, 2012) the outcome for patients can be 
poor relationships with specialists (Blair et al., 2013) and disparate care 
(Blair et al., 2013; Dovidio & Fiske, 2012; Smedley et al., 2003). While some 
specialists may look to biological explanations for treatment disparities 
between ethnic minorities and Whites (Jessup et al., 2005), Dovidio’s (2012) 
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review suggests other specialists (although not all) are increasingly 
acknowledging the contribution of non-biological factors to care disparities 
between different races. 
Van Ryn et al. (2011) suggest a range of important setting factors have the 
potential to ‘eradicate inequities in care’.  She also recommends other 
strategies including reducing specialist cognitive load, universal guidelines, 
and improving organisational racial climates.  Organisational racial climates 
refer to “employees' shared perceptions of the policies and practices that 
communicate the extent to which fostering diversity and eliminating 
discrimination is a priority in the organization” (Pugh, Dietz, Brief, & Wiley, 
2008).  Implementing quality improvement initiatives, designed to eliminate 
conditions and behaviors that contribute to the formation of inequities 
between ethnic groups, was also identified in the literature as an important 
strategy to address care inequities (van Ryn et al., 2011). 
Other non-medical factors such as practice types, age, education, area of 
expertise and experience have also been linked to specialists’ approaches to 
treatment decision-making (Lux et al., 2013; Schildmann & Vollmann, 2010; 
Shepherd et al., 2008; Tariman et al., 2012).  Given many cancer services are 
situated in large hospitals with complex systems it is important that 
specialists providing care are able to ‘work the system’.  Shepherd et al.’s 
(2008) study mentioned earlier found the place of initial medical training and 
years of experience influenced how commonly system barriers were 
experienced (Shepherd et al., 2008).  Unfortunately, this study did not include 
cultural differences or comorbidity as potential influencing factors in the 
analyses.  Tariman et al.’s (2012) review also found experts in the field of 
Hodgkin’s Disease were more likely to tailor treatment to individual patients 
than non-experts while academic specialists were more likely to use 
combined therapies (Tariman et al., 2012).  Some limitations of this survey 
however were its response rate of 50%, few treatment choices for 
participants, and lack of recognition for how decision-making may have been 
influenced by the patient context. 
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Healthcare system  
Two articles identified four system factors with the potential to influence 
specialist treatment decision-making.  Mendick et al. (2010), identified that 
‘best practice’ and multidisciplinary team policy determines most specialist 
treatment decisions (Mendick et al., 2010).  Shepherd et al.’s (2008) study 
adds two further system/setting barriers to the range of factors which 
influence specialists’ decision-making, specifically identifying insufficient 
time with patients and lack of information (Shepherd et al., 2008).  Less 
experienced specialists in this study reported difficulties with system issues 
more often and the authors suggest this could be due to more experienced 
specialists’ skill at ‘working’ the system and being more likely to take a 
patient-centred approach. 
Many treatment decisions in cancer care are increasingly being made in 
teams by a range of healthcare professionals, commonly referred to as 
multidisciplinary teams  (C. Taylor et al., 2010).  This is also true for many 
cancers treated in the NZ secondary health care system and the Ministry of 
Health have developed guidelines to guide best practice in multidisciplinary 
teams (Ministry of Health, 2010a).  Dew et al.’s (2015) study, involving 
specialists in ten NZ multidisciplinary cancer team meetings identified a 
broad typology of value positions taken by participants in expressing their 
decision-making preferences.  These included utilitarian (treatment option 
considered patient population and use of resources to maximise benefits), 
paternalistic pastoralism (focused on patient good, patient not seen as best to 
make the decision), beneficient pastoralism (treatment to enhance patient 
well-being regardless of cost or managment indication), patient 
empowerment (all information provided to patient,  patient decides in 
discussion with specialist), procedural (protocol and process driven 
treatment) and clinician’s self-preservation (specialist determines treatment 
based on interactions with patient) (Dew, Stubbe, et al., 2015). 
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In summary, a range of factors that influence specialists’ decision-making 
were identified including patient factors (e.g. their family, living situation and 
age).  Specialists have highly stressful jobs and some literature identified that 
personal characteristics, such as values, biases and experience were 
influential.  Given the complexity of cancer treatment decision-making it is 
unsurprising to find that disease and treatment factors also influenced 
treatment decision-making.  In addition to these, healthcare system factors 
such as multidisciplinary teams also feature increasingly in specialists’ 
decision-making. 
Summary 
In summary, section one outlined relevant contextual information important 
when studying cancer treatment decision-making including approaches, 
models, types and styles.  A number of studies attended to treatment 
decision-making in cancer consultations which commonly focused on 
communication, information and decision-making processes.  Patient, 
specialist and system levels were explored along with methods to monitor, 
measure and improve decision-making. 
Section two showed how important good communication is to inform 
treatment decision-making.  The literature shows that communication in 
consultations where complex treatment decisions are often made may be 
affected by multiple factors including time, system constraints, cultural 
differences, comorbidities and relationship development. 
Section three presented information about the range of factors found to 
influence patient treatment decision-making including, patients’ mental well-
being and medical factors such as disease and treatment factors.  The 
importance of the specialist’s treatment recommendation and whānau 
involvement in patient decision-making was identified consistently in the 
literature.  However, there was a lack of literature able to be sourced 
considering factors influencing treatment decision-making in cancer 
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consultations involving Māori with cancer or other indigenous and racial and 
ethnic minority populations. 
The final section reviewed a range of factors found to influence decision-
making by specialists.  This section found specialists could be affected by 
patient, specialists, healthcare system and disease and treatment factors.  
Similarly to patients there is a paucity of literature considering factors which 
influence specialist decision-making in cancer consultations.  Additionally, 
little literature was found that investigates the views of or factors which 
influence indigenous or ethnic minority specialists decision-making or 
factors that influence specialist decision-making with indigenous or minority 
populations. 
It is important that indigenous and ethnic cancer treatment inequities are 
addressed.  Factors influencing treatment decision-making in consultations 
are important.  However, literature which attends to these factors from the 
view of Māori or other indigenous peoples and ethnic/racial minority 
patients is scarce.  Further research in this area is warranted. 
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Chapter 3: Methodology 
Overview 
This research examines how comorbidities and other factors impact on treatment 
decision-making in cancer consultations.  A Māori Centred Research approach has 
been used to ensure that the research design, implementation, and interpretation 
are appropriate for Māori, ultimately contributing to increasing both Māori 
knowledge and the knowledge of those who provide cancer care services.  Māori 
Centred Research places Māori at the core of the research and encompasses 
Western based research methodologies and methods.  This thesis focuses on the 
five Māori participants and draws on case study methodology and qualitative 
methods to assist with design, data collection, analysis and interpretation of 
findings. 
The methodology utilised in this study aims to enable the following research 
questions to be answered: 
Research questions 
1. What impact do comorbidities have on treatment decision-making in cancer 
consultations with Māori patients/whānau? 
2. What other factors influence treatment decision-making in cancer 
consultations with Māori patients/whānau? 
The research questions are concerned with the perspectives of patients/whānau 
and specialists.  Consultations were recorded and patient/Whānau and specialists 
perspectives were sought.  Patients/Whānau were interviewed and specialists 
recorded their own debrief. 
This chapter begins by considering approaches to Māori research, and in 
particular, Kaupapa Māori Research and Māori Centred Research.  These 
approaches identify ways of developing and contributing to the knowledge of 
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Māori and non-Māori with the view that it is used to enhance cancer care services 
for Māori.  Māori Centred Research is also considered alongside case study 
methodology.  The chapter concludes by providing a description of the qualitative 
methods employed in undertaking this research. 
Māori research 
This section aims to provide an overview of different methodologies used to 
undertake research with Māori and brings together the methodologies used to 
guide this research. 
New research methodologies and frameworks have arisen in NZ in response to 
concern by Māori about how research is undertaken with Māori (Bishop, 1999; 
Smith, 1999; S. Walker, Eketone, & Gibbs, 2006).  For example, Māori have 
questioned whose research agenda is advanced when research involving Māori is 
undertaken by non-Māori and what Māori control there is in this type of research.  
Kaupapa Māori research and Māori Centred Research are examples of research 
methodologies which have evolved in response to such concerns (S. Walker et al., 
2006). 
Māori centred research  
Based on the premise that all research in contemporary NZ society has the ability 
to contribute to Māori knowledge, Cunningham (2000) proposes that research can 
be identified and grouped according to the ability of that research to contribute to 
Māori knowledge.  Māori Centred Research is one of the groups identified by 
Cunningham (2000). 
Taking a Māori Centred Research approach means placing Māori people at the 
centre of the research, being culturally mindful, and focused on generating gains 
for Māori development (Durie, 1996).  At the same time, taking a Māori Centred 
Research approach requires the researcher to ensure that Māori are regarded as a 
diverse people.  This approach acknowledges that Māori may both share things in 
common as well as have differences.  This is referred to in contemporary society as 
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Matatini Māori or diverse Māori realities (Durie, 1995).  Cunningham (2000) 
describes Māori Centred Research as, “research where Māori are significant 
participants, and are typically senior members of research teams, research where 
Māori analysis is undertaken and which produces Māori knowledge, albeit measured 
against mainstream standards for research” (p. 65).  
Durie (1997) identified three primary principles to guide those planning a Māori 
Centred Research approach, whakapiki tangata, whakatuia, and mana Māori (pp. 
49-50). These principles were interpreted and applied by Foster (2003) as: 
 Principle one: Whakapiki tangata – meaning Māori are enabled, enhanced or 
empowered which results in research that is of benefit to Māori and that 
Māori are in control of (Foster, 2003). 
 Principle two: Whakatuia – meaning integration, which involves using a 
‘holistic approach that incorporates notions of relationships and inter-
connectiveness’ between realms such as taha wairua (spiritual well-being) 
and taha tinana (physical well-being) as described in Durie’s (1997) Te 
Whare Tapa Whā Māori health framework (pg. 69). 
 Principle three: Mana Māori – consists of notions of Māori power and 
control over the research in its entirety (design, participation, processes 
and findings) (Foster, 2003). 
In addition to the guiding principles identified by Durie (1997) and Forster (2003), 
Cunningham (2000) attributes four key characteristics to Māori Centred Research.  
Firstly, Māori Centred Research is research which is controlled by ‘mainstream’ or 
those that are non-Māori and likely to be funded by the Crown, in contrast to 
Kaupapa Māori research which is controlled by Māori.  Secondly, Māori are major 
participants in Māori Centred Research and likely to be involved in all facets, not 
solely as participants. The third characteristic involves the use of contemporary 
mainstream and Māori research methods.  Finally, Māori Centred Research 
involves a Māori analysis (Cunningham, 2000). 
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In line with characteristics of Māori Centred Research, two common and one 
innovative qualitative methods were utilised to gather information for this 
research and generate knowledge to benefit Māori.  Knowledge, which may be 
used to better understand why treatment differences occur between Māori and 
non-Māori, and ultimately result in better outcomes for all cancer patients (Sarfati 
et al., 2009; Sarfati et al., 2016; Stevens et al., 2008). 
Baum (1995) argues qualitative research methods “are well suited to studying 
complex public health situations” (Baum, 1995).  Discovering what factors influence 
treatment decision-making by participants in cancer consultations was identified 
as complex in the previous chapter.  The use of qualitative methods in this study 
were particularly appropriate for two main reasons.  Firstly, it aims “to capture 
lived experiences of the social world and the meaning people give these experiences 
from their own perspectives” Corti & Thompson (2004, p. 326).  In this study this 
pertains to participant perspectives and meanings given to factors influencing 
treatment decision-making in the consultation (Corti & Thompson, 2004).  
Secondly, “qualitative data can be used to explain the results of quantitative 
research” (Liamputtong & Ezzy, 2005).  This is particularly relevant for this study 
as quantitative data involving treatment disparities for instance between Māori 
and non-Māori was presented in chapter one, however the reasons for those 
disparities is not well understood. 
The ‘Best Outcomes for Māori: Te Hoe Nuku Roa’ longitudinal household survey is 
one of the few publications identified which explicitly used a Māori Centred 
Research approach (Foster, 2003). On one level, the lack of published studies 
explicitly reporting a Māori Centred Research approach is surprising since there 
are a number of research projects in NZ undertaken that appear to ‘fit’ the Māori 
Centred Research description, for example work by Walker et al.. (2008).  This 
phenomenon may be due to the ‘normalising’ of Māori participation at all levels of 
research in ‘mainstream’ non-Māori research institutions, alongside growing 
numbers of Māori academics within these settings. 
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In addition to Māori Centred Research, an ethical framework founded on four 
tikanga (Māori protocols and practices) based principles, also provides valuable 
direction for this research (Hudson, Milne, Reynolds, Russell, & Smith, 2010). They 
are: 
 Whakapapa (relationships) – undertaken by researchers when ‘connecting’ 
with research participants. 
 Tika (research design) – involved the selection of Māori Centred Research 
and establishment of Community Māori Oversight Group. 
 Manaakitanga (cultural and societal responsibilities) – attended to when 
gathering and disseminating data and results. 
 Mana (justice and equity) – a key consideration in data analysis (Hudson et 
al.). 
The use of Māori centred research in this study 
A Māori Centred Research approach fits well with the work of this thesis for 
several reasons.  Firstly, the setting within which patients and specialists 
participate in consultations to discuss treatment options is controlled by 
‘mainstream’ or non-Māori.  Secondly, the C3 research programme is led by the 
University of Otago and funded by the HRC, both controlled by non-Māori.  Thirdly, 
Māori have participated in this research in a variety of roles including Co-Principal 
Investigator, as members of the research team, and as participants.  Oversight and 
advice was provided by a small group of clinical specialists (clinical advisory 
group) including a Māori surgeon and a Community Māori Oversight Group 
consisting of Māori community, consumer, provider and cancer sector specialists.  
Māori participation in all facets of this research helped ensure approaches were 
valid for Māori. 
The principles of Māori Centred Research were applied to this work in several 
ways.  Supervision was provided by Associate Professor Louise Signal (University 
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of Otago) and Dr Lis Ellison-Loschmann (Massey University), one NZ European and 
the other Māori.  At least one Māori researcher participated in interviews with 
each of the Māori participants.  A second interviewer employed on the larger C3 
Qual study assisted with arranging interviews and taking additional notes as 
required during the interview.  In this way continuity was maintained for the data 
collection phase of the C3 Qual study, although as previously noted this thesis is 
only concerned with the response/information gathered from participants in the 
Māori consultations.  I completed two of the Māori interviews with a second 
interviewer, and two alone.  The analysis of Māori data was led by myself and 
reviewed by my supervisors and other leading team members. 
Māori Centred Research principles were implemented in this study in the following 
ways.  Whakapiki tangata: this principle related to the generation of knowledge 
not previously available for use by those planning and delivering cancer services to 
Māori.  At an individual level Māori participants’ dignity and confidentiality was 
strictly maintained and consent processes followed.  Participation of the 
Community Māori Oversight Group, ongoing involvement of Māori researchers at 
all levels (design, data collection and analysis) and dissemination of research 
findings to both Māori and non-Māori organisations and communities ensured that 
the kaupapa (purpose for, principles) of Māori Centred Research was upheld. 
Whakatuia in this research was expressed by the choice of case study methodology 
(discussed in detail below) drawing on multiple data sources.  The consideration of 
several domains in the analysis is particularly suited to understanding the 
complexity of patients/whānau and specialists in the hospital setting.  Whakatuia 
also ensured this research acknowledged that while the focus was on a single 
consultation where decision-making occured at one point in time, both past, 
present and future factors were important and relevant to consider when 
researching cancer treatment decision-making. 
The principle of Mana Māori in this research was addressed by Māori participation 




Research methods used to collect and analyse information were designed to occur 
in a manner cognisant of Māori culture.  Methods used to gather information 
involved one primary research contact with participants throughout the research 
process.   Initial research contact with patients and kanoi ki kanohi (face-to-face) 
interviewing was led by one lead researcher, face-to-face interviews and Māori 
researcher participation in interviews (at times together with a non-Māori 
researcher) enhanced opportunities to develop rapport, trust and respect with 
research participants. 
The use of Māori researchers in the interviewing process was also important for a 
number of reasons.  Firstly, a Māori researcher is more likely to be familiar with 
the Māori language and culture amongst the diversity of Māori living in NZ society 
aiding cultural competency.  Secondly, there was greater potential for Māori 
researchers to find opportunities to share experiences with Māori participants, 
and the likelihood that they would feel comfortable due to having another Māori 
person to talk with.  Training a new Māori researcher potentially increases Māori 
researcher capacity. 
Reciprocity is an important element involved in building and nurturing 
relationships.  A koha (an offering) was presented to participants in this research 
as a way of expressing gratitude and acknowledging the sharing of sensitive and 
personal information by vulnerable people during a stressful time with strangers 
(researchers).  Participants’ parking costs were also paid to acknowledge the 
additional time and costs incurred when participating in the interview. 
A Māori analysis was led by a Māori researcher (thesis author) with advice and 
assistance from supervisors and key team members.  The purpose of a Māori 
researcher looking at Māori data first was to ensure that data analysis was 
undertaken in a manner open to using an integrated approach to generate 
understanding consistent with a Māori world view.  A Māori model of health, Te 
Whare Tapa Whā was drawn on to guide the analysis (Durie, 1994).  This approach 
was informed by work undertaken in a large mainstream qualitative research 
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project where Māori sought to analyse Māori data (Cram, Phillips, Tipene-Matua, 
Parsons, & Taupo, 2004). 
Case study methodology 
A case study approach provided the overarching research strategy for this thesis.  
Case study strategy “investigates a contemporary phenomenon within its real-life 
context, especially when the boundaries between phenomenon and context are not 
clearly evident” (Yin, 2003) (pg. 13).  In NZ and indeed internationally little is 
known about factors influencing cancer treatment decision-making in 
consultations with Māori or other indigenous and ethnic minority populations (E. 
L. Mead et al., 2013).   Little is known about how cancer treatment decision-making 
may be affected by the context within which it occurs.  In NZ consultations largely 
occur in hospitals founded on western medicine.  Yin (2003) notes the explicit 
inclusion of context distinguishes case studies from other research designs. 
Triangulation is a key feature of case study inquiry.  Triangulation evolved in 
response to the position that no one single method could singularly solve a 
problem involving rival causal factors (Denzin, 1978).  According to Denzin (1978), 
four types of triangulation can occur in research: theory, methodological, data and 
investigator triangulation.  Additionally, case studies often employ “in-depth data 
collection involving multiple sources of information” (Creswell, 2013, p. 97).  This 
study gathered information from three different sources, discussed later in this 
chapter. 
Findings in a case study are developed by the researcher after triangulating data 
sources which are likely to have been gathered using different data collection 
methods (Yin, 2003).  Data triangulation increases the likelihood that the reported 
findings will be comprehensive, wide-ranging and fully-developed (Denzin, 1978).  
Furthermore, Yin (2003, p. 7-8) suggests that case study research strategy is 
indicated when two further factors are present.  Firstly, the extent of control the 
researcher has over the event, and secondly a focus on contemporary events in 
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which behaviours cannot be manipulated.  In this study the researcher had no 
control over, nor ability to manipulate consultations. 
Case study strategy in this research enabled the development of a greater 
understanding of what is potentially a complex phenomenon (cancer treatment 
decision-making involving two or more parties) within the context of where it 
occurs (public hospitals).  Triangulation of three data sources also occurred in this 
study, in recognition of the fact that decision-making making is complex, and to 
ensure the views of the different participants were considered.  This case study is 
both explanatory and exploratory in that it sought to understand and describe how 
comorbidity and other factors influence treatment decision-making in cancer 
consultations with Māori. 
Methods 
This research utilised qualitative research methods to seek ‘a deeper truth’ than is 
available in statistical studies alone, through ‘the systematic collection, 
organisation, and interpretation of textual material derived from talk or 
observation’ and through exploring the ‘meanings of social phenomena as 
experienced by individuals themselves, in their natural context (Malterud). 
To capture a broad range of issues influencing decision-making, this research was 
undertaken with adult patients able to give consent, in different hospitals, with 
differing cancer types, with and without comorbidities, and who saw specialists 
offering one of two treatment modes (medical oncology and radiation oncology). 
Differing qualitative methods of data collection that could be used to gather data 
about treatment decision-making in cancer consultations were considered and 
included: surveys, focus groups, interviews and observation.  Survey options were 
discounted as so little was known about the topic of interest to inform the 
development of a meaningful survey.  Focus groups were also considered, but 
thought to be inappropriate as participants would be in a particularly vulnerable 
state having recently received a cancer diagnosis, and thus may not have felt able 
to express themselves in a group situation.  The timeframe between receiving a 
72 
 
diagnosis and discussing treatment options was also likely to be very short, in 
some cases only a few days, making the feasibility of organising a focus group that 
suited all patients virtually impossible.  Three methods were chosen to collect 
data: (a) recording of consultations; (b) recording of patient interviews (post-
consultation); and (c) specialist recording of self-debriefs (post-consultation) 
(Figure 3). 








Note: Each case comprises three types of data.  The within-case strand (grey bands) 
integrates the data within each case.  The cross case strand (indicated by dashed outer 













































The C3Qual Research Programme Clinical Advisory Committee provided advice 
about how best to recruit specialists for this study.  Four recruitment strategies 
were employed. 
 Strategy one:  At one hospital the Cancer Centre Clinical Heads of 
Department (HoDs) were briefed about the research by a Co-Primary 
Investigator and senior public health research doctor on the C3Qual 
research team.  Each of the HoDs then verbally presented the research to 
their colleagues to ascertain interest.  They also provided them with written 
information about the study and copies of the consent and demographic 
forms (Appendices A, B, C).  Specialists then indicated their interest in 
participating in the research by either directly contacting the researchers or 
via their HoDs.  Interested specialists met with the researchers to discuss 
the research in detail. 
 Strategy two:  At a second hospital a clinical specialist on the research team 
ascertained interest from colleagues in participating in this research.  
Several attempts to establish the research over a period of about a year at 
that hospital proved unsuccessful.  This was primarily due to changes in 
support personnel for the clinical specialist at that hospital, and other 
specialist circumstances. 
 Strategy three: In response to the failure of strategy two, strategy three was 
developed utilising networks amongst the wider C3Qual research team.  At 
a third cancer centre hospital the Head of the Oncology Service called a joint 
meeting with interested team members and the research team.  
Researchers from C3Qual attended the meeting where a brief was provided 




 Strategy four: A specialist recruited from strategy three who held outreach 
clinics in another city discussed the research with a colleague there and 
recruited that specialist to the study.  A Co-PI from the C3Qual study then 
contacted the specialist to provide more information about the study. 
All specialists were provided with an information sheet, consent and demographic 
forms which were developed in consultation with clinicians on the research team, 
led by the thesis author (Appendices A, B, C). 
As a result of these recruitment strategies, 12 specialists from three hospitals 
agreed to participate in the C3 Qual research.  Three of whom participated in the 
consultations with the five cases included in this study.  Two of the three hospitals 
where the five consultations occurred provide a full range of cancer services 
(blood cancers, medical oncology, radiation oncology and clinical haematology), 
while one has a limited range of services (i.e. no radiation oncology services).  Of 
the three specialists who participated in this study, one specialised in radiation 
oncology and two in medical oncology.  All provided outpatient clinics at other 
hospitals in their region.  Two specialists were female and one male, all three were 
of different ethnic groups and two trained abroad.  None were Māori. 
Individual tailoring of research processes for each specialist, cognisant of different 
treatment pathways and organisational processes at each hospital, was 
undertaken.  Tailoring was also necessary as specialists had differing 
communication preferences and support available to them within their hospital.  
For example, one specialist preferred to communicate directly with the researcher 
during the data collection phase while another did so via other hospital personnel 
(research administrator and nurse). 
The specialists were responsible for key research activities including: identifying 
patients eligible for the study from new patient clinic lists, recording consultations, 
and recording the specialist debrief as soon as possible after each consultation.  
Behind the scenes, invaluable support was provided by members of the 
department and hospital research services.  They assisted with patient recruitment 
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and supported the specialists and researchers to successfully undertake the 
research. 
On the advice of specialists who agreed to participate in this study, a strategy was 
developed to enable an appropriate response should any participants become 
upset during the interview process.  This involved gathering resources from the 
Cancer Society and ascertaining contact details for community oncology support 
services. 
Patients  
As previously mentioned the role of specialists participating in this study included 
identifying patients eligible to partake.  The following inclusion criteria were used 
by participating specialists to identify patients eligible for the research: 
 patients who were 18 years of age or older 
 of Māori ethnicity 
 had recently been diagnosed with cancer and were going to discuss 
treatment options at their next consultation (except in the case of lung 
cancer where they may have had a provisional diagnosis). 
Participating specialists also used their discretion to determine if patients were 
sufficiently well to participate in the study. 
In preparation for patient contact a researcher’s recruitment script was prepared 
to guide telephone contact with patients and ensure consistency in the information 
shared with each participant (Appendix D). 
Once a patient had been identified as eligible for the study by the specialist, s/he 
informed the nurse or hospital co-ordinator.  The patient was then contacted 
directly to ascertain their interest in participating in the study.  A referral was then 
made to the researchers for those patients who gave verbal consent for their 
contact details to be shared (Appendix E).  A record was kept of all referrals 
received.  Time available from receipt of a referral to contact and recruitment of 
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patients was limited.  Often there were four days (including two weekend days).  
Within this timeframe the necessary research activities were undertaken 
including: a) inform the potential research participant about the study before their 
scheduled consultation and b) organise logistical issues associated with the 
research process.  See figure 4 for an overview of the patient identification, 
invitation and recruitment process, responsibilities and methods. 
Figure 4:  Patient identification, invitation and recruitment responsibilities, 
overview and method by stage. 
 
On receipt of referrals, the researchers contacted each patient by phone, provided 
further information about the research (guided by the script) and answered 
questions and concerns.  Attempts to contact patients were made the same day a 
referral was received to ensure patients had as much time as possible to consider 
the information and seek advice to enable informed consent.  A record was kept of 
attempts made to contact patients.  All five participants were happy to be 
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When a patient indicated interest to the researchers in participating in the study 
their verbal consent was initially sought.  Further details about processes and 
logistics were then discussed in relation to that particular patient, e.g. meeting 
researchers, appointment time, parking etc.  The specialist and referrer were 
informed by the researcher when a patient had agreed to participate in the study 
so they could prepare for and undertake their roles and responsibilities in the 
research process. 
Patients were asked by the researchers if they were likely to have whānau with 
them on the day of their appointment.  If they had invited whānau, they were asked 
if they would like them present during their interview post-consultation.  The 
patient was asked to inform their whānau of their intent to participate in the 
research and what would occur prior to the consultation, e.g. recording the 
consultation and interview.  Patients were also informed that the researcher was 
available to discuss the research with whānau if requested.  Written information 
sheets were then sent to the patient, using one of three methods (email, post or 
courier) with email and post being the most often preferred.  Sending out 
information provided participants with an opportunity to review and consider 
their participation in the study and discuss this with others if they so desired.  
Additional copies of the information were included for whānau/support people 
when appropriate. 
On the day of the patient’s appointment, prior to their consultation, the lead 
researcher met and welcomed the patient/whānau, re-affirmed they were willing 
to participate in the study, answered any questions and obtained their written 
consent for participation in the study.  Post-consultation, before the interview 
commenced, patients were asked to provide demographic information and 
formally indicate if they wanted a copy (audio-recording and/or typed transcript) 
of their interview.  Whakawhānaungatanga (to establish relationships) and 
rapport building activities occurred during activities as indicated by patient cues. 
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Patient and whānau characteristics 
In total, 23 people were referred to the C3 Qual study.  Of those, 18 patients agreed 
to participate, three did not.  For one non-participant, reasons related to their 
illness, for another work (one Māori participant).  For a third participant, family 
commitments prevented their participation.  One participant was not interviewed 
as the researchers were uncertain if they [the researchers] had been exposed to an 
infectious disease and did not want to risk the well-being of the patient.  One 
person referred did not meet the research criteria.  Of the 18 participants, 13 
identified as NZ Europeans and five as NZ Māori.  The five NZ Māori participants 
are the focus of this research. 
Of the five Māori participants, three were female and two were male.  Ages ranged 
from 32 to 74 years.  Participants experienced a range of cancers including lung 
(unconfirmed), stomach, prostate, and breast.  Four participants also live with at 
least one other disease or health condition in addition to the cancer they were 
attending the consultation to discuss.  One participant, the youngest, did not have 
any other health concerns.  Participant health conditions and comorbidities 
included:  pre-diabetes (suspected), anaemia, cardiovascular disease, gout, chronic 
obstructive pulmonary disease and arthritis.  Participants attended different types 
of consultations, two were seen in medical oncology and three in radiation 
oncology.  Four participants were supported by whānau to their consultation and 
the fifth was supported by a Māori nurse from their primary health care service.  
All consultations occurred in hospitals in the North Island, four in cancer centres 
and one in a regional hospital. 
Four whānau were informed about the study by the patient.  Participating whānau 
consisted of a partner, sisters, a daughter and a grand-daughter and in one 
instance, a nurse from Māori Health Provider (MHP).  The MHP nurse and two of 
four whānau stayed for the interview, two chose not to.  
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Instruments and data collection 
Consultations  
Recording (using a small digital voice recorder) consultations where treatment 
decision-making was to occur was selected as one of the methods to gather data.  
This method enabled the consultation to proceed as ‘normal’, within its usual 
environmental context, a hospital consultation room, and with minimal 
interruption and influence as a result of the research process.  Specialists were 
provided with the digital audio recorder prior to the consultation and were 
responsible for undertaking the recording.  Recorders were kept in a secure place 
by specialists when not in use.  The researcher was not present in consultations. 
Recording consultations may have meant people (specialist and patient/whānau) 
did not behave as usual.  However, evidence suggests that both the patient and 
doctor quickly forget the consultation is being recorded, particularly when the 
situation in which it occurs remains ‘routine’ (K. Dew, personal communication, 
2014).  This enables discussion to occur in a reasonably similar way to that which 
would have been the case in a ‘normal’ consultation situation.  A number of 
participants reported this was the case in this study. 
Interviews 
Patients/whānau were interviewed as soon as possible after their consultation 
occurred.  Interviewing is “…valuable for exploring research topics when there is 
little known about them or the issues are complex” (Liamputtong, 2013).  
Interviewing allowed the examination of participants’ perceptions and shared 
power and control of the research process with the participants who were 
potentially vulnerable.  Interviewing participants soon after the consultation also 
increased the likelihood that information would be ‘fresh’ in participants’ minds.  
The timing of interviews was also considered to ensure participation in the 
research was as convenient for participants as possible.  As the interview was 
recorded using a digital audio recorder, the interviewer could focus on the 
participants and questions, rather than taking notes.  Brief notes were taken by a 
second researcher when present. 
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Based on literature and expert advice a semi-structured questionnaire was 
developed in consultation with C3 Qual team members and piloted.  Questions 
were designed to explore themes related to the research questions, gather rich 
data and expand on ideas raised during the interview by the patient/whānau 
(Appendix f).  Broad theme areas explored included communication, whānau 
participation and treatment (decision-making and status).  Semi-structured 
questions were used which enabled the researcher to tailor questions to 
participants and their context as well as providing an opportunity to develop 
rapport with patients/whānau.  For example, while the questions were ordered, 
how they were asked by the researcher did not always occur in a linear fashion, as 
participant talk sometimes pre-empted topics contained further down the 
interview schedule or returned to a topic discussed earlier. 
The patient/whānau interview questions (Appendix F), patient information form 
(Appendix G), consent (Appendix H), and demographic forms (Appendix I) 
developed for this study were first drafted by a few members of the C3 Qual 
research team (led by thesis author).  They were then circulated to the wider 
research team for review and finalised. 
Conscious that researcher related factors may also influence the process when 
undertaking semi-structured interviews (Dew, 2007), researchers undertook 
interview training to ensure consistency across interviews and maintain patient 
safety.  Additionally interviews were undertaken jointly with an experienced 
interviewer until all individuals were deemed competent by the principal 
investigator (primary supervisor) to interview alone.  Research interviewers 
debriefed post-patient/whānau interviews with each other (when two were 
present), and with the principal investigator (primary supervisor). 
Patient/whānau interviews took place in a variety of hospital and University 
settings.  A change in venue, from the room in which the consultation was 
undertaken, provided an opportunity for patients/whānau to take a mini-break 
and partake in refreshments prior to commencing their interview for the study.  
The change of space also provided further opportunity for the researcher to 
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whakawhānaungatanga, continue building rapport, and check patient well-being 
and willingness to proceed with an interview. 
Specialists’ debriefs 
Specialists’ debriefs capture their valuable perception as a participant in the 
consultation and as a cancer care and treatment provider.  Recognising that cancer 
specialists often work in a highly stressful area with large workloads, it was 
important to make participation in the research easy, with minimal impact on daily 
practice.   Specialists were asked to record themselves answering 12 key questions 
(open and closed) from a prompt sheet using a digital audio recorder (Appendix J).  
This approach kept the requirements of specialists suitably brief and also meant 
they could undertake the self-debrief at a time and in a venue convenient to them. 
The specialist debrief interview questions were drafted by members of the 
research team (co-led by thesis author), and were based on the research questions 
and a review of the literature undertaken for this thesis.  They were then circulated 
to the wider research team for consideration and modifications were made based 
on the feedback received.  Questions asked specialists to consider factors such as: 
what they had told the patient, overall views of the consultation, the impact of 
comorbidity on decisions discussed, and personal characteristics of the patient 
that impacted on the consultation. 
Field notes 
Field notes were made pre and post-consultation and post-interview, capturing the 
thoughts and observations of the researcher about the participants and processes  
(Patton, 2002).  According to Patton (2002) field notes “enable the capture of 
information from formal, informal and unplanned interactions that might assist 
deepen observations” (p. 286). 
Recording and transcribing the data 
Data was gathered using digital audio recordings.  Recordings made by specialists 
(consultation and debrief) were collected along with the interview recording (held 
by the researchers) then downloaded from the recording device onto a secure and 
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virus protected computer that was regularly backed up.  These files were labelled 
and the initial few minutes of each recording were checked to ensure that each of 
the three files belonged to the correct patient and had been labelled accordingly.  
Audio-files were transcribed verbatim by an expert medical transcriptionist.  
Participants were allocated unique codes to maintain anonymity.  The recording 
device was kept in a locked cabinet when not in use.  On receipt of the typed 
transcription file (password protected), original audio files were then deleted from 
the recording device. 
Hard copies of transcribed files were printed and checked for accuracy by one of 
the interviewers against the audio files.  Hard copies of the transcripts were also 
kept in a locked filing cabinet.  Audio-files and typed transcript files held by the 
transcriber were destroyed once advised that the researcher had received them.  
Finally, electronic copies of the transcript files were up-loaded to Dedoose a 
qualitative software management system (SocioCultural Research Consultants, 
2015). 
Data analysis 
A case strategy of inquiry includes a detailed description of the setting or 
individuals along-side generic analysis (Stake, 1995).  Thematic analysis involves 
the process of encoding qualitative data (Boyatzis, 1998).  Three types of case 
analysis strategies were utilised in this study.  Firstly, individual case descriptions 
which looked to identify themes from codes within cases.  Secondly, themes across 
cases were identified.  Thirdly, consideration was given to codes of interest which 
did not recur (salient analysis) yet seemed important to decision-making). 
Data were coded for the established variable of interest, comorbidity and other 
factors in an open and inductive manner, which appeared to influence treatment 
decision-making by listening to the audio-recordings and reading through of text.  
Texts were re-read several times.  An inductive approach was taken when coding 
based on the content of the data.  Codes were examined for themes.  Dedoose, a 
software programme was used to assist with data organization and analysis. 
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According to Yin (2003, p. 116) for case study analysis, pattern matching is “one of 
the most desirable techniques” and appropriate for a descriptive case study when 
specific variables have been established prior to data collection.  In this research, 
pattern matching focused on one variable, comorbidity, and themes that emerged 
within and across the cases.  A cross-case synthesis is a common analytic technique 
employed when there are multiple cases and it potentially strengthens findings 
(Yin, 2003).  Initial conclusions were then drawn within and across cases. 
Themes which emerged from the data were discussed with supervisors on the 
research team.  Given more themes emerged than able to be considered for a 
Masters thesis, selected themes were chosen to focus on.  The themes selected 
occurred frequently within and across most cases.  Comorbidity and selected 
themes were then analysed further giving consideration to a Māori world view 
informed by Durie’s Te Whare Tapa Whā model. 
Saliency analysis is associated with thematic analysis where codes that do not 
recur yet may be important to the study are identified (Buetow, 2010).  In this 
research, saliency analysis was employed when a finding of interest appeared 
important to a participant (patient/whānau, specialist), or the researcher, but did 
not emerge from pattern matching or thematic analysis. 
Final results were reviewed by supervisors and other key team members. 
Ethics 
Ethics approval for the C3 Qual study was initially applied for from the Multi-
Region Ethics Committee, as the research was to be undertaken in two localities 
situated in two different hospitals in NZ. The standard ethics application appeared 
to have been tailored for ‘intervention’ or ‘trial’ type research involving medical 
devices and drugs with the potential for patients to receive differing treatment as a 
result.  It did not lend itself well to qualitative research designed to occur in a 
hospital setting such as this research. 
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The application was heard by the Central Region Ethics Committee, delegated from 
the Multi-Region Ethics Committee at a time when the national ethics process in 
NZ was undergoing a period of change.  Two researchers (Co-PI/supervisor and 
thesis author) attended the session where the application was considered and 
provided clarifications as needed. 
The major issue of concern raised by the ethics committee pertained to the role of 
the treating specialists.  Their role in the study was further clarified to confirm that 
the specialist who was potentially providing treatment to the potential participant 
was not the one who would inform, invite or recruit patients into the study.  Other 
minor amendments were also made. The Central Region Ethics Committee 
approved this study CEN/12/06/026 (Appendix K). 
Locality approval was also sought as a requirement of ethics and to ensure the 
research was appropriately organised. Localities are the areas where the research 
would be undertaken.  Locality assessment approval was provided by the 
participating hospitals and endorsed by their respective Māori advisory groups. 
Additionally, consultation and approval was sought from the University of Otago 
Ngāi Tahu Research Consultation Committee (Appendix L).  This committee is 
appointed by Ngāi Tahu and was established under a Memorandum of 
Understanding between Te Runanga O Ngāi Tahu and the University of Otago (the 
University).  The University, in honouring its commitment to Te Tiriti o Waitangi 
and in recognition of a special relationship with Ngāi Tahu (tangata whenua of the 
South Island), requires all research undertaken by the University, which may be of 
interest to Māori, to have appropriate consultation take place with Māori in the 
development phase of the study. 
Summary 
In summary, this research has drawn on and been guided by a Māori Centred 
Research approach.  This involved a case study approach and qualitative methods.  
Participants recruited to participate in this study included patients/whānau and 
specialists from three NZ hospitals.  Data was recorded and coded from three key 
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points, the consultation, patient/whānau interviews and specialist debriefs.  
Themes emerged by triangulating codes from the three data sources.  Themes 




Chapter 4: Results 
Introduction 
This chapter presents the study results, bringing together cancer treatment 
decision-making information from the four data sources used in the research.  
The first data source was transcripts of consultations where cancer 
treatment decisions were discussed between Māori cancer patients, whānau 
and specialists.   The second was the specialists who recorded their answers 
to a set of questions post-consultation, referred to as the doctor debrief (DD).  
The third source of data was gathered from semi-structured interviews (IV) 
with Māori patients and whānau post-consultation.  The researcher field 
notes are the fourth data source used in this study, which were gathered pre 
and post the consultation and interview. 
The results are presented as a narrative of each of the five individual case 
studies.  Each case study is presented in three parts.  Part one provides an 
overview of the case, part two presents themes which appear to influence the 
patients and specialist’s decision-making and part three presents 
communication and decision-making findings in the consultation, and 
concludes with an overall summary. 
There are three types of participants in this study, patients, whānau and 
specialists.  To assist with clarity of who is being referred to in this chapter 
they have been grouped as follows: 
Each patient participant is referred to as whetū (star).  They have been 
assigned pseudonyms (inspired by Matariki, a star constellation signalling a 
Māori New Year) to protect their identity when being referred to directly or 
when being quoted.  The case names are: Waitī, Waitā, Waipuna-ā-Rangi, 
Tupu-ā-Nuku and Tupu-ā-Rangi. 
87 
 
Whānau participants present in the consultation and interview are referred 
to as either whānau or by the relationship position they hold relative to the 
whetū. 
Specialist is a term used to group medical doctors.  Radiation oncologists are 
medical specialists trained to treat cancer patients with radiation therapy.  
Radiation therapy is one treatment option able to be used in the care and 
management of some cancers.  Medical oncologists are medical specialists 
trained to treat cancer patients using medicines or drugs.  Other cancer 
treatment options include surgical oncology, haematology and palliative care.  
In each of the five cases the specialist’s area of expertise is noted.  To protect 
the identity of specialists participating in this study they are referred to as 
MS1, MS2, MS3, or specialist. 
Where relevant in the text, the particular source of data will also be 
identified.  For example, consultation (Con), Dr Debrief (DD) and interview 
(IV).  Each quote will also identify which participant the quote belongs to if it 
is not previously indicated in the relevant paragraph.  If the quote is from a 
specialist then the patient they are referring to will also be added, for 
example “the patient chose radiation” (MS1, Wai, DD), referring to Specialist 
1, Waipuna-ā-Rangi (Wai) as the patient, and the data source being a doctor 
debrief. 
All consultations were undertaken in a hospital setting, three in regional 
blood and cancer centres and one in a regional hospital.  Interviews were 
undertaken in a hospital whānau care room or in another private space.  
Details about participants and length of consultations and interview are 




Table 1:  Summary of participants in the consultation and interviews 
and recordings lengths 
Case Participants in 
consultation 






Waitī Waitī, the Māori health 
provider nurse (MHP 





Waitī, the MHP 
nurse, and two 
interviewers (thesis 
author and one NZE 
interviewer) 
20 minutes 
Waitā Waitā, his 













two sisters (S1 and S2) 
and the specialist (MS2) 
Medical 
oncology. 
1 hour and 3 
minutes 
Wai, her two sisters 
and two interviewers 






her partner (P1), the 
specialist (MS3) and a 
cancer nurse specialist  
Medical 
oncology. 
1 hour and 11 
minutes 


















Note: Data for the five cases included in this thesis was collected during the period 
August 2013 to April 2014.  
89 
 
Narrative case summary one:  Waitī 
Overview 
Waitī is a woman, mother and daughter.  She is 62 years of age and lives with 
and cares for, with assistance, her 90 year old unwell mother.  Waitī was 
early for her consultation and was assisted by a Māori Health Provider (MHP) 
nurse who drove her to the appointment and pushed her wheelchair.  Her 
daughters were unable to attend the consultation, as one lives in Australia 
and one was working. 
Waitī has severe Chronic Obstructive Pulmonary Disease (COPD) and is 
under the care of a respiratory physician.  She reported that she has lost 
about 70 percent of her lung function and had quit smoking about a year ago.  
Other than a ‘normal’ cough and chest infections which she associated with 
her COPD, she did not appear to have any symptoms.  Waitī had recently been 
advised by her respiratory physician that recent test results suggest she 
likely has lung cancer, and he referred her to see a radiation oncologist. The 
severity of her COPD however, means a definitive cancer diagnosis cannot be 
made. 
The specialist is a radiation oncologist.  He is a male and has been practicing 
medicine in NZ for the past 16 years. 
Themes influencing Waitī’s treatment decision-making 
This section begins by presenting how whānau, the specialist, patient and 
medical factors appeared to influence Waitī’s treatment decision-making.  It 
ends by describing how the specialist’s treatment decision-making appeared 




In Waitī’s case, whānau appear to influence her decision-making in two ways.  
Firstly, and possibly most importantly, she identified in both the consultation 
and interview that her two daughters would be involved and that she would 
not make a decision until she had talked with them.  Waitī is awaiting the 
return of one daughter from Australia.  On her return they would discuss her 
situation before returning to see the specialist with her answer.  Waitī also 
appeared to have been influenced by her daughters’ expectations that she 
have treatment.  She reported that one daughter had offered to go on the 
alternative treatment journey with her, a journey she started pre-
consultation and the other wanted to know why she was “not doing 
anything”, seemingly referring to treatment. 
Secondly, Waitī appears to have considered her mother in her decision-
making.  Particularly as it could compromise her ongoing ability to undertake 
her carer role if she accepted treatment.  Although Waitī rejected this idea in 
her interview, it was apparent in her answer that she had previously given 
thought to the future care options for her mother, stating “I won't put my 
mother in a rest home”. 
Specialist 
The specialist appeared to influence Waitī’s decision-making by determining 
who would be responsible.  Firstly, he did not make a clear treatment 
recommendation, which appeared to be due to uncertainty associated with 
her diagnosis, prognosis and impact the treatment may have on her quality of 
life.  Secondly, when expressing his uncertainty he clearly indicated his view 
that decision-making was Waitī’s, “I guess that's why you're here, because we 




Waitī’s hinengaro (mental well-being) appeared to influence her decision-
making.  Going into the consultation it was apparent that living with a severe 
comorbidity had taken an emotional toll.  At times, Waitī appeared sad and 
expressed hopelessness when talking about her quality of life with the 
specialist.  For example, she described how she had “Absolutely nil.  Absolutely 
none”, referring to her quality of life.  She also went on to describe how 
although she tried to do as much housework and moving about as possible 
she was often unable to complete tasks: “I try and do as much as I can 
[housework, moving around], but then I've just got to give up.” Further on she 
expressed the thought that there was “…nothing good going for me at the 
moment”. 
Having an uncertain diagnosis in itself was a cause of distress.  Several times 
throughout the consultation Waitī made comments indicating her distress at 
her situation stating:  
“I'm asking for a miracle” 
“A lot of different things going through my mind” 
“Oh God, I don't know”  
(Waiti, Con) 
Given her circumstances, it was unsurprising then that Waitī described her 
mind as “going in a whirl”. 
Medical: comorbidity, disease and treatment 
As stated earlier, Waitī has a severe comorbidity, COPD. This appeared to be a 
significant aspect which influenced many factors including her decision-
making.  COPD in her case reduced both her diagnostic and treatment 
options, surgery was ruled out for instance.  In the consultation, the specialist 
explained to Waitī that he and ‘others’ were unsure if she had cancer, 
advising her it was “important for you to know” about the uncertainty as they 
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were “not a hundred per cent.  Eighty... depending on who you talk to... ninety 
percent sure”.  Furthermore, the specialist described the impact he thought 
the treatment might have on her existing poor lung capacity as: “It might go 
from thirty per cent to twenty-seven per cent.” 
While side-effects, such as increased tiredness were of concern for Waitī, 
there was a consensus between her and the MHP nurse that the treatment 
side-effects affecting her lung were of greatest concern, as noted here by 
Waitī and the MHP nurse: 
“Which would leave me what percentage... say I've got 
thirty per cent.... How much more am I going to 
lose?....That's why I ask the question.  If they take away 
even two per cent...It's huge.   (Waitī, Con) 
Will that mean that Waitī ..., if you take away that two to 
three per cent, would she be confined to like basically 
resting most of the day…” (MHP nurse, Waitī, Con) 
Concerns about the side-effects of treatment, particularly further reductions 
in lung capacity were reiterated by Waitī and the MHP nurse throughout the 
interview. 
Prognostic information and treatment effectiveness also appeared to be 
important to the MHP nurse which was evident in questions she raised with 
the specialist.  The specialist indicated in the consultation the prognosis for 
people with a lung cancer diagnosis is usually poor: “So most people, even 
with these smaller cancers, they say ninety per cent don't last three years.  If 
this is a cancer…. And if we leave it without any treatment, most people are 
gone within three years”. 
How Waitī could be supported to live with further shortness of breath 
resulting from the proposed treatment appeared to be an important factor 
raised by the MHP nurse and echoed by Waitī in the consultation.  The 
question of how oxygen therapy might help to relieve Waitī’s shortness of 
breath post-radiation treatment was raised with the specialist by the MHP 
nurse.  Although the specialist indicated oxygen would help relieve 
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symptoms he was unable to provide any detailed information about how that 
might work on a daily basis.  Instead the specialist suggested Waitī and the 
MHP nurse “talk to Dr P [her respiratory specialist] about that”. 
While a large proportion of the consultation was focused on radiation 
therapy, the use of alternative treatments was raised by Waitī and talked 
about again in her interview.   Waitī attended the consultation while already 
using an alternative treatment regimen, which she linked to being Māori. This 
was illustrated when she informed the specialist: “don't know if you know 
much about the Māori ethnicity of ….we try other things.  Alternatives as well”.   
The specialist’s response to alternative therapy was generally positive 
however he reiterated his belief in radiation treatment; the specialist stating:  
“You're welcome to try them, of course. But I feel confident that it [radiation 
treatment] will work”. 
Speaking in detail about alternative treatment appeared to lighten her mood, 
and injected humour into the consultation.  A possible reason for this could 
be a move to talk about something seemingly positive or less gloomy than the 
negative side-effects of radiation treatment.  Waitī described what she was 
taking to the specialist as: 
Waitī: “...apricot kernels, seeds.   
MS1:   Raw?  ((chuckles))   
MHP nurse:  Kind of.  
Waitī: Not pleasant, I can tell you.   
MS1:  ((laughs))  
Waitī:  …and vitamins and all that sort of thing,... 
try and keep it... on an even keel.  But you’re 
allowed a smoothie.  So ((laughs))  
MHP nurse: ((laughs))  
MS1:  ((laughs)) Alright.   
Waitī:  And the thrill of the day:  have a smoothie.  
((laughs))  




Themes influencing the specialist’s treatment decision-
making 
Medical: comorbidity, disease and treatment  
Waitī’s age, fitness for treatment, COPD, disease and treatment factors all 
appeared to influence the specialist’s decision-making.  He assessed Waitī’s 
fitness and ability to participate in radiation treatment during the 
consultation by assessing her ability to walk (unaided) for a distance of about 
20 metres.  In determining if Waitī was ‘fit for treatment’ the specialist also 
sought information from Waitī about the impact COPD has on her activities of 
daily living including mobility asking if she could “get up a flight of stairs, or 
not” for instance.  Although Waitī’s COPD was severe, negatively affected her 
(and meant she was unable to walk up a flight of stairs), the ‘cut-off point’ 
identified by the specialist, the offer of radiation treatment was not 
withdrawn nor did it appear to be altered. 
The severity of Waitī’s COPD had resulted in surgery being ruled out as a 
possible treatment mode prior to this consultation.  Additionally, the 
specialist was also concerned about the speed at which lung cancer can 
progress. This appeared to underpin his preference for early treatment, as he 
explained to Waitī, “If it is a cancer, some cancers grow slowly, but lung cancer 
generally doesn't.  Tends to grow relatively quickly, and spread to other places.  
So it's always easier to treat early if we can”. 
Specialist 
Not unexpectedly, the specialist appears to have drawn on his experience of 
treating other cancer patients in determining the likely effectiveness of the 
proposed treatment for Waitī.  After questioning from the MHP nurse about 
the chances of eradicating Waitī’s lung cancer the specialist explained, that 
“based on what we've done here before, [there is] about seventy per cent chance 
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of getting rid of that [cancer]”.  There was no mention at that time of the 
specialist considering treatment guidelines in Waitī’s case. 
Healthcare system 
Health system mechanisms and processes appear to have influenced the 
specialist’s treatment decision-making in Waitī’s case.  There was mention of 
the specialist talking with Waitī’s respiratory specialist beforehand which 
introduced the possibility that either one or both together could have made 
the decision about which treatments would be offered to her.  It is also 
possible that her case may have been presented at a multidisciplinary team 
meeting where such decisions are increasingly being made. 
Communication  
This section begins by presenting an overview of communication related 
factors that occurred with the potential to influence treatment decision-
making in the consultation.  Treatment decision-making options, processes 
and status are also reported.  The section closes by summarising factors 
appearing to influence treatment decision-making in the consultation. 
The specialist gave Waitī information about the proposed treatment, disease 
status and prognosis which reflect elements of supportive practice that seeks 
to empower and enhance patient autonomy.  The specialist used different 
methods to communicate information (e.g. visual and verbal) and used little 
medical jargon.  Lay language was used to convey information at times but 
not others.  For example, when the specialist showed an x-ray in the 
consultation he explained, “so the black stuff's the lungs.  And I'm just going to 
change the view.  (It's very light)…. you've got severe damage in your lungs”.  
Other information such as lung function and risk of treatment side-effects 
and prognosis were conveyed using percentages.  This approach appeared to 
be effective as neither Waitī nor the MHP nurse reported having problems 
understanding the specialist in their interview. 
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The specialists ‘style’ was also evident at different times throughout the 
consultation and may have influenced decision-making.  In her interview, 
Waitī reported that the specialist was “Very straight up….you can't mistake 
what he's telling you” which may indicate his ‘style’ was clear and 
straightforward for her to understand.  Rapport was evidenced by the 
sharing of information, discussion, and laughter several times towards the 
end of the consultation.  The specialist’s manner was also evident in his 
complementary response towards Waitī’s efforts to give up smoking.  After 
the consultation, both the specialist and Waitī reported positive perceptions 
of each other: 
“He's a very nice man, and very open.  Straight up.  Love 
it….very informative.” (Waitī, IV) 
“…calm and collected and a very thoughtful type of 
person.” (MS1, Waitī, DD) 
Finally, the presence of a third party, the MHP nurse, also influenced the 
communication dynamic.  The MHP nurse potentially influenced decision-
making by asking pertinent questions and providing information about 
Waitī’s well-being.  She also contributed to discussions in a positive and 
helpful way.  For example, she asked about options such as oxygen therapy 
post-treatment to improve symptoms like shortness of breath so Waitī’s 
quality of life could be enhanced. 
Decision-making 
Four treatment options were discussed in Waitī’s consultation.  The options 
of declining treatment and complementary and alternative treatment were 
raised by Waitī, and radical and palliative radiotherapy were raised by the 
specialist.  Considering the risks of adverse impacts and side-effects of the 
proposed radiotherapy treatment from a starting point of 30% lung capacity 
appeared to be a major factor influencing treatment decision-making by both 
Waitī and the specialist.  Although the specialist expressed confidence in the 
treatment, he was unwilling to make a treatment recommendation and 
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clearly placed responsibility for decision-making with Waitī stating “we felt 
that you needed to hear this, to think about it yourself, and just be happy in 
your decision”. 
Perhaps trying to ascertain all her options, Waitī enquired about the 
consequences of declining treatment.  The specialist acknowledged this 
options and assured her she would continue to be monitored and as the 
disease progressed palliative treatment could be considered to manage 
symptoms in the future if she wished. 
In the closing phase of the consultation Waitī shared with the specialist her 
view that she would continue with the alternative treatment she was taking 
as it was not “going to do any harm to try, anyway”.  She also informed him 
she would talk with her daughters and complete a course of the alternative 
treatment prior to returning for her follow-up appointment in a month’s time 
when they could “see where we are”. 
If Waitī were to make the decision to treat, the specialist indicated she would 
be required to undergo a ‘PET’ scan to assess whether the cancer had spread 
to other parts of the body.  The results of the scan could further alter the 
treatment options made available to Waitī. 
Summary 
In Waitī’s consultation several factors emerged which appeared to influence 
her decision-making. Her whānau (daughters) and being in the position of 
having no clear treatment pathway due to the severity of her COPD, seemed 
the most important of these.  Additionally, the impact of the proposed 
treatment on her quality of life, if she chose that option, was of concern to 
both her and the MHP nurse. 
 It was not completely clear which factors were most prominent to the 
specialist and his decision-making in Waitī’s case, except that radiation 
treatment appeared to be the only option offered.  Additionally, it was noted 
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there was an apparent lack of a clear treatment protocol for the specialist to 
draw on to determine the best course of treatment for Waitī. 
Information was shared and communication between all participants 
appeared to occur in a positive manner.  The MHP nurse provided valuable 
information for the specialist, and advocacy and support for Waitī. 
Treatment decision-making also appeared to be, in part influenced by 
activities which occurred prior to the consultation, surgical treatment for 
instance was ruled out.  In the consultation, two treatment options were 
raised by the specialist, radiation treatment and palliative radiation 
treatment at a later stage.  Waitī raised alternative treatments and the option 
of ‘doing nothing’.  The specialist appeared to put decision-making into 
Waitī’s hands, evidenced by the provision of options and expert knowledge 
but no actual treatment recommendation.  Waitī’s decision was to delay 
treatment decision-making for one month, during which time she would 
continue taking the alternative medicine and talk over her situation and 
options with her daughters.  Should Waitī accept treatment further medical 




Narrative case summary two:  Waitā 
Overview 
Waitā is a father, husband and grandfather.  He is 74 years of age and lives with his 
wife who was unable to attend the consultation and interview due to work 
commitments.  Waitā’s granddaughter (adult age) provided transport and 
supported him in his consultation and interview.  He walked slowly with a slight 
shuffle, head still and in a curved downward position.  Waitā worked with heavy 
machinery up until two years ago when a significant cardiovascular event resulted 
in his retirement.  At that time he also ceased smoking and drinking.  As a result of 
multiple and serious health issues, Waitā has had numerous interactions with 
health providers.  He has also become eligible for assistance from the ‘system’ 
which despite being uncertain about, he has had some success in navigating. 
Waitā lives with a number of health issues including a heart condition, severe 
gout, pre-diabetes, arthritis (under the care of a physiotherapist) and has 
previously had a heart attack and strokes.  Furthermore, he has a cardiac 
defibrillator in place.  Waitā also talked about having a range of other health 
related issues including: memory decline, hearing loss, tiredness, and appeared to 
have some shortness of breath.  He takes a number of different medications for his 
conditions and reports taking “a lot of pain killers” and having an inhaler.  Waitā 
indicated his belief that aspirin, which he was on, had “eaten the lining” of his 
stomach and more recently he had been taken off warfarin (a blood thinning drug 
often prescribed for those with cardiovascular disease). 
Waitā reported he was initially treated with antacids by his GP for stomach pains 
thought to be indigestion.  The pain became acute resulting in a collapse at home, 
ambulance assistance and a week-long stay in hospital.  He also had bleeding from 
the bowel.  Waitā recently attended a consultation, supported by his wife and sons, 
where he was informed he had stomach cancer. 
The specialist in this consultation was the same as for the previous case. 
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Themes influencing Waitā’s treatment decision-making  
This section begins by presenting how whānau, the specialist, patient, medical 
factors and healthcare system factors appeared to influence Waitā’s treatment 
decision-making.  It ends by describing how the specialist’s treatment decision-
making appeared to have been affected by Waitā, medical and healthcare system 
factors. 
Whānau 
In Waitā’s case it appears his whānau were a motivating factor to have treatment.  
Waitā expressed concern about his cancer and the risks for his whānau, and was 
particularly concerned for his mokopuna (grandchildren) and worried that the 
cancer might be “catching”.  Waitā’s granddaughter also appeared particularly 
important to him describing her as his ‘caregiver’ and as someone who ‘knew all 
about him’.  It appeared important to him that his granddaughter was able to 
maintain his privacy, however how involved she has been or will be in his 
treatment decision-making was not obvious in the consultation or interview. 
Specialist 
The specialist’s ability to provide treatment safely appeared to be of concern to 
Waitā.  For example, he appeared apprehensive about the specialist’s uncertainty 
regarding where to aim the radiation treatment and asked him to confirm that “in 
other words, when you give me radiation, you're only guessing where it is".  He later 
reiterated his concern about the specialist ‘guessing’ where his cancer was in his 
interview although he also appeared to understand that delivering the treatment 
might be, as the specialist said, “a tricky thing”.  The specialist wishing “it was more 
straight forward” and suggesting that he and his colleagues were “good at 
guessing” did not appear to alleviate Waitā’s concerns. 
Patient 
A range of emotions were expressed by Waitā in his consultation and interview, 
however it was difficult to determine what impact they had on his decision-
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making.  These included disappointment at being refused surgery, confusion and 
apprehension.  Additionally the specialist noted in his debrief that Waitā seemed 
overwhelmed.  In both the consultation and interview Waitā talked several times 
about the pain he experienced, though it was difficult to ascertain the impact this 
was having on his emotions if any. 
Waitā also attended the consultation with a history of being motivated to seek 
treatment.  For example, he informed the specialist he had cycled twice daily 
(using a stationary indoor bike) to improve his fitness so he could have surgery.  
In addition, he appears to have a simple straightforward view of treatment and 
cancer, as he explained in his interview “if it's going to help me, well go ahead and 
do it….I know that I've got cancer, and well... that's it.  Get some treatment”. 
The specialist also noted in his debrief that Waitā’s personality did not lend itself 
to making treatment decisions and having to do so evoked an emotional response 
stating, “He's not really the kind of person that wants to make decisions regarding 
his healthcare.  Seemed a little bit unhappy about having to make those sorts of 
decisions, or even discussing them”. 
Medical: comorbidity, disease and treatment  
Although Waitā’s quality of life is adversely affected by the different comorbidities 
he has, it appears that this factor may have positively influenced his decision-
making.  His response to dealing with his comorbidities and associated symptoms 
has been to seek out help to manage them from healthcare providers.  Seeking out 
help from specialists for cancer therefore follows in this vein. 
Potential side-effects from treatment (e.g. nausea, vomiting and diarrhoea) did not 
appear to overly concern Waitā.  A possible reason for this could be because he is 
accustomed to side-effects from some of his other medications, such as “those 
water tablets”, which make him go to the toilet “every half hour”.  The specialist 





As mentioned previously, other specialists were involved earlier in Waitā’s case 
and it appears as if his expectation of radiation treatment was in part due to 
treatment suggestions made by them prior to the consultation.  Waitā explained 
“… they reckon my next move is to have radiation”.  This was also evident in his 
interview when he explained what he thought the purpose of the consultation was 
for:  “…they were going to check me up.  I thought they were going to ... get ready for 
radiation…, that's what I thought I was coming in for”.  Having multiple health 
conditions, combined with being declined for surgery and having an uncertain 
outcome from his recent chemotherapy consultation may in part explain why 
Waitā attended the consultation confused and under the impression he was going 
to commence preparations for radiation therapy. 
Themes influencing the specialist’s treatment decision-
making 
Patient  
Waitā’s quality of life, which could potentially be improved by treatment, was a 
factor which appeared to influence the specialist’s decision-making. 
Medical: comorbidity, disease and treatment 
Determining Waitā’s fitness for treatment appeared to influence the specialist’s 
decision-making.  To assess Waitā’s fitness the specialist asked him several 
questions about his ability to lie flat for instance, “If you lie down….Flat on your 
back?  No pillows, or anything like that?  Do you think you can do that for twenty or 
thirty minutes?  Lying like that?..You have to lie pretty still for the radiotherapy”.  It 
seemed Waitā’s assurances that he could do as requested was sufficient to satisfy 
the specialist. 
Waitā’s cardiovascular comorbidity was identified as a key factor in the specialists’ 
rationale to offer treatment.  According to the specialist, Waitā’s chances of 
recommencing prophylactic medication (warfarin), designed to reduce the risk of 
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further cardiovascular events, would be improved if the cancerous ulcer was 
“sealed” by radiation treatment.  The importance of this aspect was identified by 
both Waitā and the specialist.  In the consultation the specialist explained, “if we 
were to give you the radiation, it would be because we want you to go on to 
Warfarin”.  At another point he also stated: 
“It [radiation] won't get rid of the cancer, but it might heal the 
ulcer temporarily, and let you go back on the Warfarin for some 
time….right now, the only reason to give you radiation is to... so 
that you could go back on the Warfarin if you wanted to.” 
(Waitā, Con) 
Symptoms were also identified by the specialist in the consultation as a factor 
which would influence his treatment decision-making.  In particular, he urged 
Waitā to report symptom recurrence while awaiting treatment.  Symptom 
recurrence would motivate the administration of treatment regardless of 
associated uncertainty, as the specialist explained to Waitā, “I'll tell you what, if you 
definitely notice any bleeding then we'll do it for sure”. 
The prognosis for Waitā, even though his stomach cancer was small, was of 
concern to the specialist because of the potential for the cancer to grow and 
spread.  Even with the radiation treatment offered, Waitā’s prognosis remained 
poor.  The specialist explained to Waitā, “Even with the radiation therapy, the ulcer 
will come back at some stage….So you're still kind of stuck.  It just gives you a little 
bit of a window.” 
The ability to deliver treatment safely appeared to be a key concern for the 
specialist, however it would not stop ‘them’ trying.  He considered targeting the 
cancer with radiation “a little bit tricky” as there was uncertainty about the 
cancer’s exact location and furthermore it was situated on a moving organ 
(stomach).  The specialist also reported that he was not “absolutely sure” that 
treatment could be given safely but he and his colleagues were “going to try”. 
Healthcare system 
Other healthcare professionals determined which treatment options were 
available in Waitā’s case prior to the consultation, with surgery ruled out and 
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medical and radiation oncology appointments scheduled.  The specialist also used 
the word ‘we’ several times when talking about treatment and developing 
radiation treatment plans for example, indicating that other health professionals 
had been and would be involved in the future. 
Communication  
This section begins by presenting an overview of communication related factors 
that occurred with the potential to influence treatment decision-making in the 
consultation.  Treatment decision-making options, processes and status are also 
reported.  The section closes by summarising factors appearing to influence 
treatment decision-making in the consultation. 
It appears that communication in the consultation was satisfactory for the 
participants as both Waitā and the specialist spoke favourably about each other.  
The specialist reported the consult was “easy” and that there were “no 
communication difficulties” while Waitā reported in his interview, that he 
understood what the specialist had said.  The presence and contribution of his 
granddaughter, who recalled and clarified information may also have contributed 
to Waitā feeling positive about the consultation. 
Waitā’s general health status had declined in some areas which may have 
influenced communication.  For instance, in his consultation he reported having 
difficulty remembering things and spoke of having hearing loss in his interview.  
Despite this Waitā was able to recall fairly accurately in his interview what was 
spoken about in his consultation. 
Information load was noted of concern in Waitā’s consultation by the specialist.  
Narrative in both the consultation and interview indicated he had been ‘pre-
loaded’ with treatment information from other hospital services.  In addition, he 
received a significant amount of information from the specialist in the 
consultation, possibly putting him at risk of information overload, which was 
noted by the specialist in his debrief. 
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It was questionable whether Waitā understood all of what he had been informed 
about or even consented to, to date.  For example, he was unclear as to why he had 
been ”cut open” prior to the consultation until advised by the specialist.  While the 
specialist reported he believed Waitā generally understood most things related to 
his treatment, he was less sure if Waitā fully “understood his treatment options”.  
The specialist attributed his concern to Waitā’s ability to cope with the large 
amount of information given.  Despite the specialist’s misgivings, Waitā credited 
him for improving his understanding of a number of issues relevant to his 
situation.  For example, Waitā explained to the specialist “You know, I've only been 
with you what, how long, and I've learnt a lot about myself.  You see it was never 
explained to me, you know I know what to do, what to expect, what to look for”. 
A range of strategies were utilised to convey information, for example, the 
specialist explained in his debrief how after sensing Waitā had become “…a little 
bit overwhelmed with the amount of information” he then constrained the amount 
of detail given so as to take the “technical level of the discussion down to Waitā’s 
level”.  The specialist also appeared to take a ‘bilingual’ approach at times, using 
medical language first then explaining things in lay terms.  In his debrief the 
specialist explained how he was conscious he “needed to be aware about jargon, 
and sort of try and clarify some of the jargon there that we normally use”.  Perhaps 
due to these strategies Waitā felt sufficiently comfortable with the specialist to ask 
questions when he did not understand something, for example, asking the 
specialist “well what does irritate mean?”.  It also appeared that such strategies 
were effective as Waitā indicated his knowledge about symptoms had increased 
and now he knew what to “look out” for.   
The use of a range of communication strategies and Waitā’s feedback to the 
specialist may also have resulted in the specialist forming the perception that 
Waitā’s understanding of treatment details was satisfactory.  The specialist stated 
in his debrief that he was “fairly certain that he [Waitā] understood the rationale 
and the potential toxicities and the actual challenges of delivering the treatment, as 





As noted previously communication about treatment options commenced 
between Waitā and other medical professionals prior to the consultation.  The fact 
that he had attended the consultation thinking he was going to be ‘measured up’ 
for treatment suggests that Waitā may have decided to accept treatment prior to 
attending the consultation. 
Waitā’s appreciation of the seriousness of his situation appeared to grow as a 
result of talking with the specialist.  Midway through the consultation, for example, 
Waitā informed the specialist he understood “it’s a serious thing…it sounds very 
bad”.  However, a poor prognosis did not appear to negatively influence Waitā’s 
decision to seek treatment. 
Traditional Māori healing methods (traditional healing) had played a part in 
Waitā’s previous treatment choices.  He shared with the specialist his past history 
of having stopped ‘Western medicine, replacing it with traditional healing, and 
expressed his faith and belief that “It worked”.  The specialist’s response appeared 
somewhat short, as he informed Waitā “I don't know anything about that”, closely 
followed by a return to the conversation about radiation treatment.  The primary 
healer Waitā once saw had died and it did not appear as if Waitā had contacted 
any others, therefore it seems unlikely that traditional healing will play a part in 
the future treatment plans for this cancer. 
The specialist recommended radiation treatment, however who would make the 
actual ‘decision’ about this appeared to cause some tension between he and Waitā.  
Waitā’s preference was clearly for the specialist to make the decision as he 
considered him the ‘expert’, which he articulated to the specialist.  In his interview 
he also signalled this view when he stated “Like they're [the specialist’s] the 
experts”.  Ultimately Waitā appeared to consider himself to be “…in his [the 
specialists] hands”.  However, in contrast to this view, Waitā also talked in a 
manner in his consultation which suggested he saw decision-making in a 
partnership way.  For example, his response to the specialist when he was unable 
to indicate how much ‘time’ he might have, was to ask “well what's our next 
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move?”.  While the specialist acknowledged Waitā’s position, it appeared he 
believed Waitā should participate in decision-making. 
Summary 
Several factors emerged in the consultation which appeared to influence Waita’s 
decision-making.  Two central factors appeared to be his desire for treatment and 
the specialist’s treatment recommendation. 
Three key factors appeared to influence the specialist’s decision-making, the 
presence (or absence) of symptoms, Waitā’s quality of life, and treatment benefit 
for his cardiovascular comorbidity. 
Communication appeared to occur with ease in this consultation despite 
differences of opinion at times between the specialist and Waitā.  Information was 
shared between all participants including Waitā’s granddaughter, a regular carer 
for him.  Waitā had been been given a lot of treatment information prior to the 
consultation and his understanding of his situation appeared limited.  The 
specialist recognised that, at times Waitā seemed overwhelmed by the information 
detail and volume. 
Treatment decision-making was in part influenced by activities which occurred 
prior to the consultation.  In the consultation, one treatment option was raised by 
the specialist.  Waitā voiced his preference several times that the specialist make 
the decision, which the specialist did.  Waitā accepted the treatment offered 
however the specialist appeared less certain at the end of the consultation, 




Narrative case summary three: Waipuna-ā-
Rangi 
Overview 
Waipuna-ā-Rangi (Wai) is a 32 year old woman, daughter, sister, aunty and niece.  
She lives with whānau, two sisters and a nephew.  Wai is currently single, in full-
time paid employment and has no known comorbidities.  About three weeks prior 
to her consultation she sought help from her GP for persistent breast pain, outside 
that which she normally associated with menstruation.  Her GP referred her to 
radiology for further investigation. 
Wai attended a radiology appointment where she underwent three procedures 
(mammogram, ultrasound and core biopsy).  She was advised at that appointment 
her results would be discussed at a multidisciplinary team meeting.  Prior to 
visiting her GP to receive her results (which were not available when she did) Wai 
was contacted by a breast care nurse to organise an appointment with a medical 
oncologist. During this period, Wai and her sisters talked with another woman 
who had experienced similar procedures and they began to suspect a cancer 
diagnosis.  Wai was supported to the consultation and interview by her two sisters 
(S1 and S2). 
The specialist was a female medical oncologist with twelve year’s work 
experience.  Ten of those years were spent overseas practicing medicine, hereafter 
she is referred to as the specialist or MS2. 
Themes influencing Wai’s treatment decision-making 
This section begins by presenting how whānau, the specialist, patient, medical and 
healthcare system factors appeared to influence Wai’s treatment decision-making.  
It ends by describing how the specialist’s treatment decision-making appeared to 




Wai was supported to the consultation and interview by the two sisters she lives 
with and whose support and encouragement appeared to influence her decision-
making.  One sister played a larger role verbally, both in the consultation and 
interview than the other, and also supported Wai to her assessment.  The sisters 
generally participated in the consultation through asking questions, repeating 
information, providing information and sharing laughter on several occasions.  
Although one sister noted in the interview that she had gone to the consultation 
prepared to ask questions, most were either asked by Wai or addressed by the 
specialist.  Some questions asked by the sisters may have assisted Wai with her 
understanding of what was being said by the specialist and also addressed 
questions Wai may have had but was uncomfortable asking.  For example, when 
the specialist was talking about the type of surgery that may be undertaken to 
remove the cancer S1 asked her “Will they leave her lop-sided? … does she just put a 
fillet in there”. 
The impact of the support of her sisters was also noted and commented on by the 
specialist in her debrief and by Wai.  In her interview Wai expressed her view of 
support as “I do think for Māori, it is really important to have a support system in 
place“.  The type of support that the sisters offered to provide was emotional but 
also included assistance with transport and treatment administration in their 
home if needed. 
Specialist 
Characteristics of the specialist appeared too positively influence Wai’s decision-
making in the consultation.  Both Wai and her sisters were complimentary about 
the specialist’s ‘style’ in their interview.  Wai’s initial somewhat negative 
expectations of how the specialist might present were not met as she explained in 
her interview, 
“She was really good.  Like I thought it was going to be quite 
cold, but she was actually really lovely.  And she talked to me.  
Like she was talking to me. Like sometimes when you go to the 
doctor it's not like they're talking to you.” (Wai, IV) 
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The specialist’s treatment recommendation, “that we start with chemotherapy then 
go on to surgical resection, and then radiation, and then hormone therapy” 
appeared to be an important influencing factor on Wai’s treatment decision-
making.  Wai and S1’s responses, when asked in the interview if a treatment 
decision had been made or communicated to the specialist, indicated that they 
would do what the specialist recommended. 
Wai:  “Pretty much this is... yeah, this is what we're doing.  
Whenever you [the specialist] want. 
S1: Yeah.  Whatever you [the specialist] say is the best option, 
we're going with treatment.” 
(Wai, IV) 
Patient 
Prior to attending the consultation Wai had begun to prepare for receiving a 
cancer diagnosis.  She sought information about breast abnormalities from ‘Dr 
Google’ and, via her sister had talked to someone who had experienced breast 
cancer. 
“If ((FIRST NAME-S1))'s boss hadn't had breast cancer... I would 
be ill-prepared to hear the news.  I would guess not really 
prepared, but you know, because she had already had 
experience, and then she'd helped, like by talking ((FIRST NAME-
S1)) through her own experience of it, you know I would still 
probably... I'd arrive here today and be like, "Pardon?".  (Wai, IV) 
Wai also consciously prepared herself emotionally for the consultation, driven by 
concern that her emotions could make her journey tougher.  In her interview she 
explained, “before I came to the meeting, I decided to... you just have to push that 
little bit of that emotional thing aside, so that you can actually hear what she's 
saying. Because it's my body.  It's happening to me” 
Additionally Wai’s personality, described by the specialist as “introverted”, along 
with Wai’s own plan to put her emotions aside during the consultation may also 
have accounted for her managing her response to her diagnosis during the 
consultation.  Wai described in her interview how letting her emotions out might 
adversely affect her journey; “if I don't keep myself in check over that, you know, my 
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emotions, then there'd probably be quite a difficult journey for me”.  Her decision to 
manage her emotions prior, combined with the impact of also receiving her 
diagnosis in the consultation may possibly account, in part, for the limited 
emotional expression evident in the consultation.  Much of Wai’s dialogue 
consisted of ‘yes’, ‘no’, ‘okay’ and ‘yeah’ answers. 
About ten minutes into the consultation the specialist became aware that Wai had 
not ‘officially’ been told her diagnosis.  After apologising she informed Wai that 
she had “right sided breast cancer, with lymph node involvement“.  Whether 
receiving her diagnosis in the consultation impacted on her treatment decision-
making was difficult to ascertain.  However, it is possible that responses such as 
shock and anxiety may have occurred.  Despite this Wai and her sisters were able 
to chuckle, joke and laugh in the consultation.  Possible reasons for the use of 
humour may include the nature of Wai and her whānau and their general 
approach to life, or a coping mechanism used in difficult situations (or both). 
Wai expressed in her interview the view that hospital staff focused on the physical 
body whereas her view as a Māori was more holistic, stating “... for Māori, you 
know, because we're mind, body, and soul”.  A possible reason for this perception 
may be due to the large proportion of the care up until the consultation being 
focused on establishing a diagnosis, and then the care focused on the disease and 
treatment factors.  There was evidence however that the specialist did attend to 
emotional and coping factors to some extent in the consultation.  For example, the 
specialist advised Wai that cancer could be “emotionally difficult” and could “take 
you to a very dark place because that sitting at home thinking about having cancer, 
and thinking about chemotherapy for weeks on end, does not put people in a good 
mental health space”. 
Wai’s ability to remain working while receiving treatment was raised as a concern 
by her and her sisters in the consultation and was also mentioned in her interview.  
The specialist’s response indicated her preference for “my ladies to continue to 
work if they can” however she also acknowledged that “lots of women aren't able to 
continue to work on this treatment”.  In the consultation it transpired Wai had 
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already informed her workplace of her situation.  She reported that their response 
was positive as they had recent experiences with staff who had cancer. 
The specialist, in her debrief, identified that Wai was “pretty young”, which made 
her “amenable to treatment”, although Wai herself did not identify this as a factor. 
When asked in her interview about consideration of alternative medicines or 
treatments Wai’s response indicated she had not heard of any nor did she seem 
interested in seeking any out. 
Medical: treatment 
Concerns were raised by Wai and her sister about the side-effects of the proposed 
chemotherapy treatment.  In particular, hair loss and fertility which had the 
potential to influence treatment decision-making.  The specialist raised hair loss as 
a likely side-effect of the chemotherapy drugs, “You will lose your hair.  You will get 
a wig.  That is fully funded”. Wai was sufficiently concerned about her fertility and 
asked the specialist “will I be able to have children?”.  The specialist assured her 
that the treatment should have no long term effects on her fertility nor should it 
stop her from being sexually active. 
Healthcare system 
Healthcare system factors appeared to influence Wai’s treatment decision-making, 
in particular the speed of diagnosis and support available.  The speed at which 
events occurred leading up to Wai’s diagnosis was noted by her in her interview 
where she stated “I went there Monday last week.  It's Wednesday.  That's like... nine 
days later?  Nine days later you've got cancer, girl.  And I was like, ah yeah.”  Wai 
also indicated that making sense of everything that had occurred was a challenge. 
“It's like having a puzzle, but not having the front cover to see 
what the puzzle looks like.... you're getting these pieces, and... 
they just look like puzzle pieces.  But you can't see the 
picture....for me, it would have been better if I had some 




During the consultation the specialist talked about ways to manage treatment 
administration, mindful of Wai’s employment circumstances.  The specialist 
indicated she could organise for her treatment to be given towards the end of a 
week so she had some recovery time over the weekend which could improve her 
chances of being able to return to work the following week. 
The specialist also offered support by way of facilitated access to nurses, social 
workers and the hospital Māori support services, which were accepted by Wai. 
Themes influencing the specialist’s treatment decision-
making 
Medical: comorbidity, disease and treatment 
A range of medical factors including comorbidity, disease characteristics, 
treatment protocols, effectiveness and side-effects all appeared to influence the 
specialist’s treatment decision-making in Wai’s case.  At the beginning of the 
consultation, the specialist asked Wai a range of questions about her health and 
found she did not have any comorbidities to consider in treatment decision-
making. 
Treatment protocols appeared to inform the specialist’s decision-making, as she 
stated in her debrief, “It was reviewed that the standard protocol would be a more 
classic protocol would be surgical resection, but because of the size of the tumour, 
neo-adjuvant therapy is recommended” in Wai’s case. The characteristics of the 
cancer and treatment goals were discussed and linked to the chances of removing 
the cancer.  The specialist for example, informed Wai about the rationale for 
chemotherapy treatment in relation to surgery being due to characteristics of her 
cancer “the size of the lump in your breast, the size of the tumour” which 
underpinned the rationale for offering neo-adjuvant chemotherapy “up front, 
before doing surgery”.  The rationale given indicated the proposed treatment could 
improve her prognosis as they would “try and shrink down your cancer, to try and 
get it as small as possible, to try to improve the chances of fixing it”. 
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Other disease characteristics (positive oestrogen and progesterone receptors) 
were also mentioned as conducive to forming treatment options.  For example, the 
specialist explained that positive results meant the tumour was “less aggressive” 
and open to hormone therapy as a viable treatment modality later on, while a 
third receptor test with an inconclusive result, required further testing to inform 
treatment planning. 
The specialist also expressed concern about Wai’s ability to tolerate treatment, 
side-effects and her tumour’s response to treatment.  For example, an additional 
heart scan was ordered to monitor the effects of one of the proposed 
chemotherapy drugs. 
Healthcare system  
In Wai’s consultation, the healthcare system in the form of a breast 
multidisciplinary meeting was identified by the specialist as a place where Wai’s 
case would be presented, the afternoon of her consultation.  This introduced the 
potential for the breast multidisciplinary meeting to influence treatment decisions 
already made in Wai’s consultation. 
Communication  
This section begins by presenting an overview of communication related factors 
that occurred with the potential to influence treatment decision-making in the 
consultation.  Treatment decision-making options, processes and status are also 
reported.  The section closes by summarising factors appearing to influence 
treatment decision-making in the consultation. 
All parties in the consultation reported having a positive experience with each 
other.  The specialist reported in her debrief that there was “an adequate amount 
of time” in the consultation and that she was impressed by the questions asked by 
both Wai and her sisters.  The specialist also reported that Wai was “delightful” 
and that she did not have any communication difficulties.  Humour resulting in 
shared laughter was also evident several times in the consultation.   
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However there were several communication elements identified with the potential 
to influence rapport in the consultation.  For example as mentioned previously, ten 
minutes into the consultation the specialist became aware that Wai had not been 
given her diagnosis due to a communication error, seemingly between her GP and 
radiology.  This interrupted the flow of the consultation with the specialist 
deciding to go “back to the beginning” and apologising several times. 
Much of the conversation in the consultation was dominated by the specialist, 
seeking out and giving vast amounts of information.  Topics covered included 
disease characteristics, treatment (long and short term modalities, length and 
frequency), treatment side-effects and their management and social issues such as 
employment.  In the first five minutes of the consultation the specialist asked Wai 
approximately 35 questions and later gave about 36 different pieces of 
information in an eight to nine minute period about potential side-effects and 
ways they could be managed.  Wai appeared to cope with this by asking one sister 
to write things down for her so she could ‘listen’. The specialist was conscious of 
the amount of information given, and commented that she was glad Wai had “three 
sets of ears paying attention”. 
Wai’s sisters’ presence and participation in the consultation also appeared to 
influence communication and potentially decision-making.   With support from 
her sisters, Wai was able to reiterate fairly accurately information the specialist 
had provided in the interview.  However, they all struggled at times to recall 
information, particularly detailed medical information, such as the name of 
specific chemotherapy drugs for instance. 
In addition to a high information load, a vast amount of medical jargon and 
complex instructions were given, as evident from the following excerpts: 
“…invasive ductile carcenoma…. There are a few features that 
make them think that it's a particular subtype called 
metaplastic. 
There's a test called the oestrogen receptor, a test called the 
progesterone receptor, and a test called HER2.  Cancers will only 
make the oestrogen and progesterone receptor if they feed off of 
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the female hormones…. therapy targeted at that oestrogen 
receptor, called endocrine therapy, or hormonal therapy. 
You can see here that your tumour is oestrogen receptor 3+ 
positive, and progesterone receptor 2+ positive….Now your 
tumour has been tested for HER2, but the test came back 
indeterminate- which is code for 'unknown'….  So we're doing a 
special second test, called a FISH test.  And when that result 
comes back, we'll make a determination on whether or not you 
need Herceptin. 
The three drugs are 5FU, Epirubicin, and Cyclophosphamide…. 
They're given... in the vein, they're given every three weeks, and 
they're given for three cycles.  Okay, so that's nine weeks of 
treatment….At the end of that, we then transition to a medicine 
called Docetaxel.  It's given either by itself, or if your tumour 
shows that there is HER2 positivity, I would add on Herceptin 
with the Docetaxel….The Docetaxel would be given every three 
weeks for three cycles.  So it's a total of 18 weeks, or four and a 
half months, of chemotherapy. 
(MS2, Wai, Con) 
The specialist appeared to try, at times, to translate jargon into lay language, for 
example “improve surgical clearance” was translated to mean “try and make sure 
we get everything out of the breast”.  Several other communication strategies were 
also employed by the specialist including repetition of information, pausing to 
take questions, and offers of written information to take away. 
Terms used by Wai and her sisters to describe medical information such as “the 
clouds ... and the blobs” for mammogram results and Wai’s statement in her 
interview “Oh God.  Never heard those words before”, suggest they were unfamiliar 
with medical terms generally and found it challenging as many people are in this 
situation.  The challenge of developing an understanding of the language used 
when talking about cancer and how that might enable information to be processed 
was expressed by Wai in her interview: 
……like so cancer has its own language, I don't know anything 
about that language.  But if I did, it'd probably be a lot different. 
Like you know, like a double mastectomy. What does that mean?  
If I don't know that it means that both your breasts have been 
removed. Like do you know what I mean?  Like if there's an 
understanding of the language, or any language, for that, it 
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makes things easier to process, I guess. So if the language 
becomes more common, and we begin to understand what that 
language means.  (Wai, IV) 
Perhaps reflecting on her own position and generation Wai shared in her 
interview how that morning she had thought “probably if it's a little overwhelming, 
they should just make a YouTube video about it”. 
Decision-making 
An overarching treatment plan involving four different modalities was presented 
by the specialist and discussed.  The primary focus of the consultation was on neo-
adjuvant chemotherapy and Wai was provided with details on drug regimens, 
side-effects, ways to manage side-effects and treatment cycles.  The specialist also 
informed Wai of treatment benefits and indicated she would be required to 
undertake three further tests.  The specialist sought an indication from Wai that 
she wanted to proceed with treatment by asking her if it was ‘okay’ to begin 
organising scan dates while she was preparing herself for the physical 
examination.  Towards the end of the consultation Wai was given an appointment, 
for her first chemotherapy treatment.  The option of no treatment or alternative 
treatments were not raised by any party during the consultation. 
Whānau were identified by Wai in her interview as participants in decision-
making as “everything's a whānau decision”.  That statement was made despite the 
fact that Wai’s wider whānau had not yet been informed that she might have 
cancer.  It seems possible her sisters, will likely influence her treatment decision-
making going forward given their involvement to date. 
All treatment options were subject to a caveat placed by the specialist on the 
results of the three further tests, two of which would check whether the cancer 
had spread before treatment would start.  The specialist indicated that she 
undertook the consultation based on the premise the results to the three 





Wai received her breast cancer diagnosis in the consultation.  Unfortunately the 
consultation had commenced before the specialist became aware of this.  She 
revised her approach accordingly. 
Two factors which appeared to be major influences on Wai’s decision-making 
were the specialist’s treatment recommendation and whānau support.  Priority 
was also given to determining which treatment was to be given, rather than 
deciding ‘if’ Wai wanted any treatment. 
There were three key factors which influenced the specialist’s decision-making.  
Firstly, preparing the patient to improve the chance of a positive surgical outcome 
and secondly, reducing the risk of growth and spread.  Third were, treatment 
protocols and review, which recommend this approach to treatment when a 
patient presents with the disease factors Wai had. 
Communication appeared to occur with ease despite the initial challenge 
regarding Wai receiving her diagnosis someway into the consultation.  
Information was shared between all participants including Wai’s sisters who 
provided information to the specialist.  They also provided advocacy and support 
for Wai.  Suspecting she had breast cancer meant Wai attended the consultation 
with some treatment information (not all of medical origin) and was given a 
significant amount more by the specialist.  The amount of information given by the 
specialist was likely influenced by Wai not having had her diagnosis 
communicated to her prior to the consultation.  Much of the consultation 
contained medical jargon which was challenging at times for Wai to understand. 
In the consultation, medically appropriate treatment options were raised by the 
specialist, non-medical alternative treatment options did not feature.  Decision-
making in this consultation appeared to be based on the specialist giving and 
gathering information (including Wai’s values), then making a recommendation in 




Narrative case summary four:  Tupu-ā-Nuku 
Overview 
Tupu-ā-Nuku (Nuku) is a woman, mother of two, grandmother and until 
recently, a mātua whāngai (adoptive parent).  She is a widower, aged 52 years, 
who works part-time at an after-hours medical centre (nursing) and helps out 
on the family sheep and beef farm some 60km from town.  Nuku was supported 
to the consultation by her partner (P1), who chose not to participate in the 
interview. 
Nuku has a range of minor health conditions including lower back ache, 
menopausal symptoms and occasional gout.  Nuku intermittently uses an 
inhaler, takes an iron supplement monthly for anaemia and recently had 
gynaecological surgery.  She has also just completed a course of antibiotics for a 
respiratory type infection/irritation which has not fully resolved. 
While showering, Nuku discovered a lump in her armpit and went to the after-
hours service that same evening.  Nuku reported she and the after-hours GP 
focused on the lump being a possible lipoma and she was referred to a surgeon 
for further tests as a precaution.  She attended the surgeon’s appointment alone 
thinking this was the likely scenario and was overwhelmed when told she had 
breast cancer.  She also commented on the fast speed at which her tests and 
diagnosis had happened, however noted her appreciation for that on reflection.  
She was referred to medical oncology by the surgeon who performed her single 
mastectomy.  Nuku reported her case had been to a ‘multi-meeting’ and that 
there was initial uncertainty about the origin of her cancer which had delayed 
her breast surgery (mastectomy).  The wound from the surgery was still healing 
when she attended the oncology consultation in this study. 
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The specialist was a female medical oncologist (MS3).  This specialist did not 
provide her age or the number of years she has been practicing.  A cancer nurse 
specialist was also present in this consultation who had a long established 
relationship with Nuku. 
Themes influencing Nuku’s treatment decision-making 
This section begins by presenting how whānau, the specialist, patient, medical 
factors and healthcare system factors appeared to influence Nuku’s treatment 
decision-making.  It ends by describing how the specialist’s treatment decision-
making appeared to have been affected by Nuku, medical and healthcare system 
factors. 
Whānau 
Whānau had the potential to influence Nuku’s treatment decision-making in two 
different ways. Firstly, treatment timing, and secondly, by introducing the 
possibility of her cancer having genetic links. 
Nuku’s immediate supporters included her daughter who lives over 500km 
away, a son who lives in town, and her partner.  Her daughter plans to support 
her regularly during treatment.  Nuku, wanting her daughter’s support and 
conscious of the travel, childcare and employment logistics involved, asked the 
specialist to consider that in the timing of her treatment, "And I just need to let 
you know now that you know, she wants to be involved, I want her to be involved, 
so we need to involve her so she can get time off work and come home”. 
The specialist suggested, and Nuku accepted, a referral to a geneticist.  The 
specialist indicated that given her age and breast cancer diagnosis, combined 
with a family history of heart disease, it could be useful to inform how her 
children’s healthcare in the future could be managed.  Particularly for her 
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daughter, who could be advised about when to commence regular screening.  
This factor possibly provided a platform for Nuku to consider her cancer 
diagnosis in relation to the well-being of her whānau. 
Specialist 
The specialist commenced the consultation by establishing what was important 
for Nuku and further into the consultation, employed a number of strategies to 
manage treatment expectations and give support and encouragement.  For 
example, the specialist managed patient expectations by giving “the worst case 
scenario” so her patients felt as if treatment "wasn't as bad” as they thought it 
was going to be. 
The specialist shared with Nuku her understanding about how best to cope with 
treatment indicating it was her team’s job to “get you through this, to keep some 
normality and normal life going on”.  The specialist also conveyed to Nuku, her 
belief she would cope well with the proposed treatment. 
The opinion of the specialist potentially influenced Nuku’s treatment decision-
making in the consultation.  The specialist clearly recommended chemotherapy 
treatment twice in the consultation and provided information to accompany her 
recommendations. 
“So if you say to me what would my recommendation be, it 
would definitely be to try the chemotherapy, up to six cycles 
plus a year of Herceptin. In an ideal world, that's what we 
would like to give you”.  (MS3, Nuku, Con) 
In her interview Nuku indicated that the specialist had told her “exactly what the 




Leading into the consultation it appeared Nuku was struggling to cope with her 
emotions which may have influenced her decision-making.  Several times 
throughout the consultation Nuku shared information which gave some insight 
into her emotional well-being.  For example, she informed the specialist “There's 
too much time to think” and several times throughout the consultation described 
herself as having “lost the plot” in relation to her surgery, firstly because surgery 
had been cancelled and then because it was rescheduled.  There were also 
instances where Nuku expressed uncertainty about treatment and was tearful.  
Nuku also expressed some anxiety about waiting for treatment to commence, 
wishing it was “tomorrow, and then we're on the road”.  Nuku also noted that she 
and her partner “are probably focused on all the negative stuff first.  And we're not 
hearing the good bits.  Like she gave me oh, three pages of Herceptin, and I 
thought, "Oh, here we go”. 
Nuku’s well-being and possibly treatment decision-making may have been 
affected by three whānau related issues including: coping with the recent return 
of a whāngai (foster child) back to their family, her late husband’s cancer related 
death, and her whānau response and expectations related to her diagnosis.  She 
reported having had nightmares about her late husband and the impact of his 
loss was identified by Nuku in her interview as something that could be 
“compromising” her and creating treatment uncertainty.  Receiving care from the 
same doctors and nurses as her late husband seemed to contribute to her 
feelings regarding treatment. 
The burden of coping with other people’s emotions at this time was also 
identified as a concern by Nuku in her interview, “because everybody else around 
me seems miserable.  And that's what I don't want.  I don't want to be like them.  
And yet I don't know how to fix them.  Because they're worried about me”. Her 
response was to “ignore them” and decline their requests to visit “because they 
123 
 
don't look after themselves” and she didn’t want to have to “look after them” given 
her need to focus on her own well-being at this time. 
The impact of treatment on Nuku’s ability to return to nursing work was raised 
as a concern as she has not worked since having her mastectomy and was 
currently experiencing health insurance problems.  Work options were 
discussed in relation to the proposed chemotherapy treatment, in particular 
likely effects and health risks associated with Nuku’s place of employment.  
Nuku expressed concern that her immune system would be compromised as a 
result of chemotherapy and working in a place where she would be regularly 
exposed to “people coming in with bugs and things like that” would put her at 
greater risk of infection.  The specialist indicated that her experience with other 
cancer patients had shown that there were a range of possibilities with some 
continuing to work full-time or part-time with some job modifications.  Her 
experience with nursing staff particularly was that some could not continue to 
work during treatment due to the nature of their job. 
Towards the very end of the consultation the issue with Nuku’s insurance 
provider was discussed.  Although she left mentioning this until the end of the 
consultation, Nuku indicated in her interview that her “main focus for her [the 
specialist] today was…could you sort of put something on paper so that my 
insurance gets paid, and then my living gets paid”.   
Medical: comorbidity, disease and treatment 
A range of disease and treatment related side-effects appeared to influence 
Nuku’s decision-making.  Disease details given by the specialist including 
tumour size (2cm), grade (III), rate of growth (quick and aggressive), growth 
factor (HER2 positive), with lymph node involvement indicated clearly that that 
the cancer had spread outside the breast and was serious.  As Nuku is a nurse it 
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seems possible that she would have a greater appreciation of the seriousness of 
her disease than a patient without a medical background. 
Given her family history of heart disease, Nuku attended the consultation 
particularly concerned about heart side-effects associated with the Herceptin 
drug, which she had anticipated she would be offered.  She raised this within the 
first few minutes of the consultation stating, “Herceptin…. I'm concerned about 
that.  Well probably the side-effects with the heart muscle and things. Because 
we've got a family full of dicky hearts”.  The specialist acknowledged her concerns 
and provided assurance that this could be monitored and managed with regular 
testing using a “standard protocol”. 
Other side-effects commonly associated with chemotherapy such as hair loss 
were also of concern to Nuku.  In anticipation, Nuku informed the specialist she 
had already “got me wig….Picked me hat” and had cut her hair to aid the 
transition. 
Nuku reported using alternative medicines including “wheat grass shots” once 
she received her diagnosis, hoping to boost her immune system in anticipation 
of chemotherapy.  The specialist expressed interest in hearing about the 
alternative medicines. The specialist indicated that ‘they’ did not know enough 
about the “interaction of antioxidants” with chemotherapy and that some doctors 
were looking into the role of selenium.  Later, in her interview, Nuku indicated 
she was concerned about taking alternative medicine while receiving 
chemotherapy fearing “they'd [the doctors] probably give me a higher dose of 
chemo, which I wouldn't want”. 
Healthcare system 
Access to support services and advocacy from health professionals to get the 
system to work for the patient could possibly have influenced Nuku’s treatment 
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decision-making.  For instance, the specialist offered access to a social worker to 
assist with resolving her health insurance issues, and a psychologist to help her 
work through issues related to her late husband.  Nuku gratefully accepted 
referrals and explained in her interview how the referrals provided her some 
relief because she worries about “everybody else worrying about me” and it 
would also provide her whānau with “people to talk to as well”.  Additionally, 
working the treatment booking system to Nuku’s advantage so her daughter was 
able to support her was something encouraged by the specialist.  The nurse 
indicated this was something she did regularly. 
Themes influencing the specialist’s treatment decision-
making 
Patient 
In addition to clinical factors, Nuku’s age and fitness appeared to influence the 
specialist’s treatment decision-making. For example the specialist stated “as 
soon as I see a fit young lady with lymph nodes involved, I'm already thinking 
about chemotherapy”. Additionally the specialist commented in her debrief that 
Nuku was a “very well informed nurse”, who was  keen to progress treatment and 
was well supported by her partner. 
Medical: comorbidity, disease and treatment 
The specialist gathered information from Nuku about her health and well-being 
including comorbidities, and became aware that Nuku had a strong family 
history of cardiovascular disease, often occurring at young ages.  This 
information combined with a recent heart scan result (with less than optimal 
results) and known cardiovascular side-effects from one of the drugs she was 




Although the specialist voiced her position that Nuku had already received the 
most critical mode of treatment (surgery), for her breast cancer, she offered 
chemotherapy treatment due to the potential of disease recurrence and spread 
given her disease characteristics. For example, she informed Nuku that lymph 
node involvement results in “worry about the chances of cancer coming back in 
the future”.  Chemotherapy and Herceptin treatment were identified by the 
specialist as “the only thing we've got then to reduce the chance of the cancer 
coming back” and Nuku’s circumstances warranted an “aggressive approach” to 
treatment. 
Healthcare system 
Often treatment plans are formulated at multidisciplinary meetings, and in 
Nuku’s case it appears the specialist had attended a “big meeting” where her case 
had been discussed and the ”best course of treatment” determined. 
Communication 
This section begins by presenting an overview of communication related factors 
that occurred with the potential to influence treatment decision-making in the 
consultation.  Treatment decision-making options, processes and status are also 
reported.  The section closes by summarising factors appearing to influence 
treatment decision-making in the consultation. 
Information about Nuku had been communicated to the specialist by the cancer 
nurse specialist prior to the consultation, particularly about her emotional state, 
her deceased husband and the amount of information she had been given prior.  
Similarly, Nuku had gathered information about the specialist from colleagues 
and attended the consultation feeling “happy” with who she was about to discuss 
her treatment options with, based on the information she had received.  Nuku 
shared information about herself freely with the specialist and the cancer nurse 
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specialist including her emotions, concerns and her whānau, indicative that she 
felt a level of trust.  The specialist also commented on the benefit of the cancer 
nurse specialist being present in the consultation as “she’d already got a good 
rapport and established relationship with the patient”. 
Prior to the consultation Nuku had been given information by her surgeon and 
other hospital staff.  She had also sought out information from colleagues, a 
neighbour and the internet.  Communication in the consultation was largely 
dominated by the specialist who, conscious of the large quantity of information 
she was going to provide warned her accordingly “I am going to give you quite a 
lot of information”.  This included information pertaining to the disease 
treatment, side-effects and coping strategies.  Nuku indicated she would “have a 
good look at it [treatment information]” at home and take some time to “think 
about it”. 
The specialist utilised a range of approaches to convey information including: 
scenarios, repetition, written information, prioritising information to remember, 
and by regularly asking if Nuku had questions.  She also ascertained Nuku’s 
preferred method for receiving information about risks and benefits by asking 
“do you like to see facts and figures, or do you rather just talk in general terms?”.  
Several times throughout the consultation the specialist indicated there would 
be other opportunities to “recap” and “revisit” with both her and the cancer 
nurse specialist.  It was evident in Nuku’s interview that the specialist strategy of 
prioritising what was important to remember was effective as Nuku reported: “I 
know the one thing that I have to take notice of is my temperature”. 
Rarely did it appear as if the specialist attempted to ascertain Nuku’s level of 
understanding of the information that had been given to her.  In her interview 
Nuku struggled to recall specific details such as medication.  For instance she 
reported in her interview that “with regard to the medication.  I have no idea 
what she was going on about”.  Yet, she was fairly accurately able to recall 
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information about treatment cycles and side-effects.  Nuku appeared 
unconcerned about her inability to recall specific details at this stage saying that 
“by the end of the treatment I'll know exactly what they are.  So I can wait”. 
Nuku described the consultation as going “generally quite well” and her 
perception of the specialist’s communication style as “very good” and “very 
slow…very quietly” noting her belief this style was “very good for P1 as well”.  
Similarly the specialist indicated she had no communication difficulties and 
described Nuku’s preparation of questions prior to the consultation as helpful so 
she could ascertain what was important for her. 
Decision-making 
The specialist primarily discussed chemotherapy treatment details and also 
advised that chemotherapy treatment plans could be altered if needed.  
Additionally, the cancer nurse specialist raised radiotherapy in the consultation 
as a possible treatment as part of the treatment pathway given her age, but 
warned she was “on the cusp” for eligibility.  The cancer nurse specialist had 
delayed the radiation consultation until after Nuku’s medical oncology 
consultation. 
The specialist reported in her debrief that Nuku had accepted the recommended 
chemotherapy treatment perhaps informed by her responses such as “…I'm 
going to do what it takes to do everything, and I'm not going to say no…”.  Nuku 
however, reported in her interview, the need for time to decide, despite saying 
yes to treatment.  When asked if she had decided what treatment, if any, she 
wanted, her replies were somewhat jumbled. For example at one stage she 
replied “not really.  I know that I'm going to take everything that's on offer”, and 





The major factors which appeared to influence Nuku’s decision-making were her 
whānau and her own medical situation.  Additionally her emotional state 
appeared to influence her decision-making going into the consultation, and 
although by the end she seemed somewhat relieved, Nuku still expressed a need 
for time to consider her circumstances. 
Factors which appeared to shape the specialist’s decision-making were the 
multidisciplinary meeting treatment review and treatment protocols indicating 
chemotherapy as the best option for reducing the chance of disease recurrence 
or spread. 
Communication seemed straightforward and appeared to flow in this 
consultation, perhaps as both Nuku and the specialist had gathered information 
about each other prior.  Information was shared between the participants, with 
the specialist dominating a large portion of the talk throughout.  Ascertaining 
from Nuku her preferred method for receiving medical statistics was noted as a 
desirable communication tactic undertaken by the specialist.  Nuku appeared to 
struggle to remember all the information that was provided, but was able to 
focus on what was important to her during the consultation and interview. 
Treatment decision-making appeared to be in part influenced by factors which 
occurred leading up to the consultation, including Nuku changing her mind 
several times about choosing chemotherapy.  In the consultation one medical 
treatment option was raised by the specialist while Nuku also shared her use of 
alternative treatments.  Decision-making was guided by the specialist who 
ascertained from Nuku what was important to her and made a treatment 
recommendation in a seemingly non-coercive manner.  Nuku’s concerns about 
side-effects seemed to be sufficiently addressed and she verbally indicated her 
desire to undergo treatment.  Despite this, later in her interview she indicated 
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she needed more time to consider the information before definitively confirming 
that she would go ahead with chemotherapy.  
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Narrative case summary five:  Tupu-ā-Rangi 
Overview 
Tupu-ā-Rangi (Rangi) is a father and grandfather who is employed full-time in 
the scrap metal industry.  He is 74 years old and lives alone.  Rangi has two sets 
of children, some older in their 50’s and some younger, who reside in the 
Wellington and Auckland regions.  Rangi’s sister supported him to the 
consultation, although was unaware of Rangi’s appointment until he rang her 
that morning asking her to attend.  She appeared anxious about leaving her sick 
husband at home, and that combined with the clinic running late meant she was 
unable to stay for the interview which was then rescheduled.  On the day of the 
interview Rangi was in the process of purchasing a house (settlement day) with 
one of his children. 
Rangi reported taking medication daily for prostate cancer, an iron deficiency, 
cholesterol, and a combined tablet for his heart and kidney.  He has had prostate 
cancer for about 10-12 years, which was detected when he was asymptomatic at 
an opportunistic community screening event.  Rangi was referred by his GP, in 
liaison with his urologist, as recent test results indicated his cancer was growing. 
Rangi has been under the care of a urologist for approximately six years and had 
previously received treatment for his prostate cancer. 
The specialist in this consultation was the same as for Waiti and Waita. 
Themes influencing Rangi’s treatment decision-making 
This section begins by presenting how whānau, the specialist, patient and 
medical factors appeared to influence Rangi’s treatment decision-making.  It 
ends by describing how the specialist’s treatment decision-making appeared to 




Two sources of whānau support were apparent in Rangi’s interview, although it 
was difficult to detect if this influenced his decision-making.  Firstly, support was 
available from his whakapapa whānau (genetic relatives) including his sister 
who supported him to the consultation, and his children.  Secondly, he indicated 
support was available from his workplace whānau (workplace colleagues 
considered family).  He described his workplace as being “quite a family sort of 
affair”.  In his interview Rangi described how his perceived need for support 
changed during the consultation.  He went from thinking he needed support 
going into the consultation, to thinking while in the consultation that he would 
be able to ‘draw’ on himself.  Rangi indicated he would only need support 
“…maybe if I was pretty weak”.  Should he need support in the future Rangi 
described how he could get this from his children who know about his cancer 
and treatment although not how “serious” it is. 
Specialist 
The specialist made a clear treatment recommendation in the consultation 
saying “I think it [radiotherapy] would be quite useful for you” which appeared to 
influence Rangi’s treatment decision-making.  Rangi’s response “And when will 
that start?” possibly signalled a pre-existing intent to continue accepting cancer 
treatment.  Another possible reason for this may be that Rangi perceived the 
specialist as an authority on cancer and treatment.  When the specialist informed 
Rangi how treatment could be “stretched out over two weeks” to make it more 





A range of patient specific factors such as philosophical outlook and work 
retention appeared to influence Rangi’s treatment decision-making.  Rangi’s 
optimism featured in his consultation and interview.  For example, his optimism 
was highlighted towards the middle of the consultation in a response to the 
specialist, “Because like I say, if it's going to help me, all good.  That's the way I 
look at it”.  He also appeared unconcerned about side-effects: “Well hey, there's 
side-effects for from anything…. like I say, we'll have to go through it before we can 
find the effects”.  And then his will to live and easy going attitude showed later in 
his interview when he indicated he was aware that his time on Earth was limited 
and if treatment was going to “give me more living the life, yeah, hey why not?”. 
The ability to keep working while receiving treatment also appeared to be 
important to Rangi. In his consultation for example, he appeared relieved to hear 
from the specialist he would be able to go to work after each treatment 
appointment.  The importance of retaining his employment was also shared by 
Rangi in his interview when he explained how, after his treatment, if he was 
“okay” then he could drive himself “straight to work”.  It seems possible that 
despite being of pension age, Rangi may require additional income from paid 
employment to service his pending mortgage. 
In addition to the radiotherapy treatment discussed in the consultation Rangi 
talked of complementary and alternative medicine in his interview.  He 
described how a friend had encouraged him to use lemon tea as it was 
“apparently more stronger than chemo”.  While appearing open to trying it, he 
also seemed to have a low expectation of it working saying he did not expect to 
be “cured overnight” from it.  It did not appear as if this would influence his 




The specialist’s ability to work the system so that Rangi’s treatment 
appointments could be booked at a suitable time appeared to be important to 
Rangi’s decision-making.  Early morning appointments, for example, worked 
well for Rangi as they maximised the potential of him being able to go straight to 
work afterwards, which he appreciated. 
Medical: comorbidity, disease and treatment 
Comorbidity and treatment factors, while talked about in the consultation, did 
not appear to influence Rangi’s decision-making, however disease factors did.  
For example, Rangi was interested in knowing the results of his most recent 
tests to which the specialist informed him there was a change in his disease 
status due to “a growth in the prostate” which had spread by sending “seeds into 
the bones”.  It appears that the change in disease status in particular may have 
influenced Rangi’s treatment decision-making. 
Full details about what would be involved with undertaking radiotherapy were 
discussed including length, frequency, procedures, treatment goal and benefits.  
And, although the specialist warned Rangi that treatment benefits could be un-
noticeable because he was “actually really well” this did not appear to deter his 
decision to accept radiation treatment. 
Themes influencing the specialist’s treatment decision-
making 
Patient 
The specialist described Rangi as someone who did not appear to be interested 
in waiting for “more severe symptoms” to develop, which possibly indicates the 
specialist may have viewed him as a patient motivated towards treatment. 
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Medical: comorbidity, disease and treatment 
Patient symptoms and disease factors appeared to influence the specialist’s 
treatment decision-making, while patient comorbidities did not.  In Rangi’s case 
the specialist ascertained information about symptoms by asking “Any 
problems?” and although Rangi replied “No” the specialist probed further.  Rangi 
revealed he had recently experienced back spasms and swelling in his leg.  
Symptom management seemed significant to the specialist as he later explained 
to Rangi his rationale for treatment was designed to “prevent it from getting 
worse”. In his debrief, the specialist also indicated as Rangi had symptoms, 
radiotherapy treatment was indicated. 
In addition to symptoms, new information about Rangi’s disease from prostate 
antigen and other test results indicated “quite a big bulk”, and spread of the 
cancer.  These factors appeared to be important to the specialist in determining 
treatment.  The need for the specialist to have this information stood out as he 
halted the consultation until he was able to access it (it was not available in 
Rangi’s file and he had to leave the room to view films).  The specialist also 
reported that when a patient, such as Rangi, had “progressed through first-line 
hormone treatment for his metastatic prostate cancer” the “next treatment is 
radiotherapy for symptomatic areas”.  This suggested that a treatment protocol 
may have guided the approach being taken by the specialist to his treatment.  At 
the end of the consultation the specialist also indicated a further “special” 
radiotherapy scan was required to aid the development of Rangi’s treatment 
plan. 
Communication  
This section begins by presenting an overview of communication related factors 
that occurred with the potential to influence treatment decision-making in the 
consultation.  Treatment decision-making options, processes and status are also 
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reported.  The section closes by summarising factors appearing to influence 
treatment decision-making in the consultation. 
The parties in this consultation, except Rangi’s sister who did not appear to 
speak, seemed satisfied with each other and their exchanges.  Communication in 
the consultation appeared to be largely controlled by the specialist with the 
majority of talk originating from him focused on giving and collecting 
information.  The specialist confirmed with Rangi information he had received 
about him regarding his history, and gathered information on a range of topics 
including: symptoms, well-being, living situation/family, smoking and alcohol 
use.  The specialist gave Rangi explicit information about his cancer and the 
proposed treatment including goal, benefits, side-effects and limitations.  Rangi 
was provided with the opportunity to ask questions.  Once Rangi had verbally 
agreed to treatment the specialist provided more detailed information about 
treatment provision. 
Rangi appeared slightly confused about past and present medication and cancer 
treatment in his consultation and interview.  Rangi expressed his expectation 
that the doctors have that information and that they should share that with each 
other. 
Neither the specialist nor Rangi talked explicitly about prognosis at any time 
during the consultation, rather the specialist indicated to him that the goal of 
radiotherapy treatment would not be to cure the cancer, but to “shrink it down 
for some time”.  One interpretation of this portion of the transcript could be to 
suggest the specialist was implying to Rangi, that the cancer cannot be cured.  
Rangi’s general responses to information about treatment and side-effects 
suggested he had some awareness of his prognosis. 
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The specialist used a mixture of medical and lay terms to communicate 
information, for example he explained how Rangi’s cancer may have spread 
using lay terms: 
So prostate cancer is when cancer grows inside the prostate.  
So it can grow up yeah, and start affecting the bladder.  It can 
grow back and start affecting the bowel.  But it can also send 
little seeds along further to other places in your body, and they 
grow (like that). (MS1, Rangi, Con) 
Despite the missing scan results, the specialist reported that there were no 
communication difficulties in the consultation.  He reported that Rangi had 
plenty of opportunities to ask questions and there was sufficient time for the 
consultation as Rangi was the last patient in that day’s clinic.  The specialist 
described Rangi as “very easy to talk to, quite relaxed”.  The specialist also 
reported in his debrief that he thought Rangi had understood the treatment 
options but not necessarily in any depth suggesting “perhaps [Rangi] didn't want 
to understand a great level”.  The specialist believed that Rangi had made a 
“reasonable decision”. 
In his interview Rangi described the consultation positively and reported that he 
understood what the specialist had said to him.  Possibly in relation to the 
specialist having to leave the consultation to review results and not having been 
provided information about medication (e.g. from his urologist and GP), Rangi 
noted that he was “quite an efficient doctor.  But he seems to have too many things 
going at once, he wasn't quite prepared”.  Despite this, Rangi reported that the 
specialist was “great”. 
Decision-making 
Early in the consultation Rangi indicated he wanted the radiation treatment 
offered however, the specialist indicated his desire to provide more information 
about the proposed treatment first.  Towards the end of the consultation the 
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specialist explicitly ascertained Rangi’s treatment decision by asking him 
outright “sounds like you want to have radiotherapy?”.  To which Rangi’s informal 
“Yeah” reply indicated he had decided to have the treatment discussed.  The 
specialist also sought Rangi’s written consent in the consultation.  No other 
treatment options, such as no treatment, were raised by either of the 
participants. 
Summary  
Several factors emerged which appeared to influence Rangi’s decision-making 
including being prepared to continue treatment and his optimistic outlook on 
life.  Being able to undergo treatment and keep working was also appeared 
important to Rangi. 
Two key factors appeared to have an important influence on the specialist’s 
decision-making.  Firstly, Rangi’s motivation for treatment, and second, disease 
treatment protocols indicating that radiotherapy is indicated when a patient 
with Rangi’s disease characteristics is no longer responding to first-line 
treatment. 
Although communication in the consultation was interrupted by missing 
information, Rangi and the specialist both reflected positively on the 
consultation.  Rangi appeared to have a limited desire to develop any in-depth 
understanding about his disease and treatment and this was noted by, and of 
some concern to the specialist, who responded by persisting with information 
provision. 
Treatment decision-making appeared to be influenced in part by Rangi’s history 
of seeking treatment and the healthcare system (GP and Urologist) which 
referred him to the specialist.  It was unclear if his case had been reviewed in a 
Multidisciplinary Team Meeting, or if other treatment options, such as surgery, 
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had been considered.  In the consultation, one medical treatment option, 
radiation therapy, was presented.  While an alternative treatment option was 
mentioned in his interview other options such as watchful waiting were not.  
The specialist appeared to ascertain in part, Rangi’s values, determined the best 
treatment, and formally sought his consent.  Rangi agreed to undergo treatment. 
Across Case Summary 
Five narrative case summaries identifying factors appearing to influence 
treatment decision-making in consultations with Māori patients with cancer, 
their whānau and specialists were presented.  Particular attention was paid to 
comorbidities as they had previously been identified as a cause of cancer 
treatment inequities, and Māori have a higher incidence of comorbidities 
compared to non-Māori.  The findings were ascertained using the four data 
sources and qualitative methods referred to in the methodology chapter.  The 
use of Te Whare Tapa Whā and Mead et al.’s (2013) model were helpful when 
considering factors influencing patients’ decision-making. 
Of the five cases presented comorbidity appeared to have clearly influenced 
treatment decision-making in two.  The patients in these two cases appeared to 
have severe comorbidities (cardiovascular and respiratory), however their 
comorbidities did not appear to negatively influence the treatment they were 
offered in the radiation consultations studied.  The specialists did however 
inform them that other treatment options such as surgery had been ruled out 
earlier in the treatment decision-making pathway.  It appeared that risks to 
patients’ lives associated with surgery were deemed unacceptable and the risks 
appeared to be exacerbated by their comorbidities. 
Themes relating to whānau, specialists (particularly their treatment 
recommendation), patients and medical factors (including, comorbidity, disease 
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and treatment) appeared to influence patients’ decision-making in different 
ways within cases.  Healthcare system factors appeared to influence some.  
Medical (including, comorbidity, disease and treatment) factors seemed to be 
the primary influence on specialists’ treatment decision-making.  Healthcare 
system factors also appeared to influence specialists’ decision-making in four of 
the five cases. 
Patients/whānau and specialists in all five cases generally talked in a 
complimentary and positive way about each other.  Also notable, was the 
significant amount of medical information given to patients by specialists 
knowing that it was a lot for most to take in.  All specialists utilised strategies at 
times to aid patient and whānau understanding of medical jargon. 
Specialists attended consultations having prepared a treatment option (relative 
to their specialty) based on known clinical (particularly, medical history and 
disease) factors.  Other treatment options unfolded in some cases during the 
consultation.  Specialists’ treatment recommendations appeared to be very 
important to patients, and whānau were particularly important in the one case 
where no treatment recommendation was made.  A treatment decision was 
made by all five patients in their consultations.  Four appeared to accept the 
treatment option offered by the specialists and one decided to delay decision-
making due to complications caused by her comorbidity.  The themes identified 
above which appeared to influence treatment decision-making will be discussed  
in the next chapter.
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Chapter five – Discussion  
This thesis has explored factors influencing treatment decision-making in cancer 
consultations with Māori patients/whānau.  Particular attention was paid to 
comorbidity given the higher burden amongst Māori with cancer (Hill, Sarfati, 
Blakely, Robson, Purdie, Dennett, et al., 2010; Sarfati et al., 2016; Sarfati et al., 
2011).  This Māori centred research study utilised case study methodology and 
qualitative methods to collect and analyse data and to help ‘make sense’ of the 
complex phenomena of factors influencing treatment decision-making in cancer 
consultations. 
This chapter provides a discussion of the key findings and makes 
recommendations about factors influencing cancer treatment decision-making 
in the context of consultations with Māori patients/whānau.  Similarly to 
previous chapters, discussion of key findings has been organised to reflect 
factors influencing both the patients’/whānau and specialists’ decision-making 
separately.  A conceptual model draws together these factors.  The chapter ends 
with an examination of the strengths and limitations of this study, a conclusion 
and summary of recommendations. 
To my knowledge this is the first ever study which has explored factors 
influencing treatment decision-making in cancer consultations with Māori 
patients/whānau.  Factors which appeared to influence patients’ decision-
making included: whānau; specialist factors particularly treatment 
recommendations; emotional wellbeing; medical factors such as comorbidity 
(particularly when severe), disease and treatment and; the health care system 
factors.  Factors which appeared to influence specialists’ decision-making 
included: medical factors like comorbidity, disease factors like symptoms and 
treatment; health care system factors such as multidisciplinary team 
recommendations; patient factors like fitness for treatment and; specialist 
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factors such as previous experience.  Decision-making processes and 
communication factors also appeared to influence participants’ decision-making 
in the consultation. 
Factors influencing patients’ decision-making  
A number of the factors found in this study to influence patients’ decision-
making are consistent with past research involving Māori, although not specific 
to cancer.  These are whānau (Dew, Signal, et al., 2015; Durie, 1994; Glover et al., 
2007; Nikora et al., 2012; T. Walker et al., 2008), patient factors and information 
(H. Tupara, 2009).  Other factors that were identified in this study but were not 
in found in the literature relating to Māori include the specialists’ treatment 
recommendations, comorbidity, and the health care-system.  This is most likely a 
reflection of the paucity of research and published literature on Māori treatment 
decision-making. 
There is a scarcity of literature relating to how comorbidities influence 
treatment decision-making in cancer consultations and none specific to Māori, 
nor other indigenous people and racial and ethnic minority groups.  This occurs 
despite these groups commonly having higher rates of comorbidity and poorer 
cancer outcomes than their majority population counterparts.  In NZ, Māori with 
cancer tend to experience higher rates of comorbidity than non-Māori (Hill, 
Sarfati, Blakely, Robson, Purdie, Chen, et al., 2010; Stevens et al., 2008).  In this 
study, four of five Māori patient participants had comorbidities requiring 
medication.  The impact of comorbidities on patients’ lives varied and appeared 
to be affected by the type, severity and/or number of comorbidities they had and 
how well they were managing. 
In this study the lives of patients with major comorbidities were significantly 
affected by their comorbidities.  They did not work and needed additional 
support.  This finding is consistent with research by Fortin et al. (2006) which 
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found comorbidity adversely affected health related quality of life in adult 
patients (Fortin et al., 2006).  In contrast, the lives of patients with less severe 
comorbidities in our study seemed minimally affected, except perhaps for taking 
daily medication.  Patients’ views of comorbidities also varied including what 
patient’s considered to be a comorbidity and the perceived importance of this in 
relation to their cancer.  Some patients expected that doctors would ‘know’ and 
determine if their comorbidities were important to decision-making or not. 
The attitude of patients to decision-making has been noted to have an influence 
on treatment decisions (Shelton et al., 2013).  This was seen in the current study 
where patients with comorbidities had established regular treatment seeking 
patterns over time and signalled early in their consultations their intent to take-
up the treatment offered.  There appears to be a lack of literature that studies 
the attitudes of indigenous patients to cancer and treatment, with or without 
comorbidities. 
Patients who have received a cancer diagnosis are often offered some form of 
treatment  with the intent being curative or palliative and at times, may involve 
more than one treatment modality (National Bowel Cancer Tumour Standards 
Working Group, 2013; National Breast Cancer Tumour Standards Working 
Group, 2013).  Additionally, the treatment may be neo-adjuvant (lead in to main 
treatment), primary, adjuvant (in addition to primary treatment) or second line 
(treatment offered when primary treatment is no longer working or 
contraindicated).  The results of this study are consistent with the Sarfati et al.’s 
(2016) review, which reported that some patients with comorbidities are less 
likely to receive curative treatment than patients without.  This was particularly 
so for the two patients with severe comorbidities who had surgery, considered 
primary first line treatment (treatment considered optimal), ruled out because 
of their comorbidities. 
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For patients, disease progression and prognosis appeared important.  In this 
study the risk of adverse side effects was greater for one patient with a major 
comorbidity which appeared to contribute to patient distress, increased patient 
treatment information seeking and influenced the decision-making process.  
Treatment side-effects were also important to patients who wanted to know 
what to expect and what could be done to manage side-effects.  Previous 
research has identified that disease related factors influence patients’ decision-
making and treatment decision-making, including the impact of side-effects (E. L. 
Mead et al., 2013).  Specialists should be mindful that cancer patients with major 
comorbidities may have greater psychological and information needs. 
This study also supports previous research into cancer treatment and 
complementary and alternative medicine (CAM) use by cancer patients 
(Chrystal, Allan, Forgeson, & Isaacs, 2003; Horneber et al., 2012).  CAM may be 
considered and used by cancer patients as part of their cancer treatment 
regimen either in combination with or as a complete alternative to Western 
medicine.  In this study, four Māori patients with comorbidities talked about 
using alternative healing medicines and methods.  Specialists’ responses were 
generally accepting and may also relate to the patient’s prognosis.  Lack of 
knowledge about CAM has been identified in NZ as a possible barrier to 
communication between the patient and specialist (Bocock, Reeder, Perez, & 
Trevena, 2011).  Increasing specialists’ knowledge and communication skills 
when talking about CAM in cancer consultations where treatment decisions are 
made may be an area for improvement. 
Waitī’s use of CAM was the most prominent of the four cases studied.  CAM use 
by patients has been linked to hope (Richardson, Sanders, Palmer, Greisinger, & 
Singletary, 2000) which may be the case for Waitī given the risk of adverse 
treatment effects and her poor prognosis.  This research also found similarities 
with literature reporting patient desires for holistic care involving CAM and 
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traditional Māori healing methods (T. Walker et al., 2008; Walton, Reeve, Brown, 
& Farquhar, 2010). 
Patient attitudes about their cancer, treatment and decision-making varied in 
this study.  Some patients wanted the doctor as the ‘specialist’ to decide the best 
treatment while others expressed their ‘autonomy’ to varying degrees in 
information seeking and decision-making.  Some patients appeared to have an 
optimistic outlook towards life and their treatment while others were gravely 
concerned about both.  These findings are in agreement with Mead et al.’s 
(2013) literature review which found patient attitudes and concerns may 
influence treatment decision-making. 
Another important finding was how negative past experiences of cancer within 
whānau can influence participants emotional responses to their diagnosis and 
potentially their decision-making.  While family, friends and important others 
experiences of cancer have been found to influence patients’ treatment decision-
making, patient experiences of coping with cancer within the whānau were not 
(E. L. Mead et al., 2013).  Emotional responses in this circumstance are not 
wholly surprising given the emotional toll a cancer diagnosis can have on a 
person.  Concern about the psychological status of one patient was attended to 
by the specialist in the form of a referral for the patient and whānau to support 
services.  It seems plausible that the emotional burden cancer patients 
experience may be amplified in such a scenario.  These types of experiences, 
involving whānau dying after receiving a cancer diagnosis and/or treatment, 
may also increase the risk of Māori, experiencing spiritual issues.  In Tranberg et 
al.’s paper spiritual issues with Aboriginal people were linked to fatalism 
(treatment is ‘pointless’ and death as the outcome cannot be altered).  .  
Evidence of Māori fatalistic thinking however was absent from the data and 
literature reviewed in this study. 
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One unanticipated finding was the employment of humour by patients and 
whānau in some consultations.  In one consultation the patient’s predicament 
was fairly dire yet humourous talk emerged about private body parts.  In cases 
where humour was present it appeared to lighten the mood of the consultation, 
similar to findings by Dew et al. (2015).  Humour, when used at the right time 
with Māori has also been identified in the literature as something which can aid 
rapport building and put patients at ease (Cram, 2014b). 
Prior studies have noted the impact of a cancer diagnosis on patient employment 
and household income (Bennett et al., 2008).  In some cases, maintaining 
employment was identified as an important issue and workplaces were reported 
by participants as being supportive.  Rangi even attributed ‘whānau type’ 
qualities to his workplace.  Maintaining employment has been linked to 
empowering the patient to help understand and manage their cancer experience 
(Egan et al., 2016). 
The prevalence of mental disorders such as depression and anxiety is high for 
cancer patients (Mitchell et al., 2011).  Additionally the risk of mental disorders 
is higher for cancer patients than the general population (Hinz et al., 2010) and 
the prevalence is higher in patients with comorbid disease such as COPD 
(Rapsey et al., 2015).  In this study, some patients’ mental states appeared to be 
affected differently by their comorbidities, which in turn may have influenced 
their decision-making.  In Waitī’s case her vulnerable mental state was evident 
however her mental wellbeing did not appear to be well attended to by the 
specialist.  Luckett et al.’s (2011) study found some ethnic minority cancer 
patients report significantly worse distress and depression than majority 
populations (Luckett et al., 2011).  This study however did not attempt to 
compare Māori with NZ Europeans (the majority population in NZ). 
Prior studies have also noted the importance of whānau in the patient’s cancer 
experience (Dew, Signal, et al., 2015; Slater et al., 2013; T. Walker et al., 2008).  
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This study showed that patients considered and involved whānau in treatment 
decision-making in various ways.  All participants were supported to their 
consultations, four of five participants by whānau members.  Whānau support to 
consultations is unsurprising given that Māori culture is based on collectivist 
principles (Patterson, 1992) and in line with work by Durie which suggests that 
Māori health and decision-making is aligned to interdependent approaches 
(Durie, 1994). 
In this study, whānau were considered by some participants to have a right to be 
involved in treatment decision-making.  Whānau played many roles across and 
within the different cases such as provider of normality, information 
gatherer/stimulator/provider, aid to carrying the ‘load’, protector and advocate.  
Participants also considered the impact of their treatment choices on whānau.  
These findings were not unexpected, as whānau have been identified as 
important in decision-making in traditional and contemporary contexts (Durie, 
1994; Nikora et al., 2012; Hope Tupara, 2012).  There are also similarities 
between these findings and those related to whānau in New Zealand cancer 
literature by Walker et al. (2008), Slater et al. (2013) and Egan et al. (2015).  
This result also loosely matches the findings of Mead et al.’s 2013 review with 
regard to the influence of minority racial and ethnic groups family on decision-
making. 
It is interesting to note however, that not all participants involved whānau in 
decision-making directly.  No evidence was found to explain why Māori patients 
may not involve the wider whānau in decision-making at the consultation.  This 
result may simply be a reflection of differing participant preferences or may be 
for more complex reasons relating to whānau dynamics and changing realities 
for Māori, ultimately as a result of colonisation.  Additionally, many Māori living 
in modern day Aotearoa have integrated Western/NZ European cultural 
practices into their lives..  Durie (1994) argues that Western culture in NZ values 
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self-sufficiency and independence which could explain a preference by some 
participants for a more individualistic decision-making approach.  Many Māori 
have also become isolated from their home lands and other whānau members 
due to living large distances from both, therefore involving whānau in decision-
making may be more challenging.  This isolation may be further exacerbated as 
many whānau now live overseas.  Over 100,000 Māori live in Australia for 
instance (Statistics New Zealand, 2015).  Another possible reason for not 
involving whānau could be to protect them or to enable the patient to choose an 
appropriate time to share their situation and reduce anxiety. 
The role of whānau influence in patients’ treatment decision-making seen in this 
study is consistent with Lawrenson et al.’s (2010) study of rural general 
practitioners’ perceptions of Māori palliative care requirements where whānau 
were identified as key in patient management (Lawrenson, Smyth, Kara, & 
Thomson, 2010).  This research appears to be the first to attend to specialist’s 
perceptions of the influence whānau may have on Māori cancer patients’ 
treatment decision-making in the outpatient secondary cancer care setting.  A 
possible explanation for the role of whānau emerging as an influence may be in 
part due to improvements made to doctors’ training in New Zealand.  For 
example, the University of Otago medical school trains new doctors using 
models like Waikare o Te Waka o Meihana in which whānau are recognised 
(Pitama et al., 2014). 
These results may help us to understand one element, how whānau influence 
treatment decision-making, in the complex array of factors which influence 
Māori patients’ decision-making in cancer consultations. 
In NZ, the health care system (the system) has been found to influence access to 
treatment for cancer patients and Māori in particular (Cormack et al., 2005).  
The system largely sets policy, processes and procedures which guide how 
consultations are undertaken.  In this study, patients were referred for 
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treatment and consultations largely followed conventional processes whereby 
the patient (including whānau/support) met with a specialist (and a breast care 
nurse specialist in one consultation) in a private room, and shared and discussed 
information.  None of the participants had met prior.  Most consultations also 
involved a physical examination.  Consultation appointment lengths generally 
aligned to the times scheduled, with radiation oncology appointments lasting 
about 30 minutes and medical oncology about 60 minutes. 
Access to system support services such as psychologists and social workers was 
offered in some consultations along with offers to ‘work’ the system so 
treatment could be delivered in a patient responsive manner in others.  While 
specialists appeared to try and not pressure patients to make a decision, at the 
same time there appeared to be an expectation that the patient either make a 
decision or at least give an indication as to what they might choose to do.  It 
appeared the reason for this was to set in motion treatment related 
appointments which would enable further tests and treatment administration to 
commence in a timely way given system constraints.  While there are system 
issues to be overcome, it is also important to note that there are many good 
aspects to the NZ health care system and in particular the fact it is publicly 
funded increasing accessibility for NZ citizens. 
Factors influencing specialists’ decision-making 
Many of the factors found to influence specialists’ treatment decision-making in 
this study are consistent with past research.  Comorbidity, disease and 
treatment related factors for instance were identified in this study as influencing 
specialists’ decision-making as were a range of disease factors including 
symptoms, tumour growth, spread and progression.  This finding supports 
previous research into factors influencing specialist decision-making which 
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identified comorbidity and disease related factors (Grunfeld et al., 2001; 
Tariman et al., 2012)  
In this study severe comorbidity made treatment decision-making difficult in 
two cases.  This finding is similar to those of Shepherd et al.’s (2008) who found 
95% of the 605 cancer specialists surveyed identified other patient health 
problems caused difficulties in treatment decision-making (Shepherd et al., 
2008).  In Waitā’s case a unique situation occurred.  His comorbidity was 
identified by the specialist as a key factor prompting his decision to offer cancer 
treatment.  Radiation treatment in Waitā’s case would enable him to 
recommence prophylactic treatment for cardiovascular disease for a period of 
time.  It appears the Waitā’s risk of another cardiovascular event was more 
concerning to the specialist than his stomach cancer. 
The lack of high quality evidence to inform treatment decision-making for 
cancer patients with comorbidity make it difficult for patients and specialists to 
weigh up treatment benefits and harms.  Often cancer patients with comorbidity 
are excluded from gold standard studies such as randomised control trials 
because of their comorbidities alongside other factors such as age (Lewis et al., 
2003).  This creates a conundrum for the specialist in that treatment guidelines 
are often based on studies which have excluded patients with comorbidity even 
though such patients form a significant proportion of the cancer patient 
population (Sogaard et al., 2013).  Additionally these studies often have few, if 
any, indigenous participants who often have higher levels of comorbidity and 
poorer survival (Sarfati, Gurney, Stanley, & Koea, 2014; Sarfati et al., 2016).  
Future cancer studies and treatment guideline should therefore be inclusive of 
indigenous and comorbid populations. 
Specialists in this study gathered information about comorbidities in the 
consultation.  Comorbidities influenced patients’ fitness for treatment 
differently.  Additionally, patients’ medication use had to be considered for 
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contraindications and their ability to cope with treatment procedures assessed.  
Despite concerns about patient fitness in the two cases where there were major 
comorbidities, the specialist did not appear to alter the treatment option offered.  
Therefore comorbidity did not appear to be a reason for radiation treatment 
withdrawal in the cases studied. 
While treatment details such as number of medications and treatment frequency 
were attended to, side-effects appeared to feature more so for specialists, 
particularly during the treatment administration phase.  Specialists wanted to 
give this information and one could speculate that this was to insure that 
patients could be informed in their choice.  These findings are consistent with 
other studies into treatment decision-making which identified the influence 
treatment factors, including side-effects, have (Sundaresan, King, Stockler, Costa, 
& Milross, 2015). 
Another important finding was that patients’ Whānau and their medical history 
in particular was found to influence which tests specialists order to inform 
treatment decision-making and monitoring.  Gathering a medical history is 
standard procedure in many circumstances.  Given the higher incidence of 
comorbidities among the Māori population and minority groups (Centers for 
Disease Control and Prevention, 2013) ensuring this is comprehensive and 
inclusive of family history may be particularly important. 
One unanticipated finding, seemingly related to the system, occurred when a 
patient’s consultation proceeded with missing information despite it being 
relevant to the treatment offered.  This raises concerns about how a patient 
could truly make an informed choice and give consent and how the specialist 
determines best patient centred treatment when vital pieces of information are 
missing.  Ideally specialists would have all results in advance of the consultation 
to maximise resources and minimise patient distress. 
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Other factors influencing specialist decision-making matching other studies 
included patient factors like willingness for treatment (Cavalli-Björkman et al., 
2012), and system influences like multidisciplinary teams (Mendick et al., 2010). 
Communication 
Specialists, patients and whānau were complimentary of each other and good 
communication was established, which was critical to ensure that important 
information was shared between them. 
Prior studies have noted the importance of communication in the cancer 
treatment decision-making process (Hack et al., 2012; M. Johnson, 2012; 
Laidsaar-Powell et al., 2013; T. Walker et al., 2008).  Some of the communication 
findings in this study were consistent with this literature.  For example, whānau 
aided communication by providing information, some specialists established 
what was important for the patient and rapport building activities were 
undertaken (Hack et al., 2012; M. Johnson, 2012; Laidsaar-Powell et al., 2013; T. 
Walker et al., 2008). 
Information giving is complex and providing all information can be impossible 
(Mendick et al., 2011).  Deciding what the ‘right’ amount of the ‘right’ 
information is, to tell a patient, so they may make an informed treatment choice 
and give informed consent, is no doubt challenging for specialists to achieve in 
30 to 60 minute consultations.  Additionally, the results of this study show the 
information load patients had to process often began accumulating prior to the 
consultation.  Disease and treatment related information was given or sought 
from other health professionals, family and other sources such as the internet.  
Information loads also appeared to be greater and more complex in medical 
oncology consultations compared to the radiation oncology consultations.  




Support options and coping strategies were also discussed more in medical 
oncology compared with radiation oncology consultations.  Ensuring a patient 
can make an informed decision when giving consent may inadvertently be an 
underlying cause of information over-load.  One flaw or risk of giving ‘all 
information’ is completely overwhelming the patient.  Therefore it is important 
to ascertain from the patient what information they would like and tailor 
information provided in the consultation accordingly, in line with cancer 
communication guidelines (Rodin et al., 2009).   
In NZ, one description of health literacy is “the ability to obtain, process, and 
understand basic health information and services to make appropriate health 
decisions” (Ministry of Health, 2010b).  Avoiding medical jargon has also been 
found to aid effective patient provider communication (Shahid, Durey, Bessarab, 
Aoun, & Thompson, 2013).  Of the communication related activities observed in 
this study specialists tried to manage information loads, used a variety of 
information giving methods and tried to tailor information to the patient.  It was 
also interesting to note that although medical jargon was often evident, some 
specialists mentioned or were observed to translate medical jargon using lay 
terms in consultations.  Effective strategies used by specialists to enhance Māori 
patient health literacy in cancer consultations are important. 
Prior studies have noted the importance of patients trusting and having 
confidence in specialists (Henman, Butow, Brown, Boyle, & Tattersall, 2002).  An 
interesting finding in this study was the case where both the patient and 
specialist had gathered information about each other prior to the consultation.  
This activity may be possible in smaller cities where hospitals serve a smaller 
population.  In this study, Nuku had gathered information from community 
contacts about the specialist and the breast nurse specialist had provided the 
specialist information about Nuku.  A possible explanation for Nuku’s 
information gathering might be related to Nuku’s prior negative whānau 
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experience with cancer services.  Establishing trust in the specialist she would 
accept treatment from was therefore important.  A possible explanation for the 
specialist undertaking this activity could be linked to the breast nurse specialist 
having a long established relationship with Nuku.  She was able to inform the 
specialist about the patient’s concerns and anxiety which enabled the specialist 
to prepare for the consultation accordingly.   
Nuku’s consultation was also the only one where the specialist opened by asking 
the patient directly what her key priorities were prior to discussing treatment 
which was also found to be important by Henman et al. (2002).  As this specialist 
only participated in one of the cases studied it is difficult to determine if opening 
this way was unusual for her.  Nevertheless, determining patient priorities can 
help the specialist tailor information to what is important to the patient’s 
decision-making. 
Comorbidities have been found to negatively influence prognosis (Hong et al., 
2015; Sarfati et al., 2009; Stevens et al., 2008) and survival, with Māori patients 
experiencing poorer outcomes compared to non-Māori (Hill, Sarfati, Blakely, 
Robson, Purdie, Chen, et al., 2010).  Yet, within the consultations studied little 
conversation between participants attended to prognosis in any detail.  This 
finding supports previous research which suggests that specialists struggle to 
discuss prognosis and there is little to guide them on the best way to do this 
(Hagerty, Butow, Ellis, Dimitry, et al., 2005).  It is also likely that the prognosis of 
patients with comorbidity or multimorbidity is more difficult to determine. 
In two of the cases studied, it appears that the majority of information on 
patients’ comorbidity was obtained by specialists after questioning patients 
rather than through referrals.  Additionally more comorbidity information was 
generally given by patients to the researchers in interviews than to specialists in 
consultations.  Why comorbidity and medication information was lacking from 
patients’ referrals is unknown.  A possible explanation is that referrers simply 
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include information they think is relevant, not necessarily all information.  The 
lack of time pressure in the interview may also explain why some patients gave 
the interviewers more comorbidity and medication information than to 
specialists.  Additionally the cultural concept known as whakama (shyness, 
embarrassment) may provide another possible explanation for patients 
withholding comorbidity information from specialists, particularly if rapport 
had not been well established and/or the consultation was time pressured. 
If patients were whakama with specialists, the sharing of more detailed 
information with research interviewers suggests they were not whakama with 
them.  This may be explained by the researchers being Māori and having time to 
whakawhānaungatanga with patients/whānau prior to and post the 
consultation.  A different power dynamic and less stressful circumstances could 
also explain this.  Another plausible reason for poor communication relates to 
the difference in backgrounds between the specialist and patients who are from 
different ethnic groups (Boffa, 2008).  Some NZ health workers have reportedly 
found it more difficult to communicate with people not of a similar background 
(Crengle, Lay-Yee, Davis, & Pearson, 2005).  In such circumstances Hill et al. 
(2013) report specialists may be “more likely to rely on stereotypes and less likely 
to seek clarification from the patient or their family”(pg. 38) . 
Decision-making 
It is important for specialists in consultations to determine patient priorities, 
concerns and needs when working up treatment options and making decisions. 
The second question in this research was to identify factors (other than 
comorbidity) which influenced treatment decision-making in the consultation.  A 
strong relationship between specialists’ recommendations and patients’ 
decision-making has been reported in the literature and is not restricted to 
indigenous or racial/ethnic minority populations (Davidson et al., 2013; E. L. 
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Mead et al., 2013; Puts et al., 2015).  The specialists’ recommendations were an 
important factor which appeared to influence patients’ decision-making in this 
study. 
Some studies have found that patients associate treatment recommendations 
made by specialists with optimal treatment (Henman et al., 2002).  Furthermore, 
Henmen et al.’s 2002 study suggests that there is, in fact,  no decision to be made 
because having treatment is a given, meaning that the consultation is merely to 
discuss the details that need attending to.  Similarly, patients in the current 
study chose to attend a medical or radiation oncology consultation to discuss 
treatment options.  Attending the consultation could be interpreted as the 
patient expressing intent to undergoing some form of cancer treatment.  The 
vast majority of people choose (for whatever their own reasons may be) to seek 
help and care from those who are experts.  Māori, like anyone else, want and 
should have the 'best' care.  In the realm of cancer care, specialists are the 
experts and the fact that people will follow their recommendations is generally 
to be expected. 
Taking a more passive role in decision-making is linked to patients of an older 
age (Davidson et al., 2013; Obeidat et al., 2013).  In this study the age of the 
participants who appeared to base their decision on specialists’ 
recommendations varied.  Patients in two of the cases were aged in their 70s, 
and one was younger in her 30’s.  While it seems logical to follow treatment 
recommendations made by cancer experts, there are however personal 
circumstances and risks which must also be considered.  On reflection, the 
patient who defers treatment decision-making to the specialist risks feeling the 
treatment decision was not actually theirs.  They may go on to experience regret 
and it may influence their sense of satisfaction with the decision made (E. L. 
Mead et al., 2013; Obeidat et al., 2013).  It is therefore important that specialists 
invite patients to participate in decision-making and signal to them the value of 
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their participation.  After all, patients have a right to participate in decision-
making and specialists have ethical obligations to share decision-making with 
patients (Salzburg Global Seminar, 2011). 
Some studies have noted the potential for patients with comorbidities to 
experience more opportunistic screening leading to early diagnosis as a result of 
being in regular contact with health services.  Others have shown the opposite, 
where a patient’s comorbidity has distracted the patient and health 
professionals leading to a delayed diagnosis (Corkum et al., 2012; Fleming, 
Simmons, Leakehe, & Voyle, 1995; Sarfati et al., 2016; Terret, Castel-Kremer, 
Albrand, & Droz, 2009).  Both outcomes were observed in this study.  It was 
apparent in two cases that the patients’ diagnosis (or suspected diagnosis) 
occurred as a result of being under the care of a specialist.  In a third case, it 
appeared as if the initial investigation of the patient’s cancer symptoms in the 
primary care setting were distracted by the patient’s major comorbidity.  These 
findings are important as they demonstrate how comorbidities can potentially 
affect the extent of disease at diagnosis and patient prognosis. 
Comorbidities have been found to influence the ability of specialists to 
definitively make a cancer diagnosis and develop treatment options 
(Vansteenkiste et al., 2013).  In this study there was one instance where a 
definitive diagnosis could not be made due to the patient’s comorbidity, which 
added significant complexity to her case and may have resulted in her wish for 
further consultation with whānau.  Mead et al. (2013) suggests there is reduced 
treatment uptake by patients when specialists do not make a recommendation 
(E. L. Mead et al., 2013).  It would be interesting to examine cases where 
treatment recommendations had not been made to ascertain if there is an 
association with treatment decline.  Decision-making by patients with major 
comorbidities with a high risk of adverse outcomes may be more inclined to 
delay or consider the option of declining treatment. 
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In these cases decisions about which treatment options would be made available 
to these patients were often determined ‘up-stream’, some by a multidisciplinary 
team, prior to the consultations studied.  This is of concern as a recent review by 
Stairmand et al. (2014) found comorbidity was not well considered by 
multidisciplinary teams and members were likely to be unaware of the extent to 
which comorbidity is ignored (Stairmand et al., 2015).  Stairmand et al. (2014) 
argue that multidisciplinary teams should systematically consider patient 
comorbidity in treatment decision-making as it may contribute to improved 
patient outcomes. 
Several decision-making models involve the specialist making a treatment 
recommendation to the patient (Charles, Whelan, & Gafni, 1999; Kon, 2010; 
Makoul & Clayman, 2006).  In this study specialists made treatment 
recommendations in four of the consultations.  This finding is in line with 
Frongillo et al. (2013) who found that the majority of cancer patients receive a 
treatment recommendation (Frongillo, Feibelmann, Belkora, Lee, & Sepucha, 
2013).  In Waitī’s case, where a treatment recommendation was not made by the 
specialist he clearly stated that the decision was for Waitī to make.  Patient led 
decision-making aligns with informed models of decision-making. 
Conceptual model of decision-making 
The key factors found in this study to influence patient/Whānau and specialists 
decision-making have been used to create a conceptual model of decision-
making (Figure 5).  This model identifies the different levels of treatment 
decision-making determinants for Māori patients/whānau and specialists, which 
include factors at the healthcare system, patient, specialist and communication 
levels all of which influence decision-making processes in consultations. 
Figure 5: Conceptual model of factors influencing treatment decision-making in cancer 















Strengths and limitations 
This qualitative study of factors influencing decision-making in cancer 
consultations with Māori has a number of strengths and limitations.  First, and 
possibly most importantly, the major strength of this study is that it appears it is 
unique in Aotearoa/NZ in focusing on the indigenous people, Māori.  Given that 
both Māori patients’/whānau and specialists’ perspectives were required, the 
selection of a Māori centred research paradigm and a case study research 
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environment in which the phenomena occurred was also suited to the use of 
qualitative methods.   
A Māori centred research approach ensured that Māori were the focus of the 
study and a Māori world view considered by the involvement of Māori at all 
levels of the research.  Qualitative methods used in this study enabled a broad 
focus on comorbidities and consideration of real life contextual factors likely to 
influence the phenomena of decision-making not obtainable from quantitative 
studies.  Developing a deeper understanding of issues faced by Māori and 
specialists in decision-making is important in the New Zealand context.  Such 
understanding will ensure that quantitative studies which cover the range of 
related factors do not fall into the trap of over simplifying a complex process. 
The quality of information was enhanced by the decision to draw data from 
multiple sources for the different participants.  Looking for coinciding patterns 
amongst the data and data triangulation strengthened the internal validity and 
rigor of the study.  The researcher acknowledges that information may have 
been shared between patients/whānau and specialists prior to and post the 
recorded consultation.  The use of audio-recordings also meant that only verbal 
exchanges were captured.  Videoing may have provided a richer data set and 
should be considered for future studies of this nature. The literature review was 
also limited in that this is not a well indexed field meaning articles may have 
been missed and additionally only English language literature was included.  The 
literature review findings were also limited by the apparent lack of studies 
regarding indigenous peoples in this field.  Field notes enabled the researcher to 
record behaviours and activities observed during data collection. 
In this study, research activities aligned with notions of reciprocity and tika (the 
right thing to do).  For instance, participants were offered copies of information 
captured and shared with the researchers should they want it.  To ensure good 
quality research occurred, development of the research protocol, questions, and 
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analysis involved my supervisors and at different points in the process, other 
senior members of the C3 Qual research team. 
Ensuring that this research was undertaken ethically was highly important as it 
was recognised that the participants were in a ‘vulnerable’ state.  Attention was 
paid to ensure people could give ‘informed consent’ regarding their participation 
in the study and approaches to potential participants were made by a third party 
not affected by the outcome.  When people were approached to participate in the 
study they were informed clearly that it was completely voluntary, that their 
treatment would not be affected in any way and that everything they said, if 
used, would be anonymised, to maintain their privacy. 
The research protocol required eligible participants to have received their 
cancer diagnosis prior to the consultation, however in one case the researchers 
did not become aware that this had not occurred until they were in the 
patient/whānau interview.  This particular issue was discussed with a 
supervisor and it was agreed that the case would stay in despite the deviation 
from protocol on the condition that the issue was acknowledged when the case 
study was written up.  It is possible that this patient may have behaved 
differently during the consultation as a result of having just had their diagnosis 
confirmed compared to the other patients who had days or weeks to process the 
diagnosis prior to the consultation. 
Limitations of this study include a possible change to behavior by those 
participating in the consultation knowing that it was being recorded and 
response bias by the interviewees.  Despite these risks, consultations and 
interviews seemed to flow easily and no comments were made by any 
participants which suggested they were affected by the audio-recorder at any 
time.  This finding is in line with work by Henry et al. (2015) (Henry et al., 2015).  
Additionally the transcripts were reviewed by two senior clinicians (one a 
practicing oncologist) from the C3Qual study who did not note any variance 
162 
 
from what might be considered ‘normal’ practice in cancer consultations.  Future 
research could explicitly ask patients and specialists about how it feels to be 
recorded and whether they thought it changed their behaviour. 
Despite being a small study of five Māori patients, their whānau and three 
oncologists from two differing specialties, this study shows that research taking 
a Māori centred approach, with these different groups can be successfully 
undertaken.  Furthermore, this can be done in Western based hospital settings 
and a rich and comprehensive body of information can be obtained. 
Originally this study aimed to recruit 15 Māori participants from the C3 Qual 
study.  However this was impossible for two reasons.  Firstly, there were 
difficulties recruiting a large hospital and associated specialists into the C3 Qual 
study, primarily due to hospital staffing issues.  Secondly, there was an over-
estimation of the number of Māori participants that would be eligible for the 
study from participating hospitals.  Additionally, one specialist participated in 
three of the consultations studied which may mean some findings are related to 
his/her practice.  It is likely such difficulties could be overcome if the study was 
undertaken over a longer time period and more patients and specialists were 
recruited. 
A larger sample and access to patient medical records would also enable 
verification and comparison of findings.  If a similar study was to be repeated I 
would recommend the specialist debrief be expanded to a brief interview and 
that the questions asked be amended to include greater detail about how and 
who participated in the development of treatment options.  I would also 
recommend that follow-up be undertaken to ascertain the patient’s decision and 
treatment status 4-6 weeks post initial treatment consultation.  This could be 
done via a patient notes review and follow-up telephone interview. 
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It is important to take a cautious approach in generalising these results to all 
Māori cancer patients/whānau and oncologists.  However, this study does 
provide valuable understanding and insights in a field deficient of knowledge. 
Summary 
This study examined factors influencing treatment decision-making in cancer 
consultations between Māori patients/whānau and specialists with a view to 
identifying clues into the causes of Māori cancer treatment disparities.  
Consultations were recorded and participants were provided with an 
opportunity to discuss factors in their own words.  Themes influencing patient 
decision-making identified in the literature were organised based on Te Whare 
Tapa Whā and Mead el al’s (2013) conceptual model of shared decision-making. 
A number of particularly important factors were found to influence patients’ 
decision-making including medical factors (e.g. comorbidity, disease and 
treatment), patient (e.g. emotional wellbeing) and the healthcare system.  Of 
particular note was the influence of the whānau and specialists’ 
recommendations on patient decision-making.  Specialists’ decision-making was 
influenced by patient (e.g. fitness for treatment) and specialist (e.g. experience) 
factors.  Medical factors (e.g. comorbidities, disease and treatment) and 
healthcare system factors (e.g. multidisciplinary team recommendations) 
appeared to be particularly important factors influencings specialists decision-
making. 
Treatment options in these consultations were prepared in advance by 
specialists in consultation with other medical professionals.  This meant that a 
large portion of consultations were controlled by specialists informing patients 
of the medical treatment options available along with details such as side-effect 
and administration.  Other options, both medical and alternative, were only 
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discussed when raised by patients.  This suggests that an informed type model of 
decision-making occurred in the consultations studied.   
To ensure patient participation and a patient centred approach is taken it is 
important to establish the patient’s agenda in the consultation.  Additionally it is 
important that specialists translate medical jargon, and recognise that 
comorbidity may add additional load to communication.  Similarly to other 
studies the development of Māori specific resources may be helpful in improving 
patient/Whānau health literacy (Cormack et al., 2005; Slater et al., 2013; T. 
Walker et al., 2008).  In respect to treatment decision-making, treatment aids 
and support may also be beneficial to patients’ decision-making (Furber, 
Murtagh, Bonas, Bankart, & Thomas, 2014; Stacey et al., 2014). 
However, no one major thing appeared to stand out as a possible cause of Māori 
cancer treatment disparities.  Similarly, Hill et al.’s (2010) qualitative study of 
colon cancer management differences between Māori NZ and non-Māori New 
Zealanders found no dramatic difference between groups at any one 
management step.  Rather, they identified small differences which accumulated 
along the management pathway including diagnosis, waiting times, quality of 
care and interventions (Hill, Sarfati, Blakely, Robson, Purdie, Dennett, et al., 
2010). 
I was unable to determine from the findings in this study if potential causes of 
Māori cancer treatment disparities occurred in the consultations studied.  As this 
was a small case study of five patients, a larger study may better answer the 
research questions.  A comparative analysis between Māori and NZ Europeans 
consultations may also be helpful.  Additionally, treatment options were largely 
determined prior to the consultation by the specialists, multidisciplinary teams 
and other colleagues.  I suggest that further research is warranted ‘up stream’ 
from the consultation.  This might include further exploration of treatment 
processes like the referral pathway and complex case management involving 
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multiple specialties and providers.  More clues into the drivers of Māori cancer 
treatment disparities may lie there.   
Based on the findings of this study the following recommendations are 
suggested: 
Policy, service and practice 
 Acknowledge diversity amongst patients of Māori ethnicity in the 
delivery of patient centred care  
 Recognise that Māori patients are more likely to carry a greater burden of 
cancer and other diseases coming into the consultation which may 
require a suite of responses (e.g. psychology support services, genetic 
testing, modification of standard procedures and taking a comprehensive 
medical history); 
 Cultural safety training for staff (including specialists) 
 Provide additional opportunities and support to enable informed shared 
decision-making involving when there are a number of participants 
involved and the case is complex (e.g. no clear treatment pathway). 
 Provide additional space and support for whānau supporting patients 
Research 
 Undertake ethnic inequalities focused research earlier in the treatment 
decision-making pathway. 
 Undertake a comparative analysis of factors influencing treatment 
decision-making between Māori and NZ Europeans (planned as part of C3 
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C3 – Cancer Care Journeys and Clinical Decision-making 
Patient and Clinician Responses to the Consultation 
CLINICIAN INFORMATION SHEET 
Thank you for showing an interest in this research.  Please read this information sheet 
carefully before deciding whether or not to participate.  If you decide to participate we 
thank you.  If you decide not to take part there will be no disadvantage to you of any kind 
and we thank you for considering our request.   
Who is doing this study?  
This study is being led by researchers at the University of Otago Wellington, Massey and 
Victoria Universities and is funded by the Health Research Council. 
What are the aims of the study? 
There are significant inequalities in cancer survival between Māori and non-Māori, and 
evidence that comorbidity and service access play important roles.  This research aims to 
understand the independent and interacting influences of ethnicity and comorbidity on 
cancer survival and to develop interventions that will strengthen health service delivery.  In 
the first phase of the research we studied decision-making in multidisciplinary team (MDT) 
meetings.     This second phase aims to assess:  




2) understand the perceptions of clinicians and patients/whānau of the impact of ethnicity 
and/or comorbidity on cancer treatment consultations  
3) identify interventions specific to cancer treatment consultations that would reduce 
disparities in cancer survival due to ethnicity and/or comorbidity.   
In so doing, it is hoped to better understand the decision-making process in consultations 
and the ways that clinician-patient communication can be enhanced.  It is hoped to identify 
effective approaches already in use that can be promoted and to explore ways to improve 
less effective approaches through piloted interventions. Further details are outlined below. 
What does this study involve? 
This research is being undertaken with clinicians interested in reducing cancer disparities 
potentially due to comorbidity and/or ethnicity and patients who have received a cancer 
diagnosis.  Thirty consultations where clinicians discuss cancer treatment options with 
patients will be recorded (audio) and analysed.   
Potential participants will be identified by clinicians and following MDT meetings. A clinician, 
nurse, administrator or researcher will advise potential participants there is a study they are 
eligible for.  The researcher will provide information and consent those choosing to 
participate.  
If you agree to participate in this research project you will be asked to: 
Identify potential patients eligible for this research. 
Record some of your consultations (about 5).  The researcher will provide you with a digital 
recorder and the names of patients and appointment times of those who have agreed to 
participate, 
Record your responses to each of the consultations on a digital recorder (clinician debrief) 
shortly after the consult using a prompt sheet of questions (please see below). We estimate 
it will take about 3-5 minutes to complete per consultation. 
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 Provide some demographic information about yourself to enable us to broadly describe the 
range of clinicians participating in the study (please see below). 
Patients and their whānau will also be asked to participate in a semi-structured interview 
post-consultation to record their responses to the consultation.  In each case, consent from 
all participants (clinicians, patients and whānau) is required. If this is not possible, that 
consultation will not be studied. 
The recordings and transcripts will be anonymised by the researcher before other members 
of the research team hear/see the data.  This process of anonymisation will include 
removing all clinician and patient/whānau names and the anonymised linking of patient 
ethnicity and comorbidity status by using data provided by the clinician from the clinician’s 
debrief.  Once data has been analysed the research team will present the findings to the 
participating clinicians to seek feedback on the findings and advice about potential 
interventions and a paper will be drafted.  These findings will inform the development of 
questions for further stages of the research. 
You may withdraw from participating in this project at any time without any disadvantage to 
yourself of any kind.  If you withdraw, the consultation/s and clinical debriefs you 
participated in will not be used in the research. 
If you agree to participate the consultation and debrief data will be used in publications but 
you will not be named and every effort will be made to ensure that you are not identified in 
any reported data.  You will be provided a copy of the results should you wish. Transcripts 
and audio recordings will be kept on password protected computers and in locked filing 
cabinets for ten years, at which time they will be destroyed by Associate Professor Signal.   
Ethical issues 
This study has received ethical approval from the Central Region Ethics Committee (REF: 
CEN/12/06/026). If you have any queries or concerns regarding your rights as a participant 




It is hoped to collect data during 2013 and early 2014. Data will be analysed and findings 
reported back to participating clinicians by early 2014.  A paper will then be completed for 
publication. It is planned to pilot at least one intervention identified from Phase 2. This 
would likely occur in late 2014. 
If you have any questions about the research please contact: 
Associate Professor Louise Signal, Ph (04) 918-6477, Mobile 021 0324 720 University of 
Otago, Wellington, email louise.signal@otago.ac.nz  






C3 – Cancer Care Journeys and Clinical Decision-making 
Patient and Clinician Responses to the Consultation 
CLINICIAN CONSENT FORM 
I have read and understood the information sheet explaining this research.  
I have had the opportunity to talk about the research and ask questions. I am satisfied with 
the answers I have been given.  
I understand that my participation is voluntary and that I can withdraw from this research at 
any time.  
I understand that I will not be named and that every effort will be made to ensure that I am 
not identified in any reported data. 
I know whom to contact if I have any questions about this research. 
I agree to take part in this research. Please circle the option that applies to you. 
   YES   NO 
I agree to allow consultations I attend and my debrief be recorded. Please circle the option 
that applies to you. 
   YES   NO 
I ____________________________________hereby consent to take part in this study 






• I would like a copy of the findings of the research to be sent to me after the 
research is completed.  Please circle the option that applies to you. 
YES   NO 
If yes would you like this sent hard copy □or electronically□? 
In order to send you a copy of the transcripts and research findings could you please record 
your details below. 
Name:      _______________________________________________________ 
Address: _______________________________________________________ 
     _______________________________________________________ 
Email:      ____________________________________ 
Signature: ____________________________________Date: ______________ 
*Please turn over the page and complete demographic information. 
This research is being led by researchers from the University of Otago Wellington and 
Victoria and Massey Universities.  
If you have any questions about the research please contact: 
Associate Professor Louise Signal, Ph (04) 918-6477 University of Otago, Wellington, email 
louise.signal@otago.ac.nz or  







C3 – Cancer Care Journeys and Clinical Decision-making 
Patient and Clinician Responses to the Consultation 
CLINICIAN DEMOGRAPHIC INFORMATION  
We would like to collect a few details for statistical purposes.  This information will assist us 
describe the group of clinicians who took part.  No individual names will be used in any 
reports.   
Name:____________________  _______________________Position:___________________ 
 (First Name)               (Surname) 
 
1. Are you:   ⁭ Female □         Male  □ 
2. When were you born?  ____/___/____ 
  dd/mm/yy⁭    ⁭⁭       ⁭⁭⁭⁭ 
3. Which ethnic group/s do you belong to? (tick the box or boxes that apply to you) 
⁭□ New Zealand European 
⁭□ Māori 
⁭□ Samoan 






⁭□ Chinese  
⁭□ Indian 
⁭□ Other (such as Dutch, Japanese, Tokelauan)  
Please state if ‘Other’: __________________________________________________ 
How long have you been practicing medicine? 
Overseas 
In New Zealand 
What area/s of medicine do you specialise in? 




C3 PHASE 2 PATIENT INTERVIEWS INVITATION CHECKLIST 
1 
Introduce self: xxx, Researcher, University of Otago – Wellington,  
You have been referred by …, XX  
as someone who may be interested in participating in our research?   
Is that correct?  And are you still interested?  Is now an OK time to talk?     
2 
You  are under no obligation to participate,  
and that it will in no way will your decision affect their treatment or how the Doctors/nurses will treat you   
3 
Why? The journey of a person with cancer can be  
complex and  
people may receive care from multiple doctors and nurses  




often away from home.   
People must make critical decision about many things including which treatment to have.   
These decisions are often made in or soon after consultation with a doctor.   
This study explores the things that people and their doctors consider when making treatment decisions.   
4 
What's involved? 3 things.   
1) Your informed consent is required to participate.   
2) The doctor will record your next consultation as normal (researcher not present)and   
3) you will be be asked to participate in a private interview after your consultation (about 30mins, cupa tea)   
5 What then?  The researchers will analyse all the information they collect and see if they can find some clues/answers.  Optional 
6 
Who's doing this?  Our doctors and doctors from (xx and xx Hospitals) and researchers who come from the University of 
Otago-Wellington, Victoria & Massey Universities)s are working with the doctors from XX and XX Hospital    
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7 Any questions? 
 
7 
Three Likely responses.   
1) Yes interested and would like to find out more  
2) May be unsure/maybe (would like some time to consider) 
3) No, not interested   
8 
Patient response Yes interested:   
Seek verbal consent to participate  YES/NO 
OK method to send info/consent forms etc.  email/post/hard copy prior to appointment   
confirm appointment details  date ______________/time___________/venue (check referral) 
Check if bringing whānau support  YES/NO  how many?  _________ 
Check if they want the support person/whānau to be in the interview with us  YES/NO 
How best to advise the support person/whānau about the research  _______________________   
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Parking  arrangements (Cancer Soc, xx) 
Meet briefly prior (see bottom section of referral form).  We’ll need about 5-10 mins prior to appointment to discuss 
research and get written consent. 
Patient response Unsure/Maybe:   
ask if they would like time to think and then be contacted again at a later time?  Today/Tomorrow? 
Patient response No:  
Thank-you for listening and giving it consideration 
9 
In closing for patient who wants to proceed 
Remind patient that they are under no obligation to participate,  
that it will in no way will their decision affect their treatment 
or how the Doctors/nurses will treat them  
and they may withdraw from the research if they change their mind. 
Look forward to meeting you on xxx and thank you again.     
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REFERRAL FORM:  
Patient Name: Ms/Miss/Mr/Mrs ___________________   ___________________________ 
 First Name   Surname 
Contact Details:  Home phone:___________________  
Work phone:  _________________________ Cell phone: __________________ 
Email:  _______________________________ 
Preferred method of contact:   _____________________ 
Special considerations e.g. disabilities 
Eligible for study:  
  Has received cancer diagnosis    NZ European 
 Will be discussing treatment options in next consult  NZ Māori 
 18yrs+ old 
Verbally consented to be contacted by researchers    Date:  ___________     
Entered on patient file:   






Date Referral Received:  ______________________ 
Record of contact made with patient 
Date Time Method Outcome 
    
    
    
    
    
Additional Information provided by patient:  
Will bring whānau/support person/s:   No   Yes   If yes, their consent required if going 
to participate in interview 
Address/s to send information to:   
Appointment date:  _____________________________Time:  ________________________ 
Venue:  _____________________________________________________________ 
Preferred parking: XXXX           Car park #________   XX    Petty cash required  
Interview room booked:  Location:______________________Time:  ________________ 
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PATIENT/WHĀNAU INTERVIEW SCHEDULE 
1. INTERVIEWER INTRODUCTIONS 
Mihimihi as appropriate to the patient/whānau. 
Ascertain if patient/Whānau is well enough to participate at this time and that other 
‘practical issues’ e.g. parking in hand, missing rush hour traffic. 
Check amount of time patient is able to be available for interview.  
Reminder: Can take a break, just ask 
2. INTERVIEWER TO REVISE WITH PATIENT/WHĀNAU THE STUDY 
This study is by researchers at Otago - Wellington, Massey and Victoria Universities 
The study aims 
We know that the journey of a person with cancer is complex, and often people receive care 
from many doctors and nurses in different places far away from home.  Deciding what 
treatments to have is an important part of the cancer journey. In our study we are interested 
in exploring the things that people and their doctors think about when they are making 
treatment decisions.  
3 INTERVIEWER TO RECORD (turn on recorder & check numbers moving) 
 Date and venue  
 Name of researcher/s 
 Name of patient 
 Names of others present and relationship to the patient 
 Clinician that this patient saw 
QUESTIONS FOR THE PATIENT/WHĀNAU 
1. Can you tell me what brought you here to meet with Dr _____ today? 
Explore: initial symptoms and decision/influences to access health care (GP/acute?); 
Investigation’s and experiences with other services/clinician’s; background leading up to the 




(information seeking, friends/family etc.); what were the patient’s expectations of the 
consultation? 
2. How did your meeting with Dr ____ go today?  
o How do you feel about that meeting? 
o Did you understand everything that the doctor told you?  
o Were there any things said that you did not understand?  
 Why not?  
o Did you say everything you wanted to?  
 Why/why not? 
o If Whānau present, did you all get the chance to join in the discussion (if you 
wanted to) 
3. What did Dr ____ say to you about how your cancer might be treated? 
o Have you made a decision about which treatments to have?  
 If yes: what have you decided, 
  Why?  
 If maybe: what will help you make that decision?  
 Is there a timeline for making that decision? 
 If no: What are the reasons why you haven’t made a decision yet? 
o Do you think you might try different treatments/make a different decision in the 
future? 
o If Whānau present, how have you been involved in the treatment decisions? 
4. Do you have any other health issues you think might affect your treatment or what 
treatments you choose?  
o Could you please tell me about them?  
5. Do you have any other issues you think might affect your treatment or what treatments you 
choose?  
o Could you please tell me about them?  
6. Is there anything else you would like to tell me about the meeting today or your treatment? 
7. Do you have any questions for me? 
8. Has this interview raised questions or concerns you that you would like to talk with 
somebody about? (If so, provide information about where to seek advice).  
 
Mihi whakamutunga: explain the process from here, offer koha (get signature acknowledging 









C3 – Cancer Care Journeys and Clinical Decision-making 
Consultations 
PATIENT/WHĀNAU INFORMATION SHEET 
Thank you for showing an interest in this research.  Please read this information sheet carefully before 
deciding whether or not to participate.  If you decide to participate we thank you.  If you decide not to 
take part there will be no disadvantage to you of any kind and we thank you for considering our request.   
Who is doing this study?  
This study is being led by researchers at the University of Otago-Wellington and Massey and Victoria 
Universities. This research is funded by the Health Research Council. 
What are the aims of the study? 
The journey of a person with cancer can be complex.  Typically people receive care from multiple 
doctors and nurses in many different settings, often remote from their home.  Throughout the journey 
people must make critical decisions on many things including which treatment to have.  These decisions 
are often made in, or soon after, a consultation with a doctor.  This study explores the things that 
people and their doctors consider when making treatment decisions.   
What does this study involve? 
This research is being undertaken in Auckland and Wellington.  Thirty consultations where cancer 
treatment options are discussed with patients will be recorded (audio) and analysed.  If you decide to 
take part in this research you will be asked if one of your consultations can be recorded.  If any 




whānau/support people) in the consultation will need to consent for that consultation to be recorded 
and used in the research. If this is not possible, that consultation will not be studied.   If you and your 
whānau/support people consent, the researcher will meet with you just prior to your scheduled 
appointment and answer any questions you may have and collect written consent. The consultation will 
occur as per usual and the time will be determined by standard hospital systems used to book 
appointments. The doctor will record the consultation and the researcher will wait for you in the waiting 
room. 
Soon after your consultation is finished, you will be asked to participate in an interview with a 
researcher which will be recorded.  You will be asked if you want your whānau/support people to 
participate in this.  You do not have to answer all the questions, and you may stop the interview at any 
time.  We would also like to collect information on you including: your age, gender, ethnicity and health 
status.  The name/s of everyone participating in the consultation and interview will be anonymysed and 
names will not be linked to any comments in reports of the research.  In recognition of the additional 
parking costs you may incur by participating in the interview our researcher will organise with you to 
pay your parking costs.    
Participation in this study is voluntary (your choice).  You may withdraw from participation in this project 
at any time.  This will have no affect on your future health care. If you withdraw, the information on you, 
your consultation and the interview you participated in will not be used in the research.  
If you do participate the results of the project may be published but you will not be named and every 
effort will be made to ensure that you are not identified in any reported data. Information about your 
age, gender, ethnicity and health status will be used to describe the people who participated in the 
research.  It will be used collectively and will in no way identify you as an individual.  Transcripts and 
audio recordings will be kept on password protected computers and in locked filing cabinets for five 
years, at which time they will be destroyed by Associate Professor Signal. You are most welcome to 
request a copy of the results of the project should you wish.   
 
Ethics Approval 
This study has received ethical approval from the Central Region Ethics Committee  
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(REF: CEN/12/06/026).  
If you have any questions about the research please contact:  
Associate Professor Louise Signal, Ph (04) 918-6477, Mobile 021 0324 720 University of Otago, 
Wellington, email louise.signal@otago.ac.nz  







C3 – Cancer Care Journeys and Clinical Decision-making 
Consultations 
PATIENT/WHĀNAU CONSENT FORM 
I have read and understood the information sheet explaining this research.  
I have had the opportunity to talk about the research and ask questions. I am satisfied with the answers 
I have been given.  
I understand that my participation is voluntary and that I can withdraw from this research at any time.  
I understand that I will not be named and that every effort will be made to ensure that I am not 
identified in any reported data. 
I know whom to contact if I have any questions about this research. 
Please circle the option that applies to you 
I agree to take part in this research. 
YES   NO 
I agree for my GP to be advised I am a participant in the study 
YES NO  Name:  Practice:  
I agree to allow the consultation I attend to be recorded. 
YES   NO 




YES   NO 
Please circle the option that applies to you 
I agree for my interview to be recorded.  
   YES   NO 
I agree for my whānau/support person/s to be present during my interview. 
   YES   NO 
If you have any queries or concerns regarding your rights as a participant in this study, you may wish to 
contact an independent health and disability advocate: 
Free phone: 0800 555 050 
Free fax: 0800 2 SUPPORT (0800 2787 7678) 
Email: advocacy@hdc.org.nz 
If you have any questions about the research please contact: 
Associate Professor Louise Signal, Ph (04) 918-6477 University of Otago, Wellington, email 
louise.signal@otago.ac.nz or  
Professor Chris Cunningham, Ph (06) 380 0627 Massey University, Wellington, email 
c.w.cunningham@massey.ac.nz 
I ________________________________________hereby consent to take part in this study 
  (First Name/Surname) 
Signature:___________________________________ Date: __________________________ 
Project explained by: __________________________ Signature: ______________________ 
Project role:_________________________________  Date:  _________________________ 
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PARTICIPANT DEMOGRAPHIC INFORMATION 
We would like to collect a few details for statistical purposes.  This information will assist us describe the 
group of people who took part.  No individual names will be used in any reports.   
Name: ________________________  _________________________________ 
 (First Name) (Surname) 
1. Are you:    
⁭ Male  □ Female □  
 
2. When were you born? 
Day:____ Month:________________ Year you were born:  19____ 
⁭    ⁭⁭       ⁭⁭⁭⁭ 
3. Which ethnic group do you belong to? (tick the box or boxes that apply to you) 






⁭□ Cook Island Māori 
⁭□ Tongan 
⁭□ Niuean 
⁭□ Chinese  
⁭□ Indian 
⁭□ Other (such as Dutch, Japanese, Tokelauan)  
Please state if ‘Other’: __________________________________________________ 
Thank you 
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CLINICIAN PROMPT SHEET  
Clinician Prompt Questions  
1) Please record the date and your name. 
2) Please state the name of the patient. 
3) Please describe the outcome of the consultation.  
4) Please describe briefly the treatment option/s discussed with the patient. 
5) Please describe any factors that influenced the treatment option/s developed for 
this patient. 
6) Does the patient have any comorbidities that impacted on treatment options?  
Yes/No 
4.1 If yes: Please describe the impact they had.   
4.2  If no: go to question 5. 
 
7) Please describe how the consultation went and why? 
8) Did you have enough time to spend with the patient today discussing their 
treatment options? 
9) Are there any personal characteristics of the patient that impacted on the 
consultation and if so what were they and why did they impact? 
10) Do you think the patient understood their treatment options?  What makes you 
think this? 
11) Were there any difficulties communicating with the patient for any reason? 
12)  Is there anything else you would like to say?  
Thank you for your participation in this study. 
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